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THE ROLE OF FOXD1 IN CLEAR CELL RENAL CELL CARCINOMA
By Kyle H. Bond
Dissertation Advisor: Dr. Leif Oxburgh
An Abstract of the Dissertation Presented
in Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
(In Biomedical Engineering)
May 2022
Renal cell carcinoma (RCC) is the 8th most common cancer in the United States, with the clear
cell variant (ccRCC) being the most prevalent. Over 14,000 people die every year to RCC, with rates
continuing to increase with an aging general population. Patients suffering from metastatic RCC (mRCC)
have extremely poor prognoses, with a 5-year survival of only 11.2%. Current treatment options include
resection of primary lesions, tyrosine kinase inhibition (Sunitinib, Pazopanib), mTOR inhibition
(Temsirolimus, Everolimus), and immune checkpoint inhibition (Nivolumab, Atezolizumab). Recent
attention has been drawn to inhibition of transcription factors like HIF2α (Belzutifan). There is a need to
discover new targets, as well as gain better insight into the molecular signatures for patient specific drug
response prediction.
The work presented herein presents our investigations into the transcription factor FOXD1, and
the role it plays in regulating ccRCC growth. We knocked out FOXD1 in a classic model ccRCC cell line,
the 786-O (786-OFOXD1null). Loss of FOXD1 led to growth inhibition and reduced tumor forming capacity in
vivo. We uncovered a cell-cycle specific role of FOXD1 in promoting progression through the G2/M
phase and phosphorylation of Histone H3.
Due to the limitations in vivo using 786-OFOXD1null, we designed an in vitro tumor model meant to
recapitulate the human tumor microenvironment. This model was based on extracellular matrix profile
of patient ccRCC tissue through proteomic analysis. Using this model, we were able to create tumor

avatars containing heterogenous cell populations. In addition to this, the model system could be used to
analyze 3D tumor growth of cell lines in response to drug treatments.
We used this model system to examine how FOXD1 regulates the cell cycle and 3D tumor
growth. An analysis pipeline was devised to delineate targets downstream of FOXD1 that utilized RNAsequencing, predicted transcription factor binding, toxicity screening, and cell cycle analysis. Using our
newly devised 3D tumor model allowed us to confirm the applicability of this approach to a broader
population of primary tumor cells. This pipeline uncovered novel signaling pathways regulating cell cycle
progression in RCC lines and may have therapeutic implications.

DEDICATION
To my grandfather, who taught me how to connect a circuit before how to ride a bike.

iii

ACKNOWLEDGMENTS
I would like to acknowledge those who believed in me before I ever got my hands dirty; my
undergraduate mentors Dr. Yin and Dr. Rubenstein, who encouraged me to pursue a PhD. As they said
best: “why wait on something you know you are going to do anyways?”.

iv

TABLE OF CONTENTS
DEDICATION ................................................................................................................................................................. iii
ACKNOWLEDGMENTS .................................................................................................................................................. iv
LIST OF TABLES ........................................................................................................................................................... viii
LIST OF FIGURES ........................................................................................................................................................... ix

Chapter
1. REVEW OF FOXD1 IN CANCER ...................................................................................................................................1
1.1.

INTRODUCTION ...............................................................................................................................................1

1.2.

FOXD1 IN DEVELOPMENT ................................................................................................................................3

1.3.

FOXD1 IN CANCER .........................................................................................................................................6

1.3.1.

Rationale................................................................................................................................................6

1.3.2.

Literature review methodology and results ..........................................................................................6

1.3.3.

FOXD1 is an oncogene .........................................................................................................................11

1.4.

THE FUTURE OF FOXD1 .................................................................................................................................12

2. FOXD1 REGULATES CELL DIVISION IN CLEAR CELL RENAL CELL CARCINOMA .........................................................13
2.1.

INTRODUCTION .............................................................................................................................................13

2.2.

MATERIALS AND METHODS .............................................................................................................................14

2.3.

RESULTS ......................................................................................................................................................20

2.3.1.

FOXD1 expression in ccRCC correlates with poor patient survival ......................................................20

2.3.2.

FOXD1 expression in ccRCC correlates with poor patient survival ......................................................22

2.3.3.

Effect of FOXD1 knockout on expression of known transcriptional targets ........................................23

2.3.4.

FOXD1 influences cellular energetics, but does not affect overall ATP production ............................24

2.3.5.

FOXD1 is essential for tumor growth in vivo .......................................................................................27

2.3.6.

Loss of FOXD1 causes cell cycle delay at G2/M and inability to phosphorylate histone H3................28

2.3.7.

FOXD1 expression is necessary for genomic integrity through mitosis ...............................................31

2.4.

DISCUSSION .................................................................................................................................................34

v

2.5.

ACKNOWLEDGMENTS .....................................................................................................................................36

3. THE EXTRACELLULAR MATRIX ENVIRONMENT OF CLEAR CELL RENAL CELL CARCINOMA DETERMINES
CANCER ASSOCIATED FIBROBLAST GROWTH ..............................................................................................................37
3.1.

INTRODUCTION .............................................................................................................................................37

3.2.

MATERIALS AND METHODS..............................................................................................................................39

3.3.

RESULTS ......................................................................................................................................................48

3.3.1.

Isolation and culture of cells from ccRCC tumors using standard methods ........................................48

3.3.2.

Differences in ECM composition between ccRCC and neighboring healthy cortex ............................49

3.3.3.

Transcriptional analysis indicates that tumor fibroblasts are major contributors to ccRCC ECM .......52

3.3.4.

Binding of tumor and stromal cells to ccRCC ECM components .........................................................54

3.3.5.

ccRCC ECM blend binds diverse cell types isolated from patient tumors ...........................................58

3.3.6.

Design of a 3D model of ccRCC with native ECM environment ...........................................................59

3.4.

DISCUSSION .................................................................................................................................................66

3.5.

ACKNOWLEDGMENTS .....................................................................................................................................71

4. UNCOVERNG THE FUNCTION OF FOXD1 REGULATION OF CCRCC CELL CYCLE PROGRESSION USING A
NOVEL TRANSCRIPTION FACTOR FOCUSED ANALYSIS PIPELINES ...............................................................................72
4.1.

INTRODUCTION .............................................................................................................................................72

4.2.

MATERIALS AND METHODS .............................................................................................................................72

4.3.

RESULTS ......................................................................................................................................................79

4.3.1.

FOXD1 mutants have 3D growth defects ............................................................................................79

4.3.2.

Loss of FOXD1 shows defects in growth, not secreted signaling .........................................................81

4.3.3.

Changes in extracellular matrix deposition and interaction between 786-O and 786-OFOXD1 .............81

4.3.4.

RNA-seq analysis identifies novel targets downstream of FOXD1 ......................................................83

4.3.5.

Candidate drug targets inhibit cell growth, induce cell cycle arrest....................................................84

4.3.6.

Drug induced growth delay effects 3D growth, nuclear structure ......................................................86

4.3.7.

Characterization of FOXD1 and drug response in primary ccRCC tumor lines ....................................90

4.4.

DISCUSSION .................................................................................................................................................92

vi

4.5.

ACKNOWLEDGEMENTS ...................................................................................................................................98

5. CONCLUSIONS AND RECOMMENDATIONS .............................................................................................................99
REFERENCES ..............................................................................................................................................................102
APPENDIX A ...............................................................................................................................................................129
APPENDIX B ...............................................................................................................................................................143
APPENDIX C ...............................................................................................................................................................158
BIOGRAPHY OF THE AUTHOR ....................................................................................................................................162

vii

LIST OF TABLES
Table 1.1. Summary of FOXD1 in Cancer......................................................................................................10
Table 3.1. Tissue samples used in ccRCC study...........................................................................................39
Table 4.1. Isolated tissue samples used in drug study..................................................................................78
Table 4.2. Drug targets identified using drug discovery analysis pipeline....................................................86
Table 4.3. Drug toxicity screening on 786-O cultured for three days..........................................................87
Table A.1. Summary of patient clinical data used for FOXD1 immunohistochemistry analysis..................129
Table A.2. Primers used for FOXD1 genotyping and off-target analysis.....................................................130
Table A.3. Primers for reference genes and FOXD1 targets.......................................................................131
Table A.4. Nuclear morphology analysis of 786-O and 786-OFOXD1null.........................................................134
Table C.1. Summary of drug titrations used for toxicity screen..................................................................158

viii

LIST OF FIGURES
Figure 1.1. PubMed FOXD1 Literature Review...............................................................................................7
Figure 2.1. FOXD1 expression in ccRCC........................................................................................................21
Figure 2.2. FOXD1 knockout affects expression of cell cycle regulators and alters cellular energetics……...25
Figure 2.3. FOXD1 influences mitochondria levels, but does not promote glycolysis..................................27
Figure 2.4. Loss of FOXD1 reduces tumor growth in vitro and in vivo..........................................................28
Figure 2.5. G2 progression and histone H3 phosphorylation at ser10 are impaired in FOXD1 null cells…....29
Figure 2.6. FOXD1 is necessary for maintaining DNA integrity following mitosis………………………………..…….32
Figure 3.1. Identification and culture of fibroblasts from ccRCC tumors…….…………………………..……………….50
Figure 3.2. ECM protein upregulation in ccRCC.…….…………………………..……………….…………………………..………53
Figure 3.3. Prediction of cellular sources of matrix molecules based on scRNA-seq…………………….……..……56
Figure 3.4. ECM effects on tumor and stromal cell attachment.……..……………….…………………………..………….57
Figure 3.5. 3D culture of 786-O utilizing tumor-specific ECM.……..……………….…………………………..……….……61
Figure 3.6. Fibrin/ccRCC ECM 3D culture maintains viable ccRCC fibroblasts.…………………………..……..………63
Figure 4.1. FOXD1 regulates 3D growth and multiple related signaling pathways.…………………..……..……….80
Figure 4.2. RNA-sequencing analysis and drug discovery pipeline.……..……………….……………………….…………83
Figure 4.3. Drug screening pipeline for toxicity screening.……..……………….…………………………..……………….…85
Figure 4.4. Synchronized cell cycle analysis identifies targets that inhibit G2/M progression…………………..88
Figure 4.5. 786-O 3D tumor growth is effected by identified drugs.……………….…………………………..…………..89
Figure 4.6. Nuclear defects of 3D 786-O cultures analyzed from drug treatments.………………..…………………91
Figure 4.7. Drug treatment analysis of primary tumor cell lines.……………….…………………………..………………..95
Figure 4.8. Primary tumor cells can be targeted using AAV delivery system.………………………..………………….96
Figure A.1. FOXD1 grade and stage analyses……..……………….…………………………..……..……………….……………135
Figure A.2. FOXD1 antibody validation…..……………….…………………………..……..………..……………….……………..136

ix

Figure A.3. FOXD1 qPCR reference gene selection.…….…………………………..……..………..……………….……….…137
Figure A.4. FOXD1-null cells difficulty in tumor establishment.………………..……..………..……………….………...138
Figure A.5. Histone H3 Phosphorylation analysis.…….…………………………..……..………..……………….…………….139
Figure A.6. CDC2 Phosphorylation analysis. .…………………………..……..………..……………….…………….……………140
Figure A.7. Cyclin B1 and MICU1 protein analysis. ……..……………….…………………………..……..……………….……141
Figure A.8. EdU pulse-chase analysis..…………………………..……..………..……………….…………….…………………..…142
Figure A.9. FOXD1 correlated genes involved in cell cycle regulation. …….…………………………..……..…………143
Figure B.1. Flow cytometry based cell type marker analysis of three tumors.……………………..……..………….144
Figure B.2. Loss of PDGFRα/β after passaging primary ccRCC cultures.….…………………………..……..……..……145
Figure B.3. Pathway analyses of ccRCC mass spectrometry dataset. ….………………………….………………………146
Figure B.4. Cell attachment on ECM..…………………………..……..………..……………….…………….…………………..….147
Figure B.5. ccRCC cell marker analysis of primary cell lines...………..……………….…………….…………………..……148
Figure B.6. EdU analysis of primary tumor isolates.…………………………..……..………..……………….…………….….149
Figure B.7. Analysis of fibrinogen transcripts from TCGA.………………..……..………..……………….………………….150
Figure B.8. Primary RCC cultures create viable structures in fibrin/ccRCC ECM after 3 weeks. ……………….151
Figure B.9. Incorporation of ECM into fibrin domes.………………..……..………..……………….…………………………152
Figure B.10. ccRCC tumor isolate culture in Matrigel vs fibrin/ccRCC ECM...………..……………….……………….153
Figure B.11. Media formulation influences cell viability of 3D cultures. ..……..………..……………….…………….154
Figure B.12. Further characterization of 3D cultures.…………..……..………..……………….…..…………………………155
Figure B.13. Immunostaining analysis of fibrin/ccRCC ECM cultures for fibroblast markers.………………….156
Figure B.14. Additional analysis of fibroblast markers after 90 days of culture.………….…..……………………..157
Figure B.15. Protein localization in ccRCC tissue.…………..……..………..……………….…..…………………………..…..158
Figure C.1. Cell cycle inhibition by Mitomycin C prevents sphere formation.…….…..…………………………..….160
Figure C.2. FOXD1 status effects ability to grow in 3D tumors, requires ECM addition.………………………..…161

x

Figure C.3. 3D tumor cultures treated with FOXD1 related drugs……………..……..………..……………….…..…….162

xi

CHAPTER 1
REVIEW OF FOXD1 IN CANCER

1.1.

Introduction
Forkhead transcription factors have a variety of roles in cancer [1]. Members of the FOXA, C, M,

O, and P subfamilies regulate cancer initiation, progression and drug resistance. This review focuses an
exciting, but understudied member of this family, FOXD1.
FOXD1 (also known previously as BF-2, FREC-4, and FKHL8) is a transcription factor member of
the FOX “winged helix” superfamily, defined by ~100 amino acid long the helix-turn-helix binding
“forkhead box” DNA binding motif (FKH). Across 19 subclasses (A – S), the FKH domain is conserved
among all members of the family. However, all forkheads have functional diversity, creating great
interest in the differences in the peptide regions outside of the FKH domain [2]. Overlapping and
redundant conserved features allowed for phylogenetic analysis and classification of each forkhead
family member. This structural analysis allowed for some inferences regarding the binding activity
differences between family members with the same domain. One selective factor regards the genomic
location of each FOX gene and their relation to CpG islands for silencing after cell differentiation [3, 4].
Since DNA regions are silenced in large blocks around CpG islands, this would allow control of which
forkheads are actively transcribed and which FKH motifs are accessible. Additionally, amino acid changes
between proteins can conformationally alter the access of the FKH to DNA [5]. More classical control
mechanisms, such as upstream regulation of transcription and post-translational modification by
enzymes and co-factors can control FOX gene activities and explain FOX gene functional diversity.
Although some may bind as homodimers, most FOX genes require binding partners to initiate gene
transcription, leading to another level of FOX activity regulation [2]. By reviewing FOXD1 genetics and
protein sequence, we can get a better understandin`1g regarding FOXD1 and its role in disease.
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FOXD1 is a single exon gene located on chromosome 5: 73,444,826-73,448,777 (465 amino
acids). Genetically, FOXD1 has several GC-rich regions, making it difficult to clone and sequence [6]. At
least one known antisense-RNA associated with FOXD1 is known and validated; FOXD1-AS1. The
function of this lncRNA in regulating FOXD1 itself is not known, although evidence suggests that
antisense-RNA serve as negative regulators of their associated genes [7]. Interesting, an alternative nonprotein coding transcript for FOXD1 (OTTHUMG00000162495) has been predicted by HAVANA project, a
group dedicated to manual annotation of non-coding RNAs [8]. This transcript has two exons and has it’s
start codon at the 5’ end of the FOXD1 gene. We have found through qPCR analysis that both FOXD1AS1, as well as this novel lncFOXD1 transcript, are transcribed even in FOXD1-null cells (data not shown).
How these genes are regulated, and their regulation relative to FOXD1 transcription, needs further
investigation. Besides the forkhead domain, FOXD1 is evolutionarily conserved among mammalian
species. Conservation analysis between 27 mammalian species using PHAST analysis shows high
conservation (56.26%), with the highest level of conservation being within coding regions (data not
shown) [9]. Mutations have been reported and identified for FOXD1 and have been associated with
embryonic resorption and recurrent spontaneous abortions [10]. FOXD1 mutations are uncommon in
most cancers and, in general, is genomically stable [11].
At the protein level, FOXD1 only has a handful of distinct annotated motifs; the forkhead binding
domain (IPR001766), a forkhead-like N-terminal conserved site (IPR018122), and a forkhead-like central
heptapeptide conserved site (IPR030456). These additional conserved sites have been previously
described as essential for the structural helix-turn-helix structural conformation of the FKH domain [12].
A predicted nuclear localization sequence appears on amino acid residues 216-221(RRRKRF), followed by
two polyproline runs with the COOH-terminal domain are predicted to be protein interaction sites [13,
14]. Neither of these have been validated for their functionality. Additionally, the highly GC-rich regions
encode stretches of homopolymeric polyamino acids, currently of unknown function. The NH2-terminal
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domain is hyperacid, potentially serving as a transactivating region [15]. Interestingly, FOXD1 also
contains a predicted TLE/Groucho binding domain (FSIESIIG). TLE/Groucho are a family of transcriptional
corepressors shown to work in conjunction with other forkheads to regulate transcription [16]. In
conclusion, although no physical interaction between FOXD1 and any other protein has been validated,
there are several potential regions for co-factor interactions that may regulate FOXD1 transcriptional
activity.
FOX family genes are classically described as transcriptional repressors [17]. RNA microarray of
Foxd1-/- and wild-type littermates from E14.5 mice indicates that FOXD1 serves a predominantly
inhibitory role during kidney nephrogenesis [18]. However, recent studies have shown the ability of FOX
proteins to promote gene transcription [19, 20]. These studies advance our understanding that FOX
transcriptional regulation is context dependent, and likely determined by their binding partners. Our
misconception of transcriptional suppression by FOX genes may be due to the use of overexpressionconstructs to analyze FOX gene activities. FOX proteins are “potent” when activated and are only ever
found at modest levels in nature [20]. Thus as we review the known and predicted functions of FOXD1,
we need to remember the context which this occurs.
1.2.

FOXD1 in Development
FOXD1 has reported roles in development, having been particularly well characterized in kidney

and eye development, where it marks the interstitial progenitors and ventrotemporal retinal ganglion
cells, respectfully [21]. The role of FOXD1 in these organs has been well reviewed [21]. However, it is
also reported to have a role in brain, lung, reproductive, and skeletal development. Of particular interest
is the role FOXD1 has in kidney, which we believe is the most informative for its role in kidney cancer.
In kidney development, FOXD1 labels the interstitial progenitor cell population during
nephrogenesis. During the early stages of nephrogenesis, the ureteric bud (UB) tips stimulate induction
of metanephric mesenchyme (MM) into SIX2+ nephron progenitor cells (NPC), which go on to
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differentiate into epithelial segments of the nephron why inducted by WNT9b from the UB. At the
cortical edge farthest from the UB tips, mesenchymal cells start expressing FOXD1 and differentiate into
the cortical and renal medullary interstitial progenitors [22]. These FOXD1+ progenitors begin to express
the stromal transcripts PDGFRB, GATA3, and GLI1. FOXD1 is essential for kidney morphogenesis, with its
loss preventing establishment of the stromal progenitor pool [23]. The exact role of FOXD1+ progenitors
in nephrogenesis is still being actively investigated, but current studies point to a direct role of these
cells on epithelization of the SIX2+ progenitors.
Regulation of WNT/β-catenin activity in the nephron progenitors is a key determinant of NPC
epithelization. [24] β-catenin signaling within the stromal progenitors is necessary for WNT9b induction
of NPCs, although a direct pathway has not been elucidated [25]. One key difference between SIX2+
NPCs and FOXD1+ stromal progenitors is the transcription of matrix interaction proteins (ITGA9, ITGA1,
COL3A1) [26]. FOXD1 has been shown to repress the proteoglycan Decorin (DCN), which antagonizes
BMP and SMAD signaling, which is required for transition of NPCs into the WNT-inducible state [18].
Evidence suggests that these early stromal progenitors can modify the extracellular matrix surrounding
NPCs to direct epithelization.
Secreted factor signaling from the stromal progenitors has also been shown to direct
nephrogenesis. Evidence suggests stromal progenitors activate YAP through secretion of FAT4,
concurrently enhancing WNT9b signaling in the nephron progenitor population [27]. Additional evidence
suggests that R-spondin secretion by interstitial progenitors is necessary for maintenance of the
progenitor pool, while also promoting epithelization of induced progenitors by enhancing WNT/βcatenin signaling that drives LEF1 expression [28]. Interestingly, stromal progenitors can also secrete
SFRP1, a WNT antagonist that blocks canonical signaling to maintain the progenitor pool [25]. We can
deduce that the FOXD1+ progenitors are responsible for secreting signals that are NPCs respond to
differentially based on their differentiation state.
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NPCs require signaling cues from the FOXD1+ stromal cells, leading us to ascertain that a deeper
level of regulation of secreted signaling within the FOXD1+ progenitor pool is necessary for
nephrogenesis. However, not much information is currently available regarding the regulation of these
stromal progenitors. It is known that these stromal cells are responsive to sonic hedgehog (Shh)
signaling through a GLI1 dependent expression of smoothened (SMO). Shh is necessary for
differentiation of these stromal cells, with ablation leading to loss of the stromal lineage and improper
nephron differentiation. Additionally, Shh signaling induces TGFB2 expression, which is secreted to
promote NPC epithelization [29]. Stromal progenitors are highly oxygen sensitive and require functional
HIF inhibition for proper nephron patterning. Ablation of VHL from the FOXD1+ lineage inhibits NPC
differentiation, suggesting a potential interaction between FOXD1 and HIF transcription factors [30].
As previously discussed, FOX family gene activity is regulated by interactions with other
transcription factors. Both DCN and FAT3 are regulated by the transcription factor Sall1, although it is
unclear if this is associated directly with FOXD1 [31]. Both WT1 and TP53 have been implicated as having
cross-talk with FOXD1 as well [15]. Recently, interest has been placed on influence of FOXD1 on
transcriptional components of the renin-angiotensin system including ACE, AT1R, and RAS [32]. FOXD1
has also been implicated in regulation of Shh signaling, in which activation causes direct downregulation
of CDKN1C [33]. How FOXD1 is regulated, its transcriptional activity, and its cofactors are still in need of
further analysis.
Looking briefly at other developmental systems, we can spot similarities in the presumed
activity of FOXD1. FOXD1 labels interstitial progenitor cells in the lung and modulates WNT/β-catenin
signaling [34]. In skeletal development, FOXD1+ stromal cells induce fibrotic remodeling by regulating
CCN2 [35]. In testis development, FOXD1 upregulates AMH, SOX9, and PKARIA while downregulating
Androgen receptor in sertoli cells, which is important for development of the organ [36]. FOXD1 was
originally identified in forebrain and is expressed in neural crest cells [37]. FOXD1 is well described in its
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role during development of the optic chiasm and retina [38]. In the optic vesicle, FOXD1 represses
FOXG1, GH6, SOHo1, and ephrin-A5. Interestingly, it was reported that FGF and WNT can induce FOXD1
expression in these same cells [39]. FOXD1 can regulate hormone signaling and secretion, and has been
previously reviewed [40]. In the pituitary, essential FOXD1+ mesenchymal cells secrete signaling factors
necessary for organogenesis [37]. Additionally, reports implicate FOXD1 in regulating cAMP-PKA, PIGF,
VEGF, and TGFB independently [41-43]. We can conclude that FOXD1 labels different populations in
multiple developing organs, controls secreted factor signaling, and regulates gene transcription.
1.3.

FOXD1 in Cancer

1.3.1. Rationale
Outside of development, FOXD1 has reported roles in renal ischemic injury and fibrosis,
osteroarthritis and ossification, inflammation, and rejection of implants [44-47]. A review of FOXD1 by
Quintero-Ronderos et. al in 2018 briefly discussed the role of FOXD1 in disease, as well as in a variety of
cancers [21]. Revisiting the literature, we took particular note of how many articles related to FOXD1 in
cancer have since been published. Hypothesizing that a correlation exists between FOXD1 and cancer,
we performed a literature review to answer this.
1.3.2. Literature review methodology and results
We searched the PubMed database for articles related to FOXD1 and cancer. To include articles
from before completion of the human genome, we included search results with all alternative names of
FOXD1; FOXD1, FREAC4, FREAC-4, BF-2, and FKHL8. Additionally, since there are many different cancers,
we included keywords for every major cancer type: cancer, sarcoma, carcinoma, lymphoma, and
leukemia. Thus we utilized to search queries:
1. FOXD1 articles: (FOXD1) OR (FREAC4) OR (FREAC-4) OR (FKHL8) OR (BF-2)),
2. FOXD1 & CANCER: ((FOXD1) OR (FREAC4) OR (FREAC-4)) OR (FKHL8) OR (BF-2)) AND
((CANCER) OR (SARCOMA) OR (CARCINOMA) OR (LYMPHOMA) OR (LEUKEMIA))))
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The search results were downloaded and annotated the year they were published (Figure 1.1).
What we found was that the number of articles published per year related to FOXD1 increased
dramatically over the last 10 years, with the most publications occurring in 2018. Even more interesting,
studies of FOXD1 and cancer increased as well at that time, with the majority of FOXD1 related articles
published since 2018 being cancer related. We can conclude that there is indeed a role of FOXD1 in
cancer. We next asked if FOXD1 has a negative (suppressor) or positive (oncogene) effect on tumor
growth. To answer this, we reviewed all articles related to FOXD1 and cancer and annotated the tumor,
effect, and reported mechanisms FOXD1 was reported to have (Table 1.1).

Figure 1.1. PubMed FOXD1 Literature Review
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Table 1.1. Summary of FOXD1 in Cancer
Cancer
Head and neck
squamous
carcinoma

Oncogene
or
suppressor?
Oncogene

Colorectal cancer

Oncogene

Nasopharyngeal
carcinoma

Oncogene

Lung cancer

Oncogene

Non-small cell
lung cancer
(NSCLC)

Oncogene

Melanoma

Oncogene &
suppressor

Reported mechanism
- Upregulated in primary tumors.
- Correlated d with metabolic pathways, macrophage
infiltration, EGFR expression, cervical node
metastases
- FOXD1 overexpression increased DNA replication,
cell cycle progression, glycosaminoglycan
biosynthesis, DNA repair, and metabolism
- FOXD1 knockdown inhibited proliferation, migration,
invasion, increased apoptosis
- Upregulated in primary tumors.
- Identified as a top target of prognostic value that
discriminates high and low risk patients.
- FOXD1 upregulated by CXCL5 and VEGFA
- Associated with tumor size, stage, grade, lymph
node metastases, sessile serrated lesions (SSL), and
poor prognosis
- FOXD1 knockdown suppressed proliferation, cell
cycle progression, and induced apoptosis. Elevated
Plk2.
- FOXD1 overexpression activates ERK1/2, migration,
proliferation, decreased apoptosis, improved
radiation resistance.
- FOXD1 knockdown decreased proliferation,
migration, and invasion.
- Downregulated by miRNA-95
- Upregulated in primary tumors.
- Promotes proliferation, migration, invasion, and
resistance to radiation.
- Expression sustained by FOXD1-AS1 and LINC00641
- Overexpression promotes proliferation, migration,
invasion, glycolysis, and suppresses apoptosis.
- Overexpression transactivates Gal-3, ETS-1, and
promotes aggressiveness.
- Upregulated in primary tumors.
- Correlates with malignancy and metastasis.
- Knockdown inhibits proliferation, migration,
invasion, in vivo growth, and activates vimentin.
- Upregulated in primary tumors.
- Correlates with resistance to BRAF and MEK
inhibitors.
- Upregulated by CTGF, ADAR1, and miR-22.

Citation
[48]
[49]
[50]
[51]
[52]

[53]
[54]
[55]
[56]
[57]
[58]

[59]
[60]
[61]

[62]
[63]
[64]
[65]
[66]
[13]
[67]

Table 1.1. Continued.

Oral squamous
cell carcinoma

Oncogene

Oral cancer

Oncogene

Osteosarcoma

Oncogene

Ovarian
carcinoma

Suppressor

Breast cancer

Oncogene

Triple negative
breast cancer

Oncogene

Glioma

Oncogene

- Downregulation decreased MMP19 expression,
increased ITGB3 expression, invasion and migration
in a negative RAC1B dependent manner.
- Inhibited by FZD3, increasing MAPK signaling and
growth
- Upregulated in primary tumors.
- Correlates with stage, relapse, cervical node
metastases, and poor outcomes.
- Promotes tumor cell EMT, stemness marker
expression via SNAI2 and lncRNA CYTOR, and tumor
forming ability in vivo.
- Competitive against miR-1252-5p and miR-3148,
promoting LPP expression.
- Upregulated in primary tumors.
- Correlates with poor patient outcomes, poor
response to radiotherapy, poor immune response.
- Regulates G3BP2 and TP53.
- Inhibits TXNIP and immune response pathways.
- Upregulated in primary tumors.
- Knockdown suppresses proliferation, migration,
invasion.
- Downregulated by miR-30a-5p
- Downregulated in primary tumors. Downregulated in
chemo-resistant tumors.
- Correlated with good prognosis
- Overexpression inhibited proliferation, induced G1
arrest, promotes p21 in a p53-independent manner
- Regulated by miR-30a-5p and miR-200a-5p.
- Upregulated in primary tumors. Upregulated in
irradiation-resistant cells.
- Top scoring gene in hazard ratio analysis. Top scoring
in high risk ER+ breast cancer tamoxifen-treated
patients.
- Knockdown decreased proliferation,
chemoresistance
- Overexpression increased proliferation,
chemoresistance, p27 expression, and G1/S
transition.
- Identified as top prognostic marker of TNBC,
correlating with poor prognosis.
- Knockdown decreased chemoresistance.
- Upregulated in primary tumors.
- Correlates with grade, poor patient outcomes.
- Knockdown decreases cell growth, colony formation
ability, migration, clongenicity, promotes apoptosis
and nuclear fragmentation.
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[68]
[69]
[70]

[71]

[72]
[73]

[74]
[75]
[76]
[77]

[78]
[79]
[80]
[81]
[82]

Table 1.1. Continued.
- Stem-like glioma cells regulated by FOXD1-ALDH1A3
axis. Increases MAPK and signaling.
- Repressed by miRNA-338-5p. Activated by SNHG18
via suppression of miRNA-338-5p.

Esophageal
squamous
carcinoma
Pancreatic ductal
adenocarcinoma

Oncogene
Oncogene

-

Cervical cancer

Oncogene

-

Hepatocellular
carcinoma

Oncogene

-

Prostate cancer

Oncogene

-

Digestive system
carcinoma
Hodgkin
lymphoma (HL)

Overexpressed in primary tumors.
Anticorrelated and downregulated by miR-30a-5p
Promotes invasion in an ERK1/2 dependent manner.
Upregulated by lncRNA OIP5-AS1 which suppresses
miR-30a-5p, enhances ERK1/2 signaling.
Overexpression increases chemoresistance.
Correlated with high LINC0113 overexpression in
primary tumors, which suppresses miR-30a-5p.
Inhibited by miR-127-5p, which is suppressed by
POU3 F3. POU3 F3 overexpressed in primary tumors.
Identified as top target regulating tumor growth.
Upregulated by NORAD through inhibition of miR211-5p.
Enhances angiogenesis through upregulation of
VEGF-A.
Overexpressed in primary tumors and lymph node
metastases.
In castrate-resistant prostate cancer, associated as
target of miR-30a.
Knockdown downregulates cell cycle control genes,
AR-mediated transcription, and suppresses
androgen-independent growth.
Predictive prognostic marker.

[83]
[84]
[85]
[86]
[87]
[88]
[89]

[90]
[91]

Oncogene

-

Oncogene

- Overexpressed in primary tumors.
- Modulates TGFB and WNT signaling pathways,
deregulates B-cell differentiation.
- Upregulated by sonic-hedgehog signaling,
downregulating Nkx2-2as
- Correlated with poor patient outcomes.

[93]

- Top target in list of transcription factors regulating
gastric cancer growth.
- Identified as regulatory element enriched in
metastases.
- Correlated with poor prognosis.
- Knockdown reduced N-cadherin and vimentin,
increased E-cadherin expression.
- Overexpression increased N-cadherin and vimentin,
decreased E-cadherin expression.
- Enhances ZNF532 target gene transcription.

[96]
[97]

Medulloblastoma Oncogene
Renal Cell
Carcinoma
Gastric cancer

Oncogene

Laryngeal
squamous cell
carcinoma

Oncogene

Oncogene
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[92]

[94]
[95]

[98]

1.3.3. FOXD1 is an oncogene
Based on the review of the literature, we conclude that FOXD1 can generally be considered as
an oncogene, or tumor promoting gene. Only two tumor types reported a tumor suppressive role of
FOXD1. First, in melanoma it was claimed that FOXD1 was downregulated by FZD3 based on an enriched
pathway analysis, resulting in a suppression of MAPK-mediated migration and invasion. However, other
publications showed an oncogenic role of FOXD1 in melanoma, being upregulated in primary tumors
and correlating with drug resistance. A more convincing suppressive role was found in ovarian
carcinoma, with publications implicating a downregulation of FOXD1 in both primary tumors and
chemo-resistant tumors. Overexpression actually inhibited proliferation in vitro, leading us to ascertain
that FOXD1 may have a contextual role in normal ovaries that is yet to be defined.
A holistic view of FOXD1 shows similarities between tumors, as well as a few consensus
pathways. In all cases, FOXD1 is upregulated in primary tumors and corresponds to poor patient
outcomes. Knockdown experiments, using cell lines from each tumor type, all showed similar results;
suppressed proliferation, impaired migration and invasion, and increased chemoresistance. Mechanisms
accounting for these phenotypes fall under regulation of the cell cycle, or signaling pathways that
promote cell cycle progression. Cell cycle delays as a result of FOXD1 loss have been shown to cause
dysfunction of DNA repair, regulation of essential cell cycle regulators such as p53, p21, and p27, and
resulting in phase specific stalling at G1/S or the G2/M DNA repair checkpoint. While some publications
attempt to create a direct role of FOXD1 in controlling the cell cycle, no definitive target of FOXD1 has
yet to be identified to account for these effects. Several different signaling pathways have been
implicated that may also account for growth inhibition, including EGF, WNT, and VEGF. However, the
most reported signaling pathway associated with FOXD1 is ERK/MAPK. Regulation of ERK/MAPK controls
whole cell functions, including migration and invasion, and thus is an attractive pathway to analyze.

However, the broadness of ERK/MAPK makes it difficult to delineate a specific role of FOXD1 in the
pathway, and thus further investigation is still warranted.
Another interestingly consensus regarding FOXD1 is regulation by microRNAs. MicroRNAs are a
broad class of non-coding RNA transcripts that control gene expression, usually through silencing by
mRNA degradation. However, recently a greater appreciation of microRNAs has developed due to their
complex and multifaceted roles in direct interactions with transcription factors [99]. In the case of
FOXD1 in cancer, several microRNAs have been implicated in its regulation; LINC00641, LINC0113, miR1262-5p, miR127-5p, miR-211-5p, miR-3148, and miR-30a-5p. Of these, several publications have
pointed to miR-30a-5p as having a direct role in silencing the activity of FOXD1. miR-30a-5p is known to
have tumor suppressive functions, as well as a role in driving ERK signaling [100]. miR-30a-5p is
suppressed by other microRNAs as well, so resolving the regulatory axis of Suppressor-miR-30a-5pFOXD1 will lead us to understand which signaling events are required to induce FOXD1 expression and
activation.
1.4.

The future of FOXD1
FOXD1 clearly has an important prognostic role in many cancers. While a few, such as glioma

and melanoma, have multiple investigators pursuing the understanding of FOXD1 in those contexts,
other cancer fields require more attention into the function of FOXD1. Both the direct transcriptional of
activity of FOXD1, and the signaling necessary to drive its expression and activity, are unknowns. One
possible explanation for FOXD1 overexpression in cancer may have to due to its genomic location on the
short arm of chromosome 5. Translocation and rearrangement of the short arm of chromosome 5 in
common in certain cancers, such as acute myeloid leukemia, melanoma, and clear cell renal cell
carcinoma[101-103]. Polyploidy may also account for these findings and require further analysis. In the
case of this study, we present our investigations into FOXD1 in kidney cancer, and our attempts to
delineate and target its functions within this context.
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CHAPTER 2
FOXD1 REGULATES CELL DIVISION IN CLEAR CELL RENAL CELL CARCINOMA
2.1.

Introduction
Forkhead transcription factors play diverse roles in cancer cells [1]. Members of the FOXA, C, M,

O, and P subfamilies are involved in cancer initiation, progression and drug resistance. Expression of
several forkhead family members has been described in clear cell renal cell carcinoma (ccRCC), a highly
angiogenic tumor originating from nephron epithelium in the cortex of the kidney [104, 105].
The forkhead transcription factor FOXD1 plays an essential role in kidney development [23], and
because developmental programs are frequently misregulated in cancer, we were interested to know
what role it plays in cancer of the adult kidney, specifically ccRCC which is the most common form.
Studies in other types of cancer suggest that it may be an important determinant of tumor biology.
FOXD1 is highly expressed in Hodgkin’s lymphoma and in breast cancer, where it suppresses p27
expression, thereby promoting cell proliferation [74]. In non-small cell lung cancer, FOXD1 expression
correlates with poor survival and increases proliferation [64]. In glioma, FOXD1 expression correlates
with tumor grade and influences proliferation and migration of cells [79]. FOXD1 expression is also
downregulated in chemoresistant ovarian cancers [73].
In this study, we defined an inverse correlation between probability of survival in ccRCC patients
and expression of FOXD1 in their tumors. A knockout was generated to investigate the biological
function of FOXD1 in ccRCC cells. Expression of the known transcriptional target MICU1, a regulator of
mitochondrial bioenergetics, was increased. While a shift in balance between mitochondrial respiration
and glycolysis was seen, overall energy production in null cells was unaltered. Inactivation of FOXD1
caused a significant reduction in cellular proliferation both in vitro and in tumor xenograft assays, and
studies of cells with synchronized cycling times revealed that the G2/M phase of the cell cycle was
extended in mutant cells. Transcriptional pathway analysis in patient tumors supported this finding, and
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investigation of phosphorylation state of histone H3 revealed that it is almost completely abrogated in
FOXD1 null cells. We propose that FOXD1 is required for histone H3 phosphorylation, which is an
essential step in the transition through G2/M.
2.2.

Materials and Methods

2.2.1. Cell lines
786-O (ATCC® CRL-1932™) cells and 786-O FOXD1null were maintained in RPMI 1640 with 1x
GlutaMax, 25mM HEPES, 10% FBS, and 1x penicillin-streptomycin in 37 °C cell culture incubators at 5%
CO2. Cells were passaged for expansion using TrypLE express. For immunostaining, cells were grown on
gelatin-coated sterile coverslips. Mycoplasma testing was performed prior to all experimental testing.
2.2.2

In vivo animal studies
Animal care was in accordance with the National Research Council Guide for the Care and Use of

Laboratory Animals, and all experiments were approved by the Institutional Animal Care and Use
Committee of New York Blood Center, where the Rogosin Institute laboratory is located. All animal
experiments followed the following housing protocols of the New York Blood Center. Complete health
surveillance testing is performed for each murine room quarterly. Interim testing is performed as
necessary. Serology is performed by Charles River Laboratories. Parasitology is performed in-house. The
mice are housed in ventilated microisolator cages with 1 cup of 1/8 inch bed o cobs. Mice are on 5P76
rodent feed and acidified water. Full PPE including head and shoe covers, isolation gown, mask and
gloves, and required before room entry. All procedures are done inside a hood. Once animal leave the
room they do not return. Cages and water bottles are change weekly and other cage materials are
changed every 2 weeks. 6 week old female NCr nude mice (CrTac:NCr-Foxn1nu) were purchased from
Taconic and housed at the New York Blood Center animal facility. Animals were housed in groups of 3-4
per cage. To establish xenografts, 786-O cells and 786-OFOXD1null were expanded, resuspended at 10
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million cells per 200 µl PBS and injected intraperitoneally in the right flanks of 6-week old NCr mice, 6
animals per cell type. 48 hours post-injection, tumor volume was measured using electronic calipers
(V=LxW2). Tumor establishment was determined 7 days from first measurement, as determined from
pilot studies (Figure S3). Tumor growth was monitored every 2-3 days for 60 days. At the end-point,
animals were euthanized with isoflurane followed by cervical dislocation.
2.2.3. TCGA data analysis
Level 3 RNA sequencing data from the Illumina HiSeq platform was downloaded from the TCGA
data portal (www.cancergenome.nih.gov) for 20,532 genes and 528 unique samples. We used the RPKM
(reads per kilobase mapped) as gene expression values and linked this data to the clinical patient data
using the patient barcode. Kaplan-Meier analyses were performed by stratifying gene expression data
for each gene at the median and tested using the log-rank statistic. The survdiff and survtest R functions
were using for Kaplan-Meier analyses, and the coxph function was used for fitting a Cox Proportional
Hazards model to each gene to obtain the hazard ratio.
2.2.4. Patient samples
142 de-identified formalin-fixed, paraffin-embedded ccRCC samples from resected tumors were
obtained from the Maine Medical Center BioBank. This study was approved by the Maine Medical
Center Institutional Review Board (IRB #4202X and IRB #4392).
2.2.5. Immunohistochemistry
Section immunostaining was conducted as previously described REF (Fetting et al., 2014).
Primary antibody FOXD1 (1:100, LSBio LS-B6453) and biotinylated rabbit anti-goat (1:500, Vectorlabs BA5000) were used for immunohistochemistry using Vectastain ABC Elite kit (Vectorlabs PK-7100), and the
color reaction performed using DAB. FOXD1 immunofluorescence in embryonic sections was amplified
using the TSA amplification kit per manufacturer’s instructions (Perkin Elmer NEL756001KT).
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2.2.6. FIJI analysis and quantification of expression
To quantify molecular marker expression, immunostained tumor sections were imaged at five
separate regions, and the percentage of stained cells in each image was calculated using FIJI and used to
calculate FOXD1 staining confidence ratio. To assign FOXD1+ scores to individual tumors, the mean
percentage of FOXD1+ cells from all five images was calculated.
2.2.7. Generation of the 786-OFOXD1null line
786-O cells (ATCC: CL-188; 7 000 3535) were the parental cells used to generate a pool of
FOXD1-null cells. CRISPR/Cas9-mediated knockout cells were generated by the Synthego Corporation
(Cambridge, MA, USA). In brief, guide RNAs were designed to create premature stop codons through
frameshift mutations in the coding region via insertions and/or deletions (Indels) directly upstream of
the start codon of FOXD1. The following sgRNA sequence was used: 5ʹ AUCGGACAUCUCAGUGCUCA-3ʹ
[GGG]-PAM. To generate these cells, ribonucleoproteins (RNPs) containing the Cas9 protein and
synthetic sgRNA were electroporated into the cells. Editing efficiency was assessed upon recovery, 48
hours post-electroporation. Genomic DNA was extracted, PCR-amplified, sequenced using Sanger
sequencing, and analyzed for editing efficiency using Synthego Inference of CRISPR Edits (ICE) software
(ice.synthego.com). Limiting dilution was performed to generate 84 clonal populations and screened for
indels using ICE software as described above. Top scoring lines were analyzed for FOXD1 protein
expression using immunocytochemistry described below.
2.2.8. qPCR analysis of predicted FOXD1 targets
RNA was extracted from 786-O and 786-OFOXD1null cells at 70% confluency using Qiagen RNeasy
Minikit (Qiagen Cat#74134) with DNase step included. cDNA was generated using BioRad iScript
Synthesis kit (BioRad Cat#1708891). A screen of 31 reference genes was performed using BioRad
SsoAdvanced Universal SYBR Green Supermix using the manufacturer’s protocol, and selection of
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appropriate reference genes was performed using BioRad CFX Maestro software Reference Gene
Selector Tool. RPLPPO, HBB, and B2M were chosen for this application. qPCR primers of predicted
FOXD1 target genes were assayed and fold changes were calculated using BioRad CFX Maestro software
using parental 786-O as reference. All assays were performed on CFX384 or CFX96 Touch Real-Time PCR
Detection Systems, in triplicates.
2.2.9

Immunocytochemistry analysis
Immunostaining for FOXD1 in cells is described in brief; cells were fixed in 4% PFA for 12

minutes at room temperature, permeabilized with 0.2% Triton X-100 for 10 minutes at room
temperature and blocked with 10% Chicken Serum in PBS for one hour at room temperature. Binding of
FOXD1 primary antibody (1:100, LSBio Cat#LS-B6453), biotinylated chicken anti-goat (1:250,
ImmunoReagents Cat#CkxGt-003-EBio), and Cy5-conjugated streptavidin (1:250, Jackson
Immunoresearch Cat#016-170-084) were performed sequentially at room temperature, 1 hour each
step and counterstained with DAPI. Coverslips were mounted using ProLong Diamond (Invitrogen
Cat#P36961) mounting medium. The staining protocol was modified for phosphoproteins γH2AX (1:400,
EMD Millipore Cat#05-636) and pH3 (1:100, EMD Millipore Cat#06-579) as follows; cells were fixed in ice
cold 100% methanol and blocked overnight with 10% goat serum and 0.1% BSA in TBS. Primary antibody
incubation was performed overnight, followed by secondary antibody incubation in goat anti-mouse
IgG1 568 (Life Technologies Cat#A21124) and goat anti-rabbit 647 (Life Technologies Cat#A21245).
Coverslips were counterstained with DAPI, Phalloidin Oregon-green (Invitrogen Cat#07466), or EdU
(Invitrogen Cat#C10337) as pertaining to experiment. Staining for mitochondria using TOMM20 (1:100,
abcam Cat# ab186735) was performed using standard immunocytochemistry techniques. Coverslips
were mounted in EverBrite Mounting Media (Biotium Cat#23001). All staining was repeated to confirm
staining patterns.
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2.2.10. In vitro growth rate analysis
5,000 cells of 786-O parent or 786-OFOXD1null were plated into each well of a 6-well plate.
Every 24 hours for 4 days, cells were trypsinized and counted in triplicates. After 4 days, cells were
collected and counted every 48 hours. This experiment was repeated 3 times.
2.2.11. DNA Damage analysis (TUNEL)
786-O or 786-OFOXD1null cells were plated in 8-well chamber slides and cultured for 24 hours. Cells
were then fixed in 4% Paraformaldehyde, permeabilized with 2:1 Ethanol:acetic acid, and DNA damage
was detected using the ApopTag® Red In Situ Apoptosis Detection Kit (Millipore Cat#S7165). In brief,
damaged DNA was tagged with digoxigenin-dNTP, then detected using a fluorescently conjugated antidigoxigenin antibody. Cells were counterstained with DAPI. Extent of DNA damage was analyzed by
counting the number of TUNEL positive foci per nucleus in approximately 300 cells in each group.
2.2.12. Metabolic analyses
2,000 cells of 786-O and 786-OFOXD1null were plated into Seahorse XF96 Cell Culture Microplates
and assayed using XF Glycolytic Rate Assay (N=2) (Agilent Cat#103592-100), XF Cell Mito Stress Test
(N=3) (Agilent Cat#103015-100), or XF ATP Real-Time rate assay (N=2) (Agilent Cat#103020-100)
following manufacturer procedures. 6 technical replicates were analyzed for each biological replicate.
2.2.13. EdU pulse-chase analysis
786-O parent and 786-OFOXD1null were treated (“pulse”) with 5µM EdU for 6, 8, or 10 hours. After
treatment, cells were washed and media was replaced with standard cell culture media. Cells were
cultured (“chased”) for an additional 0, 2, 4, or 6 hours. At each time point, cells were fixed in 100% ice
cold methanol and stored in TBS at 4°C until all time points were collected. Following all collections, cells
were stained using the ICC protocol above, and counterstained with DAPI. EdU was detected following
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the manufacturer’s protocol. Cells were imaged using a Leica Thunder Imager. Cells were analyzed for
co-expression of EdU, γH2AX, and pH3 using the Leica LasX multi-channel analysis package.
2.2.14. Cell Cycle Analysis
786-O parent and 786-OFOXD1null were synchronized using double thymidine block. In brief, cells
were treated for 16 hours with thymidine, washed, and cultured for 9 hours. A second round of
thymidine was added for an additional 16 hours to synchronize cells into G1. Cells were washed and
fresh media was added. Cells were collected at various time points and either fixed in 100% ice cold
methanol or protein extracted using Laemmli Buffer. Following fixation, cells were stained overnight
with DAPI at 4°C before flow cytometry. Flow cytometry was conducted at New York Blood Center Flow
Cytometry Core Facility. Cell cycle distribution was performed on FlowJo software. Entry into mitosis
was determined by Western blot analysis staining for H3 (CST Cat#9706L), pH3(Ser10) (CST Cat#9715),
CDC2 (CST Cat# 28439S), pCDC2(Tyr15) (CST Cat#9111S), pCDC2 (Thr161) (CST Cat#9114S), Cyclin B1
(CST Cat#12231), and Cyclin D1 (CST Cat#2978S). Molecular weight and densitometry analysis were
performed using BioRad Imagelab software and normalized to total protein loaded.
2.2.15. In silico FOXD1 molecular signaling pathway prediction analysis
Gene correlation values were ranked for correlation strength and analyzed using Gene Set
Enrichment Analysis (GSEA), mapping pathway interactions using the Reactome database and further
analyzed using Gene Ontology (GO) analysis [106]. Pathways and interactors were mapped using
Cytoscape [107]. Genes involved in pathways grouped under “Cell Cycle” were summarized and marked
for further investigation.
2.2.16. Quantification and Statistical Analysis
For in vivo experiments, 3-4 animals were used per group. Due to the low tumor retention rate
after 2 weeks of 786-OFOXD1null (12.5%), statistical comparisons between end-point tumor size at 60 days

19

were not possible, and instead comparisons at 15 and 30 days were performed, using Student’s two
tailed t test. All in vitro experiments utilized the Student’s t test for comparisons between 786-O and
786-OFOXD1null. Correlation analyses were conducted using either the Pearson or Spearman rank
correlation as implemented with the R function cor.test, and chi-squared tests were conducted to test
the association between dichotomized variables.
2.3.

Results

2.3.1. FOXD1 expression in ccRCC correlates with poor patient survival
To understand if there could be a role for FOXD1 in ccRCC, we correlated tumor expression with
patient outcomes using data from The Cancer Genome Atlas (TCGA). 528 ccRCC cases were grouped into
high or low FOXD1 expression relative to the median. Patients with FOXD1-low tumors showed
significantly higher probability of survival at all time-points analyzed (Figure 2.1A), supporting a role for
tumor expression of FOXD1 in disease progression. Comparison of FOXD1 expression in tumors of
different grades showed higher FOXD1 levels in higher grades (G1 vs. G3 p=1.2x10-2; G1 vs. G4 p=5.0x104

; G2 vs. G3 p=3.8x10-2; G2 vs. G4 p=1.4x10-3) (Figure A.1A). Comparison of FOXD1 expression at

different tumor stages revealed a significant difference only between stage 1 and stage 4 (S1 vs. S4
p=1.9x10-2) (Figure A.1B). We further investigated if increased FOXD1 expression could have poor
outcomes related to any particular stage and found that high FOXD1 expression significantly correlated
with worse outcomes for patients at stages 2 and 3 (stage 2 p=4.5x10-2; stage 3 p=3.3x10-3) (Figure A.1CF).
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Figure 2.1. FOXD1 expression in ccRCC (A) Kaplan-Meier survival analysis for ccRCC patients with
high versus low tumor expression of FOXD1 based on transcriptome data from The Cancer Genome
Atlas (TCGA). High and low expression were plotted relative to median expression of FOXD1.
*p=6.85E-05. (B-E) FOXD1 expression in ccRCC tumors. Representative examples of tumors with
mosaic nuclear staining (B) and ubiquitous nuclear staining (C). Black arrows indicate positive and
red arrow indicates negative nuclei. (D) Scoring of percentage nuclear staining in 142 resected ccRCC
tumors. For each tumor, five high power fields were scored for percentage of positive nuclei. (E) The
median percentage of FOXD1-positive nuclei in tumors is 58.15% (95% CI 50.6 to 65.7).
To define the expression pattern of the FOXD1 transcription factor in ccRCC, we immunostained
142 patient tumors with a histopathological diagnosis of ccRCC (Table A1). Considering the high degree
of relatedness between forkhead proteins, cross-reactivity of antisera presents a problem. To identify a
FOXD1-specific antibody for these studies, we used Foxd1 null mice to screen for specificity. Foxd1 is
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strongly and specifically expressed in cortical interstitial cells of the developing kidney [23]. Comparison
of immunohistochemical staining using several commercial FOXD1 antibodies revealed that the LS Bio
FOXD1 antibody (LS-B6453) showed specificity for nuclear FOXD1 in cortical interstitial cells of the
developing kidney and did not stain Foxd1 null tissue (Figure A.2A,B). In immunohistochemistry, diffuse
staining is seen in epithelial tubules of adult human kidney tissue (Figure A.2C), and
immunohistochemical analysis of Foxd1 null mouse tissue reveals a similar pattern (Figure A.2D),
indicating that this is antibody trapping. For this reason, we limited our analysis to nuclear staining.
Nuclear FOXD1 was observed in all tumors (Figure 2.1B,C), with extensive inter-tumor variability in
proportion of positive nuclei (Figure 2.1D). Taking into account the variability of scores between and
within samples, we generated a 95% confidence interval for proportion of FOXD1-positive nuclei in
tumors as 58.15 +/- 7.55% (Figure 2.1E).
2.3.2. FOXD1 expression in ccRCC correlates with poor patient survival
To understand if there could be a role for FOXD1 in ccRCC, we correlated tumor expression with
patient outcomes using data from The Cancer Genome Atlas (TCGA). 528 ccRCC cases were grouped into
high or low FOXD1 expression relative to the median. Patients with FOXD1-low tumors showed
significantly higher probability of survival at all time-points analyzed (Figure 2.1A), supporting a role for
tumor expression of FOXD1 in disease progression. Comparison of FOXD1 expression in tumors of
different grades showed higher FOXD1 levels in higher grades (G1 vs. G3 p=1.2x10-2; G1 vs. G4 p=5.0x104

; G2 vs. G3 p=3.8x10-2; G2 vs. G4 p=1.4x10-3) (Figure A.1A). Comparison of FOXD1 expression at

different tumor stages revealed a significant difference only between stage 1 and stage 4 (S1 vs. S4
p=1.9x10-2) (Figure A.1B). We further investigated if increased FOXD1 expression could have poor
outcomes related to any particular stage and found that high FOXD1 expression significantly correlated
with worse outcomes for patients at stages 2 and 3 (stage 2 p=4.5x10-2; stage 3 p=3.3x10-3) (Figure A.1CF).
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To define the expression pattern of the FOXD1 transcription factor in ccRCC, we immunostained
142 patient tumors with a histopathological diagnosis of ccRCC (Table A.1). Considering the high degree
of relatedness between forkhead proteins, cross-reactivity of antisera presents a problem. To identify a
FOXD1-specific antibody for these studies, we used Foxd1 null mice to screen for specificity. Foxd1 is
strongly and specifically expressed in cortical interstitial cells of the developing kidney [23]. Comparison
of immunohistochemical staining using several commercial FOXD1 antibodies revealed that the LS Bio
FOXD1 antibody (LS-B6453) showed specificity for nuclear FOXD1 in cortical interstitial cells of the
developing kidney and did not stain Foxd1 null tissue (Figure A.2A,B). In immunohistochemistry, diffuse
staining is seen in epithelial tubules of adult human kidney tissue (Figure A.2C), and
immunohistochemical analysis of Foxd1 null mouse tissue reveals a similar pattern (Figure A.2D),
indicating that this is antibody trapping. For this reason, we limited our analysis to nuclear staining.
Nuclear FOXD1 was observed in all tumors (Figure 2.1B,C), with extensive inter-tumor variability in
proportion of positive nuclei (Figure 2.1D). Taking into account the variability of scores between and
within samples, we generated a 95% confidence interval for proportion of FOXD1-positive nuclei in
tumors as 58.15 +/- 7.55% (Figure 2.1E).

2.3.3. Effect of FOXD1 knockout on expression of known transcriptional targets
To understand the function of FOXD1, we generated a loss of function renal cell carcinoma cell line
using CRISPR/Cas9. The 786-O cell line, which has a mutation in the VHL gene, is diploid for chromosome
5 on which FOXD1 is located [108] and is therefore a good candidate cell line in which to generate a loss
of function. A guide sequence was identified that would cleave the gene 4 codons downstream of the
ATG and enable selection of edited clones with insertions or deletions causing truncating mutations
(Figure 2.2A). Inference of CRISPR Edits (ICE), a regression algorithm for predicting editing outcomes
from Sanger sequencing data, was used to predict knockout of FOXD1 in clones of edited cells (Figure
2.2B). Clone 2, with a single thymine insertion at the same position in both copies of FOXD1, was
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predicted to encode a protein that is truncated 4 amino acids downstream of the methionine (Figure
2.2C). Sequencing of the top potential off-target genes revealed no unwanted modifications (Table S2).
Immunostaining showed an absence of FOXD1 in the nucleus and cell body of Clone 2 (Figure 2.2D). We
conclude that Clone 2 carries a null mutation in FOXD1 originating from a homozygous single nucleotide
insertion, and we refer to it hereafter as 786-OFOXD1null.
To understand transcriptional effects of inactivating FOXD1, we compiled a list of candidate targets
from previous reports [18, 21, 55, 109]. To ensure accurate measurement of expression by RT-QPCR, we
selected reference genes with stable expression between 786-O and 786-OFOXD1null. Commonly used
reference genes such as GAPDH, HPRT, TUBB, and TBP showed very poor stability between these cell
lines (Figure A.3A). We selected RPLPPO, B2M, and HBB (Figure A.2B-D), and used the geometric mean
of these three assays as the reference value. Target genes associated with the cell cycle were
misregulated, with the exception of PRC1, suggesting a cell cycle perturbation (Figure 2.2E). DCN, PGF,
PUM1, and MICU1 were also misregulated in 786-OFOXD1null.
2.3.4. FOXD1 influences cellular energetics, but does not affect overall ATP production
Considering that ccRCC is a disease of cellular metabolism, misregulation of MICU1 is particularly
interesting because it affects calcium signaling between cytoplasm and mitochondria [109]. In
agreement with previous studies, our data shows that FOXD1 represses MICU1 transcription [109].
Immunoblot revealed a significant increase in MICU1 protein in the 786-OFOXD1null compared to the
parent 786-O (Figure 2.3A). To understand if this reflects an increased abundance of mitochondria in the
786-OFOXD1null, we immunostained both lines for the mitochondrial marker TOMM20, and found
increased signal intensity in 786-OFOXD1null , suggesting increased mitochondrial abundance (Figure
2.3B,C). To test if this altered utilization of oxidative metabolism, we compared 786-O versus 786OFOXD1null using Seahorse XF. Surprisingly, we found a significant reduction in basal mitochondrial
respiration in 786-OFOXD1null (Figure 2.3D), and an increase in basal glycolysis (Figure 2.3E).
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Figure 2.2. FOXD1 knockout affects expression of cell cycle regulators and alters cellular energetics (A)
CRISPR/Cas9 knockout targeting strategy for FOXD1. The FOXD1 locus on chromosome 5 shows the
single FOXD1 exon with the CDS in dark blue and UTRs in light blue. The placement of the guide RNA
(red) relative to the ATG (underlined) is shown below. (B) Knockout prediction score and percentage
of alleles with insertions or deletions (indels) for 82 clones isolated from the CRISPR-edited pool.
Chromosome 5 is diploid in 786-O and clones with 50% indel frequency are predicted to be
heterozygous, while those with 100% indel frequency are predicted to be homozygous. (C) Sequencing
trace of 786-O versus 786-OFOXD1null. Red arrow indicates nucleotide insertion. Bottom: Predicted
protein sequence showing insertion event resulting in modified amino acid sequence (red text) and
premature stop (*). (D) FOXD1 (red) immunofluorescence staining in 786-O versus 786-OFOXD1null,
counterstained with DAPI (blue). (E) Expression of predicted FOXD1 target genes in edited versus
parent cells. *p<0.05.
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However, total ATP production between the lines was equivalent (Figure 2.3F), indicating that
energy derived from increased glycolysis compensates for the decrease in mitochondrial respiration.
Thus, despite elevated MICU1 expression and evidence of increased mitochondrial abundance,
mitochondrial respiration is depressed in the 786-OFOXD1null. The 786-O cell line has a VHL inactivating
mutation and is constitutively hypoxic with elevated baseline expression of HIF2. Persistent expression
of HIF transcription factors represses respiratory chain subunits [110], and we therefore analyzed
expression of genes in the mitochondrial respiration pathway (Figure 2.3G). Modest changes were
found for electron transport chain components, with UQRC2 and COXIV showing elevated expression in
786-OFOXD1null. The ATP transporters ANT1 and ANT2 both showed significant changes, but in opposite
directions making the net effect unclear. Expression of genes encoding pyruvate dehydrogenase kinase
1 (PDK1) and pyruvate dehydrogenase phosphatase catalytic subunit 1 (PDP1) was significantly elevated.
PDK1 and PDP1 act in opposition on the enzyme pyruvate dehydrogenase, which is essential for energy
production from the
TCA cycle. Their simultaneous upregulation in the 786-OFOXD1null suggests that elevated PDK1 may
inhibit the TCA cycle, reducing mitochondrial respiration [111], with concomitant upregulation of the
PDP1 phosphatase as a feedback response. This would be predicted to result in aerobic glycolysis being
favored over mitochondrial metabolism in the 786-OFOXD1null cell. In summary, although mitochondria
may be more abundant in 786-OFOXD1null, our data support reduced mitochondrial energy production, and
our gene expression analysis suggests inhibition of the TCA cycle.
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Figure 2.3. FOXD1 influences mitochondria levels, but does not promote glycolysis (A) Western Blot
analysis of MICU1 in 786-O versus 786-OFOXD1null. Loading was normalized by total protein in each
lane and the full length blot is available in Figure A.7. (B) Immunofluorescence analysis of
mitochondria marker TOMM20 (red). Actin filaments (green) used to outline cell body and DAPI
(blue) used to outline nucleus (N=2 biological replicates). (C) Quantification of TOMM20
fluorescence intensity between 786-O and 786-OFOXD1null using integrated density. * p<0.05. (D) Basal
mitochondrial respiration measured by Seahorse XF mitochondrial stress test (3 biological
replicates). (E) Representative basal glycolytic rate comparison via Seahorse XF glycolytic rate assay
(2 biological replicates). (F) Representative total ATP production rate comparison via Seahorse XF
real-time ATP rate assay (2 biological replicates). For all Seahorse measurements, each biological
replicate was measured in 5 technical replicates. *p<0.05 (G) Expression of genes involved in
mitochondrial respiration in edited versus parent cells. *p<0.05.
2.3.5. FOXD1 is essential for tumor growth in vivo
Although total ATP production is unaffected by inactivation of FOXD1, proliferation is attenuated in
786-OFOXD1null (Figure 2.4A), suggesting that effects on the cell cycle (Figure 2.2E) may be primary rather
than a consequence of energy deficit. To understand if the effect of FOXD1 on cellular proliferation is
reflected in a tumor model, we xenografted cohorts of 6 nude mice with either 786-O or 786-OFOXD1null
(Figure 2.4B) as previously described [112, 113]. After tumor establishment, 70% of 786-OFOXD1null tumors
regressed, compared to only 30% for 786-O (Figure A.4A,B). 786-OFOXD1null tumors that were established
showed significantly reduced growth rate compared to 786-O (Figure 2.4C). FOXD1 promotes expression
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of CDKN1A/p21 [72], and our expression analysis of 786-OFOXD1null showed reduced CDKN1A/p21
expression (Figure 2.2E). CDKN1A/p21 delays the G1 to S transition, and reducing its expression is
predicted to accelerate cycling time, which is contradictory to our observations in vitro and in vivo. To
investigate if FOXD1 inactivation influences the G1-S transition, we performed an EdU pulse-chase
experiment to analyze the percentage of cells able to enter S phase. A 2 hour EdU pulse followed by a 4
hour chase did not show any difference in S phase entry between 786-O and 786-OFOXD1null (Figure 2.4D),
and it is unlikely that the reduced proliferation in FOXD1 null cells is due to delayed G1-S transition.

Figure 2.4. Loss of FOXD1 reduces tumor growth in vitro and in vivo (A) In vitro growth curves for
786-O and 786-OFOXD1null. (B) Xenografts of 786-O versus 786-OFOXD1null cells in nude-beige mice.
Dotted yellow lines outline tumors on days 7 and 60 after injection. (C) Xenograft growth rate
analysis. (D) 786-O and 786-OFOXD1null cells pulsed with EdU for 2 hours and chased for 4 hours. The
percentage of all cells,stained with DAPI (blue) positive for EdU (green) is shown in the bar chart
(N=3).
2.3.6. Loss of FOXD1 causes cell cycle delay at G2/M and inability to phosphorylate histone H3
To determine if the reduced proliferation caused by loss of FOXD1 may be due to stalling at the
G2/M checkpoint, we synchronized cells with a double thymidine block and timed phases of the cell
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cycle by analyzing DAPI incorporation (Figure 2.5A). Corroborating the EdU analysis, both lines proceed
at the same rate from G1 to S phase and by 8 hours both have entered G2/M. While 786-O cells have
largely transitioned out of M by 10 hours, the transition of 786-OFOXD1null out of M is delayed by 2-4
hours. G2/M delay provides an explanation for the reduced growth of 786-OFOXD1null in tumor xenografts
and in vitro.

Figure 2.5. G2 progression and histone H3 phosphorylation at ser10 are impaired in FOXD1 null cells.
(A) Cell cycle analysis of synchronized cells at intervals after release from double thymidine block.
Red arrows indicate a significant difference in phase distribution between lines after 10 hours postblock (N=2). *p<0.05. (B) Western blot analysis of proteins necessary for progression through G2/M
at intervals after release from synchronized block, comparing 786-O and 786-OFOXD1null. Full-length
blots are presented in Supplementary Figures S5, S6, and S7. (C) Representative pH3 (green)
immunocytochemistry of 786-O parent and 786-OFOXD1null of cells in metaphase, counterstained with
phalloidin (blue) and DAPI (gray).
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To further understand when cells pass the G2/M checkpoint, we investigated a panel of markers
selected as follows.. CDC2 and CyclinB1: The activated CDC2-CyclinB1 complex is necessary for
progression through the G2/M checkpoint into mitosis [114]. CyclinB1 steadily rises through the early
stages of the cell cycle until peaking at late G2, after which its level rapidly declines. CDC2, when
phosphorylated on T161, activates the CDC2-CyclinB1 complex and initiates progression through the
G2/M checkpoint. However, phosphorylation at Y15 inactivates the complex and prevents progression
through the checkpoint. In order for cells to proceed into mitosis, CDC2 would need phosphorylation at
T161 and dephosphorylatiom at Y15. In 786-O cells, phosphorylation of CDC2 occurs at both T161 and
Y15 until 10hrs, at which time phosphorylation significantly decreases while T161 levels are still
elevated. By 12 hours, phosphorylation at T161 significantly drops, indicating completion of mitosis.
Additionally, CyclinB1 levels steadily increase until 8hrs before rapidly dropping at 10hrs. This supports
our previous prediction that cells enter G2/M by 8hr post-synchronization, and complete mitosis by 12hr
post-synchronization. In comparison, the 786-OFOXD1null cells maintain elevated p-CDC2(T161) levels
through the same time course, only reducing levels at 14hrs. p-CDC2(Y15) levels in parallel showed
constitutively high levels till 12hr post-synchronization. CyclinB1 peaks at 8hrs, like the parental line, but
this level is maintained until 12hr post-synchronization. Serine 10 phosphorylation of histone H3 at
promoter regions of select genes such as FOS and JUN [115] regulates abundance of the AP1
transcription factor that is required for expression of mitotic regulators including Aurora kinase B [116].
Because of the abundance of this phosphorylation, it is commonly used as a marker of mitosis. We thus
chose to look additionally at pH3 and found that 786-OFOXD1null showed significantly reduced levels of pH3
compared to 786-O at the G2/M-G1 interface (Figure 2.5B, Figure A.5). Despite abundant expression of
histone H3 in 786-OFOXD1null, phosphorylation is very modest compared with 786-O.
Cells were immunostained to understand if the phosphorylation of H3 is reduced in all cells, or if
there are fewer cells with H3 phosphorylation in 786-OFOXD1null compared with 786-O. All nuclei in 786-
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OFOXD1null showed depressed phosphorylation of H3. Phosphorylation of H3 peaks at metaphase, a stage
that is defined histologically by colocalization of actin fibers with chromosomes. Comparing nuclei of
786-O with 786-OFOXD1null at this stage revealed little pH3 in the 786-OFOXD1null (Figure 2.5C, Table A.4).
These findings support a requirement for FOXD1 in pan-chromosome phosphorylation of H3 serine 10.
Overall, loss of FOXD1 results in prolonged time spent at the G2/M checkpoint and an inability to
phosphorylate Histone H3.
2.3.7. FOXD1 expression is necessary for genomic integrity through mitosis
A second essential function of Histone H3 phosphorylation is the condensation of chromosomes,
which depends on serine 10 phosphorylation of H3 throughout each chromosome [117]. Improper
chromosome condensation promotes DNA damage [118], and we therefore compared strand breaks in
786-O with 786-OFOXD1null by staining for TUNEL and found that 786-OFOXD1null cells show a significantly
increased numbers of TUNEL-positive foci per nucleus than 786-O (Figure 2.6A). Each TUNEL puncta
represents DNA strand breakage, and the analysis suggests that only approximately 50% of 786-OFOXD1null
cells have intact genomes compared with 80% of 786-O. In response to DNA damage, cells typically
phosphorylate H2AX (γH2AX) at locations of double strand breaks to indicate regions needing DNA
repair. We further investigated if γH2AX levels were also elevated in 786-OFOXD1null cells, and found a
similar pattern to TUNEL, although the proportions of nuclei staining with γH2AX was greater, suggesting
that this assay is more sensitive (Figure 2.6B). DNA damage is normally repaired during G2/M and cells
that have undergone mitosis should display strongly reduced γH2AX staining.
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Figure 2.6. FOXD1 is necessary for maintaining DNA integrity following mitosis (A) Representative
TUNEL (red) staining of 786-O versus 786-OFOXD1null, counterstained with with DAPI (blue) .
Nuclear TUNEL foci were counted and compared using students t-test (N=3). *p<0.05 (B)
Representative γH2AX (red) immunocytochemistry of 786-O versus 786-OFOXD1null cells,
counterstained with DAPI (blue). Nuclear γH2AX foci were counted and compared using student’s ttest (N=3). *p<0.05 (C) EdU pulse-chase cell cycle progression analysis. Cells in G2 were labeled with
EdU following 8 hour incubation with EdU. Labeled cells were analyzed for pH3 expression every two
hours post-labeling using immunocytochemistry. 100 EdU+ cells were analyzed (N=3). (D) Analysis of
EdU labeled cells in G2 for γH2AX expression every two hours post- labeling by
immunocytochemistry. 100 EdU+ cells were analyzed (N=3). (E) Immunocytochemistry analysis of
γH2AX (green) at different phases of the cell cycle, costained with DAPI (gray) and Phalloidin (blue).
Early M represented by cells in metaphase and late M representing cells undergoing cytokinesis and
entering post-mitosis G1. (F) Correlation of mean FOXD1 expression against all genes found in the
KIRC TCGA database. Ranked values scored using the Pearson correlation coefficient. Gene set
enrichment analysis of ranked FOXD1-correlated genes shows enrichment of REACTOME pathways
related to mitotic entry and progression.
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To understand if DNA damage is repaired during G2, we performed an EdU pulse-chase
experiment. Although synchronizing cells as shown in Figure 2.5A would facilitate this experiment, the
synchronization procedure introduces DNA damage, and would confound the analysis. Based on an S
phase length of approximately 6 hours (Figure 2.5A), we performed an 8 hour pulse to label cells
entering G2 (Figure A.6). Expression of pH3 in 786-O showed a peak at 2 hours following EdU wash-out
and defined a subpopulation that had synchronously transitioned to mitosis (Figure 2.C). By 4 hours
after wash-out, the number of pH3+ cells had returned to baseline, indicating exit of this subpopulation
from mitosis. Immunostaining for γH2AX in this subpopulation revealed that staining peaked
concomitantly with pH3 and declined to 0% 4 hours after wash-out (Figure 2.6D), showing a complete
reset of the chromosomal markers for DNA damage and suggesting comprehensive DNA damage repair
in 786-O. As anticipated, 786-OFOXD1null did not show a pH3 peak (Figure 2.6C), but γH2AX
immunostaining of the pH3+ subpopulation did show a peak at 2 hours after wash-out (Figure 2.6D).
However, γH2AX declined only modestly following the peak, showing that chromosomal damage
markers were not reset, and suggesting remaining DNA damage following mitosis in 786-OFOXD1null. These
findings were replicated with 3 different EdU-pulse labeling time periods (Figure A.6). To determine if
DNA damage was reduced in all 786-OFOXD1null cells, or if the 786-O culture may be a mosaic of cells in
which DNA damage is repaired and cells in which it is not, we compared nuclei of 786-O and 786OFOXD1null cells immunostained with γH2AX, phalloidin, and DAPI to define mitotic cells with colocalized
chromatin and actin (Figure 2.6E). Interestingly, while γH2AX was not detected in cells going through
anaphase in either 786-O or 786-OFOXD1null, we found a significant number of cells with γH2AX in at least
one daughter cell during cytokinesis, indicating that the sustained DNA damage found in 786-OFOXD1null is
likely due to strand breaks that arise during mitosis (Table A.4).
Taken together, our data shows that FOXD1 is required for 786-O tumor cells to undergo mitosis
with DNA damage repair of both daughter cells. To understand if this mechanism could underlie the

33

reduced patient survival seen in ccRCC cases with high FOXD1 tumor expression (Figure 2.A), we
performed a correlation analysis between FOXD1 expression in ccRCC tumors and biological pathways.
First, FOXD1 expression was correlated with expression of all other genes in ccRCC transcriptomes from
the TCGA database (Figure 2.6F). Strongly correlated genes were then analyzed using Gene Set
Enrichment Analysis to identify biological pathways (Figure 2.6G). FOXD1 expression was associated
with cell cycle checkpoint pathways and pathways controlling chromosomal architecture in mitosis,
suggesting that FOXD1 may indeed participate in these processes in patient tumors. The top common
pathway components include members of the nuclear pore complex (SEC13, NUP37), centromere
subunits (CENPM, CENPN, CENPQ), and enzymes (PPP2R5A, PPP2R5B, CDC20, BUB1). Candidate genes
within the top scoring pathways include kinases and phosphatases involved in phosphorylation of
Histone H3 (Figure A.7).
2.4.

Discussion
Our analysis indicates that FOXD1 is required for the appropriate phosphorylation of histone H3,

which maintains DNA integrity during mitosis. The capacity for DNA damage repair differs widely
between different types of tumors, and ccRCC displays moderate genomic damage [Cancer Genome
Atlas Research 119]. ccRCC is generally resistant to both cis-platinum and radiation-induced DNA
damage, suggesting active DNA damage repair in these tumors. Our data suggests that FOXD1
expression is necessary for proper cell division and may serve a protective role during mitosis in tumor
cells predisposed to severe genetic damage.
Based on previous work demonstrating a role for FOXD1 in controlling expression of MICU1,
which regulates calcium flux in the mitochondrion, we hypothesized that reduced proliferative capacity
of FOXD1 null tumor cells may be due to reduced energy production capacity [109]. Metabolic analyses
revealed a bioenergetic shift away from mitochondrial respiration but also demonstrated compensation
by increased glycolysis resulting in unaltered ATP production. In light on this finding, reduced energy
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production does not explain the reduced proliferative capacity. Despite maintained energy production, a
shift towards glycolysis may have consequences for basic cell behaviors such as proliferation through the
production of a range of metabolites for biosynthetic pathways, and in other tumor cell contexts this is
characteristic of increased proliferation [120]. Thus, it is counterintuitive that the bioenergetic shift seen
in FOXD1 null cells would explain reduced proliferation, and the cause is more likely to be a direct effect
on the cell cycle.
The loss of histone H3 phosphorylation seen upon FOXD1 inactivation does not prevent entry
into mitosis, and compensatory mechanisms, such as CENPA nucleosome formation, may allow mutant
cells to complete the cell cycle [121]. We found centromere subunits associated with this complex were
highly correlated with FOXD1 expression, further supporting this possibility (Figure 2.6G). However, the
CENPA nucleosome complex is known to be unstable in vivo and this compensatory mechanism may be
limited to cell culture [122, 123], providing an explanation for the difficulty in generating tumors from
786-OFOXD1null xenografts.
FOXD1 expression is tightly controlled in the adult, and our analyses of healthy human kidney
tissue showed no expression in tubule epithelium, which is the cell population of origin for ccRCC [124].
Foxd1 was initially characterized as a regulator of kidney development through studies in knockout mice
[23], and it is specifically expressed in the progenitor population of the kidney interstitium [125].
Interestingly, recent gene expression analysis has shown a slightly broader expression pattern for FOXD1
in the human fetal kidney, including a subset of progenitor cells of the tubule epithelium [126]. Thus, the
expression of FOXD1 in dedifferentiated tubule epithelial cells in ccRCC may represent partial regression
to a developmental progenitor for the tubule epithelium. The nephron progenitor cell population of the
developing kidney is highly proliferative, and studies in mouse suggest that it relies heavily on glycolysis,
similarly to the ccRCC cell [127]. FOXD1 is located on chromosome 5 approximately 60 megabases from
VHL, which is the most common primary mutation in ccRCC. Thus, an alternate possibility is that FOXD1
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expression becomes deregulated by the genetic hit at the VHL locus that initiates transformation, rather
than being activated as a component of a dedifferentiation program
The finding that FOXD1 expression is mosaic in the majority of tumors indicates that it may be
activated or inactivated in subpopulations of tumor cells. Given its role in promoting cell cycle
progression and DNA damage repair, FOXD1 would be expected to confer a growth advantage, and for
this reason it seems most likely that it is activated in subsets of cells as the tumor ages. Mechanisms
governing cellular localization of FOXD1 are not known, and an alternate explanation for the mosaicism
that we see in patient tumors may be that nuclear FOXD1 accumulation is dynamic and regulated by
environmental factors that differ in distinct regions of tumors. Structure-function studies of the FOXD1
protein and a better understanding of tumor architecture will be required to evaluate these possibilities.
This study uncovers a novel and important role for FOXD1 in controlling division and DNA repair
of ccRCC tumor cells. Further studies aimed at defining how the activity of FOXD1 is regulated will
determine if this is a tractable therapeutic pathway.
2.5.
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CHAPTER 3
THE EXTRACELLULAR MATRIX ENVIRONMENT OF CLEAR CELL RENAL CELL CARCINOMA DETERMINES
CANCER ASSOCIATED FIBROBLAST GROWTH
3.1.

Introduction
Renal cell carcinoma (RCC) is among the ten most common cancers [129], and the most

common histological subtype is clear cell renal cell carcinoma (ccRCC) [130]. Loss of the tumor
suppressor VHL through genetic or epigenetic mechanisms is seen in over 90% of ccRCCs [131]. VHL is an
essential component of the cellular oxygen sensor [132], and its loss induces a persistent pseudohypoxic state that results in a strong angiogenic profile of tumors [133]. Epithelial cells within the kidney
cortex are thought to be the cells of origin for ccRCC, most likely proximal tubule epithelial cells [134].
Within the tumor, transformed epithelial cells are interspersed with a network of blood vessels, and the
ccRCC stroma also contains interstitial fibroblasts, inflammatory and immune cells [135]. Cellular
components of the tumor are embedded in extracellular matrix (ECM).
The ECM environment controls many fundamental properties of tumors including their
proliferation [136, 137], vascularization [138, 139], and invasion [140], and is therefore a key
determinant of their malignancy. The interplay between ECM and tumor cells is complex and
multifactorial. In addition to providing the substrate for cancer cell attachment, ECM determines rigidity,
which profoundly influences tumor malignancy [141]. Also, it directly controls signal transduction in
cancer cells, which governs their behaviors [142]. The ECM is a complex mix of components [143], each
with distinct physicochemical and signaling properties. Thus, the particular ECM composition
characteristic of a tumor type is predicted to play an important role in determining the tumor’s
behavior. Distinct tumors are predicted to differ in their ECM profiles, and this is likely characteristic of
the organ from which they arise as well as the tumor’s cellular composition, with cancer associated
fibroblasts (CAFs) acting as a major source of new tumor ECM [144]. CAFs are major contributors to the
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tumor ECM, but difficulties in isolating and maintaining these cells has limited their study. One
important contributing factor to the difficulties in culturing CAFs may be their dependence on the
complex ECM environment that they generate [145]. Very little has been reported on CAFs in ccRCC, a
tumor type with extensive angiogenic and immunomodulatory stromal component. CAFs are lost over
the course of a few weeks in cultures of dissociated ccRCC tumors encapsulated in collagen I [146], and
mimicking the ECM from which these cells are isolated may be key to their longer-term maintenance.
Cell culture provides an essential tool for the study of human tumor biology, and cultured cells
can be used as avatars of individual patient tumors for drug-response prediction [147]. Considering the
strong influence of ECM on tumor cell biology, it is important that cultures replicate this component of
tumors in addition to the cellular components. The matrix produced by the Engelbreth-Holm-Swarm
(EHS) mouse sarcoma [148] known as Matrigel, Geltrex or EHS matrix extract is widely used to replicate
the ECM environment for cultured tumor cells. The matrix isolated from this tumor is composed of three
major components: laminin, collagen IV, and entactin/nidogen. It is used as the substrate to form
organoids from both healthy and transformed intestinal tissue [149], and has been widely applied to the
study of transformed tissues from other organs [150]. However, the composition of EHS matrix is similar
to the ECM composition of healthy kidney cortex, leading us to question its utility in modelling ccRCC in
vitro. We employed mass spectrometry to identify the major components of ccRCC ECM, and found that
in contrast to healthy kidney cortex, laminin, collagen IV, and entactin/nidogen are minor contributors.
Instead, the tumor ECM is composed largely of collagen VI, fibronectin, and tenascin C. Analysis of single
cell expression data indicates that CAFs may be a major source of tumor ECM production. Tumor cells as
well as stromal cells bind efficiently to a 9-component ECM blend characteristic of ccRCC, whereas little
binding is seen to Matrigel. Primary patient-derived tumor cells bind the 9-component blend efficiently,
allowing us to establish mixed primary cultures with representation of tumor cells and stromal cells.

38

These miniature patient-specific replicas are conducive to microscopy and can be used to analyze
interactions between cells in a model tumor microenvironment.
3.2.

Materials and methods

3.2.1. Sample Collection
Kidney tumor tissue was obtained from surgical nephrectomies performed at the University of
Pittsburgh Medical Center. Cancer diagnosis was performed by certified pathologists. Tissue adjacent to
the surgical biopsy was collected at the discretion of the surgeon. All tissue was maintained in PBS at 4°C
and tested within 24 hours of collection. All tissue specimens received were de-identified using an
honest broker system. Demographical and pathological information provided for the nephrectomy
specimens and whole kidneys may be found in Table 3.1.
Table 3.1. Tissue samples used in ccRCC study. Stage and grade determined by pathologist using the
TNM and Fuhrman systems, respectively. p = primary T = Tumor N =lymph nodes (x = not determine, 0
= none detected, 1 = spread) M = metastasis (x = not determined, 0 = none detected, 1 = spread)

3.2.2. Sample Processing
Samples were processed following the protocol from Pauli et al. [151]. Fresh tumor and adjacent
normal tissue samples were diced and weighed. 100 mg of tissue was flash frozen for Mass
Spectrometry analysis, while remaining tissue was digested in 20x volume DMEM containing 250 U/mL
Collagenase IV (Gibco) + 0.02% Trypsin-EDTA at 37˚C in a shaking incubator set to 200 RPM for up to 2
hours or until media became cloudy. Digest was stopped by adding equal volume of ice cold DMEM
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containing 10% FBS. Any undigested material was filtered with 100 µM filter and placed in vessel
containing 5x volume TrypLE Express (ThermoFisher) and returned to the 37˚C shaking incubator set to
220RPM for an additional 15 minutes. Samples were pooled if necessary and centrifuged at 500xg for 7
minutes 30 seconds at 4°C. Cells were washed with ice cold DMEM, counted and viability determined
using Trypan Blue exclusion, and utilized for downstream assays or frozen in Nutrifreeze (Sartorius)
freezing media.
3.2.3. Proteomic Analysis
Peptide quantitative SWATH mass spectrometry was conducted as described elsewhere [152,
153]. Proteins were prepared to provide approximately 100 µg total protein lysates. Proteins were
reduced (DTT, 60 minutes at 30˚C) and then thiols were capped (iodoacetamide, 30 minutes at 30˚C) in
8M urea. Urea was diluted to 1M with Tris-HCl 8.0, and 1 µg sequencing grade trypsin was added per 3040 µg protein and incubated overnight at 37˚C. Peptides were isolated on preparative C18 reverse phase
spin columns. LC for mass spec: 30 cm x 75 µm (inner diameter) high resolution C18 reverse phase
chromatography. For proteomics informatics, an isotope-free unbiased scanning workflow, SWATH
(Sequential Windowed Acquisition of All Theoretical Mass Spectra) [154, 155] was used to allow isotopefree quantitation of proteins via LC/MS-based measurement of the levels of constituent tryptic peptides.
A Triple-TOF 5600 (Sciex) was programmed to acquire MS/MS data from as many as 100 variable
retention time-widths, as determined by the LC trace of the proteome being analyzed. From these data,
lists of proteins and their relative levels, with appropriate statistics (e.g., p-values <0.05, false discovery
rate, FDR<1%) were provided using a software workflow that is comprised of Sciex proprietary
programs; ProteinPilot (data-dependent peptide ion libraries), PeakView (SWATH app to link SWATH
data and ion library data, quantify peaks, provide FDR and quality control analytics), and MarkerView
(Principle component visualization [156] and statistical analysis of group comparisons). Additional detail
may be found in Supplemental Methods. SWATH and ion library raw data will be located at the
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PeptideAtlas repository, and accessible via the web. PeptideAtlas is a part of the ProteomeXchange
Consortium.
3.2.4. Pathway Analysis
Processed SWATH data was functionally annotated using DAVID, Gene Set Enrichment Analysis
(GSEA), and Gene Ontology Analysis (GO) using only proteins showing significant differential expression
(p-val < 0.05). Exported data can be found in Tables S2, S3, and S4. Additional detail may be found in
Supplemental Methods.
3.2.5. Kidney Tumor ECM Analysis
Processed Mass Spectrometry data was further annotated and sorted using definitions from
matrisomeDB [157, 158]. Samples were grouped and analyzed based on origin, either tumor or adjacent
normal kidney. ECM components containing the gene ontology term GO:0050817 (coagulation) were
labeled and excluded from this analysis. SWATH and DIA datasets were combined and annotated for
differential expression (p-value < 0.05) and relative total protein abundance (%LFQ). Highly abundant
core matricellular proteins (>0.1% LFQ), were renormalized to total percent core matrisome and
statistically characterized. The most abundant targets (% => Quartile 3) were used in the construction of
“ccRCC ECM” blend.
3.2.6. Flow Cytometry
Digested tumor or adjacent normal cells were centrifuged and resuspended at 5x105-2x106
cells/100 µl FACs buffer (Miltenyi). Cells were divided into no antibody control, viability analysis panel
[Propidium iodide, Hoeschst33342, DRAQ7], IgG control [REA-VioBlue, REA-FITC, REA-PE, REA-APC, REAPE-Vio770], staining panel 1 [1:50 CD31-VioBlue (Miltenyi 130-117-227), 1:11 CA9-PE (Miltenyi 130-110057), 1:10 PGFR -APC (Miltenyi 130-105-322), 1:10 PGFRα-APC (Miltenyi 130-115-239), 1:50 CD326-PEVio770 (Miltenyi 130-111-002), 1:50 CD45-FITC (Miltenyi 130-110-631), Propidium Iodide], or staining
panel 2 [1:50 CD10-VioBlue (Miltenyi 130-114-509), 1:11 CA9-PE, 1:50 CD105-PE-Vio770 (Miltenyi 130-
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112-167), CD184-APC (Miltenyi 130-098-357), 1:50 CD326-PE-Vio770, Propidium Iodide), and incubated
in the dark at 4°C for 15 minutes. Cells were washed two times with flow buffer and analyzed using
Miltenyi AutoMACs flow cytometer. Side and forward scatter gating were determined using viability
analysis panel to identify cells vs. debris. Doublets were discriminated against using SSR-H against SSR-L.
Positive gating for each marker was determined using IgG control. Compensation was performed using
the MACS Comp Bead kit, anti-REA (Miltenyi 130-104-693).
3.2.6. Primary Cell Culture
Adapted from Williams et.al [108]. Digested tumor cells were washed and resuspended in 1x106
cells/5 mL High Glucose DMEM containing 10% FBS, 1% GlutaMax (ThermoFisher), 1% PenicillinStreptomycin, 1% Non-Essential Amino Acids (Gibco), and 1% Sodium Pyruvate, and plated onto 5 cm
tissue culture treated plates. Plates were incubated at 37˚C for 24 hours before media change and
imaging. Cells were monitored with media change every 72 hours After reaching 70-80% confluency,
cells were expanded into a 10 cm tissue culture treated dish. Upon reaching 70-80% confluency,
passaged cells were either frozen in FBS/DMSO freeze media or further expanded for downstream
applications.
3.2.7. Cell Line Culture
All cells were obtained from ATCC. 786-O (ATCC CRL-1932), NRK-49F (ATCC CRL-1570), MS1
(ATCC CRL-2279), and RAW264.7 (ATCC TIB-71) cells were maintained or adapted to RPMI-1640
containing 10% FBS, 1% GlutaMax (ThermoFisher), and 1% Penicillin-Streptomycin and grown to 70-80%
confluency on tissue culture treated plates before experiments. Cells were detached from plates using
TrypLE Express (ThermoFisher) with the exception of RAW264.7 cells, which required use of a cell lifter.
3.2.8. Immunocytochemistry Validation of primary cell lines
Upon freeze or expansion of primary cell cultures, 5000 cells in 500 µl of culture media were
transferred into a Cytofunnel and centrifuged for 5 minutes at 1000 RPM in a Shandon CytoSpin
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centrifuge (ThermoFisher cat#A78300003). Slides were dried and frozen at -70˚C. Slides were brought to
room temperature submerged in 4% PFA for 15 minutes. Slides were washed before permeabilization
with 0.02% TritonX-100 in PBS for 10 minutes. Blocking was done using 5% Donkey Serum in PBST for 1
hour at room temperature. Primary antibody staining was done at 4˚C overnight with the following
antibodies and dilutions: Vimentin 1:400 (Sigma V6630), Cytokeratin 18 (R&D AF7619), and PDGFRa/β
1:100 (abcam ab32570). Secondary staining was done alongside DAPI using the following antibodies:
Donkey anti-Mouse AlexaFluor 647 (Invitrogen A31571), Donkey anti-Rabbit AlexaFluor 568 (Invitrogen
A10042), and Donkey anti-Sheep AlexaFluor 488 (Invitrogen A11015). Slides were mounted in
Vectashield (Vector) and imaged on a Leica DMI 6000B. Tumor cells were identified as
VIM+CK18+PDGFRα/β-, while fibroblasts were defined as VIM+CK18-PDGFRα/β+. Analysis was repeated
for three primary tumor lines at passages 1, 2, and 4.
3.2.9. Cell Line Attachment Assays
One day in advance, sterile non-tissue culture treated 96-well plates were coated with ECM
substrates at a concentration of 2 µg/ml in sodium carbonate/bicarbonate binding buffer for 2 hour at
37˚C. Matrigel coating was created by dilution to 8 µg/ml in cell culture media. Plates were then
transferred to 4˚C to incubate overnight. Uncoated wells were incubated with just binding buffer. ECM
coating solution was aspirated before preparing cells and left to air dry in the back of the tissue culture
hood. The following proteins were used for this and all other experiments: Collagen VI (Corning
8064002), HSPG2 (R&D 2364-ER), Laminin (Sigma L6264), Tenascin-C (R&D 3358-TC-050) Fibronectin
(Millipore FC010), Fibrillin-1 (R&D 10224-F1-050), Lumican (R&D 2846-LV), Collagen 12 (Novus NBP188062PEP), Periostin (R&D 3548-F2-050), and TGFBI (CF 3409-BG-050). Single cell suspensions were
diluted to 20 cells/µl in assay media (RPMI-1640 without FBS) and 100 µl were added to each well of
coated or uncoated 96-well plates. Plates were incubated at 37˚C in a cell culture incubator. After 2
hours, wells were aspirated and briefly rinsed with DPBS. Wells were imaged using EVOS microscope
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(ThermoFisher). Cell attachment was determined by morphological characteristics such as cell
spreading, elongation, and presence of projections.
3.2.10. Primary Cell ECM Attachment and Growth
8-well Permanox chamber slides (Nunc) were coated with ccRCC ECM blend or DPBS only and
incubated for 2 hours at 37˚C. Plates were then transferred to 4˚C to incubate overnight. Prior to cell
seeding, chambers were aspirated and dried in back of tissue culture hood. Primary cell digests were
diluted in DMEM without FBS and cultured up to 4 hours at 37˚C. Chambers were then either rinsed and
fixed in 4% PFA for 15 minutes or replaced with DMEM +10% FBS culture media for an additional culture
period of 72 hours before fixation. Fixed chambers were rinsed with PBS before permeabilization with
0.02% TritonX-100 in PBS for 10 minutes. Blocking was done using 5% Donkey Serum in PBST for 1 hour
at room temperature. Primary antibody staining was performed overnight at 4˚C against the following
targets; PDGFRα/β 1:100 (abcam ab32570), CD45 1:100 (Novus NBP2-80652), CD34 (BioRad MCA547G),
PAX2/8 1:200 (Invitrogen 71-6000, ProteinTech 10336-1-AP), Vimentin 1:1000 (Millipore AB5733), CK18
(R&D AF7619), and CXCR4 1:100 (abcam ab124824). After washing, secondary antibody staining
alongside DAPI was performed for 1 hour at room temperature with the following antibodies: Donkey
anti-Rabbit AlexaFluor 568 (Invitrogen A10042), Donkey anti-Chicken AlexaFluor 488 (abcam ab150169),
Donkey anti-Mouse AlexaFluor 647 (Invitrogen A-31571), Donkey anti-Rat AlexaFluor 647 (Invitrogen A21247), and Donkey anti-Sheep AlexaFluor 488 (Invitrogen A11015). Mounting in EverBrite (Biotium
cat#23018). Imaging was performed using Leica Thunder Imager. Images were deconvolved using the
Leica Thunder small volume processing algorithm and analyzed using LASX software. Fibroblasts were
defined as PDGFRa/β +CD45-Vim+ and negative for all carcinoma markers. Endothelial cells were defined
as CD34+CD45- and negative for all carcinoma markers. Immune cells were defined as CD45+CXCR4+/- and
negative for remaining carcinoma markers. Tumor cells were defined as PDGFRa/β -CD45-CD34- and
positive for any two of the following carcinoma markers: CK18, VIM, PAX2/8, and CXCR4. All other cells
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were categorized as “Other”. Distribution of cell types was clustered using ClustVis webtool
(https://biit.cs.ut.ee/clustvis/) using Pareto row scaling. For EdU incorporation analysis, EdU was added
to culture media at final concentration of 5 µM and added to wells of 4 hours after attachment. Cells
were cultured for up to three weeks, at which chambers were fixed in 4% PFA and immunostained as
previously summarized. EdU was detected using the Click-iT EdU Cell Proliferation Kit (ThermoFisher)
standard protocol. Imaging was conducted as stated above.
3.2.11. 3D cultures
Fibrin domes were created following modifications to protocol by Liu et al. [159]. In summary,
fibrin domes were generated by combining fibrinogen (Sigma cat#F8630) at a 1:1 ratio with cells
suspended in culture media with or without addition of ECM proteins. Cell concentration was cell line
dependent following testing; 786-O = 50 cells/µl, S108 = 150 cells/µl, S109 = 150 cells/µl, S114 = 100
cells/µl, Primary Tissue Digests = 200 cells/µl. Thrombin (Sigma cat#10602370001) at a concentration of
0.01 U/µl was added at a volume equal to 10% of total to cell-fibrinogen mix, then immediately spotted
onto glass coverslips at 5 µl per replicate. Domes were immediately placed into a 37˚C cell culture
incubator for 10 minutes to facilitate gelation. Pre-warmed cell culture media (RPMI-1640 containing
10% FBS, 1% GlutaMax (ThermoFisher), and 1% Penicillin-Streptomycin) was carefully added to wells
and allowed to culture in cell culture incubator. Media was changed every 2-3 days. Matrigel domes
were created following modification of protocol by Sato et al [149]. In summary, Matrigel domes were
generated by combining Matrigel GFR (Corning cat#354230) at a 1:1 ratio with cell suspended in culture
media at before mentioned concentrations, then immediately spotted onto glass coverslips at 5 µl per
replicate. Domes were immediately placed into a 37˚C cell culture incubator for 30 minutes to facilitate
gelation. Pre-warmed cell culture media was carefully added to wells and allowed to culture in cell
culture incubator. Media was changed every 2-3 days.

45

3.2.12. Live/Dead and Structure Analysis
At designated end-points (786-O = 6 days, Primary ccRCC Tumor Lines = 30 days, Primary Tumor
Digests = 19 days), media was replaced with Live/Dead staining solution containing 2 μM Calcein-AM
and 4 μM Ethidium homodimer-2 (Ethd2) in culture media (Thermo cat#L3224) and incubated for 30
minutes in culture incubator. In last remaining 8 minutes, Hoechst 33342 (Thermo cat# H3570) at a final
concentration of 5 µg/ml was added to each sample. 3D domes were washed 3x with DPBS and
mounted for fluorescent imaging in phenol-free media. Collected images were deconvolved using Leica
LasX Thunder deconvolution algorithm. Deconvolved images were analyzed for Hoechst 33342 positivity
to identify number of cellular structures. Each structure was designated as either live (Calcein+) or dead
(Ethd2+). Comparisons between culture conditions were done via Students’ T-test.
3.2.13. 3D Dome Immunostaining
3D cultures were fixed in 4% PFA for 15 minutes at room temperature and washed 3x with PBS.
Cell permeabilization was performed using 0.2%TritonX-100 in PBS for 15 minutes. Blocking was
performed using 5% Donkey Serum (JIR cat# 017-000-121) in PBST for 1 hour. Primary antibody
incubation against listed targets was done by incubating overnight at 4˚C at associated dilutions in PBST;
PDGFRa/β 1:100 (abcam ab32570), CD31 1:200 (Invitrogen MA3100), Vimentin 1:1000 (Millipore
AB5733), Renin 1:100 (abcam ab212197), CD45 1:100 (Novus NBP2-80652), ACTA2 1:50 (Sigma A5228),
and CXCR4 1:100 (abcam ab124824). Rigorous washing was performed next day for 6 hours before
secondary incubation with DAPI and following antibodies at 1:250 dilution in PBST at 4˚C overnight;
Donkey anti-Rabbit AlexaFluor 568 (Invitrogen A10042), Donkey anti-Chicken AlexaFluor 488 (abcam
ab150169), Donkey anti-Mouse AlexaFluor 647 (Invitrogen A-31571), and Donkey anti-Rat AlexaFluor
647 (Invitrogen A-21247). Rigorous washing was performed the next day for 6 hours, followed by an
additional overnight wash at 4˚C overnight. Sample clearing was performed in series moving from 25%,
50%, and 80% glycerol every 30 minutes before mounting in EverBrite (Biotium cat#23018). Imaging was
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performed using Leica Thunder Imager. Selected images for publication were deconvolved using Leica
LasX Thunder deconvolution algorithm.
3.2.14. EdU Incorporation and detection
EdU was added to culture media at final concentration of 5 µM and maintained for 48 hours.
Domes were then fixed and immunostained following above procedure above. EdU was detected using
the Click-iT EdU Cell Proliferation Kit (ThermoFisher) standard protocol. Imaging was conducted as
stated above.
3.2.15. scRNA-seq Analysis
scRNA-seq data from Young et al. 2018 was downloaded from BBrowser and used for analysis
[160]. Plots were generated using t-SNE, and clusters were generated by unsupervised k-means.
Identification of clusters was determined through the normalized expression of chosen cell identity
markers (Fibroblasts: PDGFRB, PDGFRA; Epithelia: AQP1, AQP2, EPCAM; Endothelia: PLVAP, CD31, CD34;
Immune: CD45; Cancer; CXCR4, VIM, KRT18, PAX8, PAX2, CA9, CD10), in which a cluster presented
higher than average expression levels of one or multiple cell fate markers and exclusion of other fate
determining markers. After manual categorization of clusters, expression of identified ECM markers was
scored across all clusters based of normalized expression (above average = +, 2x above average = ++, >2x
above average = +++). Comparisons between clusters was done via differential expression analysis of
transcript counts and weighted by log fold change. Data can be found in Tables B.5 and B.6.
3.2.16. ProteinAtlas Analysis
Identified ECM proteins were investigated for expression pattern from immunostained tissue on
ProteinAtlas [161]. If multiple antibodies were available for reference, we chose the one with the
highest level of validation (“Enhanced”). We included or eliminated ECM markers from further analysis
if they met the following criteria: A. If present, had only an interstitial staining pattern in tumors B. If
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present, had only an interstitial staining pattern in normal kidney and C. If present, did not have staining
in the glomeruli of normal kidney. Summarized in Figure B.14.
3.2.17. Immunohistochemistry
Immunostaining of serial sections was conducted as previously described [18] on paraffin
embedded ccRCC tumor sections. Primary antibody PDGFRa/β 1:100 (abcam ab32570) or ACTA2 1:50
(Sigma A5228) and biotinylated goat anti-rabbit 1:500 (Vectorlabs BA-1000) were used for
immunohistochemistry using Vectastain ABC Elite kit (Vectorlabs PK-7100), and the color reaction
performed using DAB. Imaging was performed on a Zeiss Axioskop 2.
3.3.

Results

3.3.1. Isolation and culture of cells from ccRCC tumors using standard methods
To understand the representation of cell types in cultures of ccRCCs, we dissociated 4 ccRCC
tumor samples using previously published methods [151] and analyzed cells by flow cytometry (Figure
3.1A, B.1). Using a panel of markers for tumor cells (CA9 and CD10), immune cells (CD45), endothelial
cells (CD31), epithelia (CD326) and fibroblasts (PGFRα/ +), we found significant representation of viable
cells, determined via propidium iodide exclusion, corresponding to all of these different cell types
(Figure 3.1A-B, B.1). In particular we were interested to see that approximately 7% of cells isolated from
tumors were PGFRα/

+

putative fibroblasts (Figure 3.1B-C). Using a standard protocol for monolayer

tumor cell growth on tissue culture treated plastic in serum-containing medium [108], primary cell
cultures were established and stained for tumor (CK18, vimentin) and fibroblast (PDGFRα/b) cell
markers. PDGFRα/b+ cells were poorly represented in these monolayer cultures; initially the proportion
of PDGFRα/β+ cells plated was 15.04±3.76% but after outgrowth the percentage was only 3.22±0.39%
(Figure 3.1D, B.2). The discrepancy between the flow analysis (7% of cells PGFRα/b+) and first passage of
culture (15% of cells PGFRα/b+) indicates that other cell types may also disadvantaged in this culture
system. One explanation for the paucity of fibroblasts seen after outgrowth of primary cells may be a
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lack of attachment; in establishment of monolayer cultures from primary tumor isolates, a substantial
proportion of cells remained unattached 48 hours after plating. However, the small number of
fibroblasts that did grow out displayed a rounded morphology rather than the characteristic elongated
morphology of fibroblasts, and they were outcompeted after serial passaging (the proportion at passage
5 was 0.55±0.15%) (Figure B.2). This was unanticipated since the culture conditions included 10% fetal
bovine serum, which is reported to provide a potent growth advantage to fibroblasts in primary cell
culture [162, 163]. To ask if we could use a three-dimensional (3D) culture system to improve the
representation of tumor fibroblasts, we seeded cells into Matrigel domes using standard tumor organoid
procedures [149]. While viable cells were detected in the Matrigel (Figure 3.1E), no PDGFRα/

+

fibroblasts could be found after 19 days of culture (Figure 3.1F), demonstrating that these conditions
further disadvantaged fibroblast growth. Based on these findings we concluded that primary ccRCCderived fibroblasts are unexpectedly fastidious in their culture requirements and may require growth
conditions that more accurately reflect the tumor microenvironment. The ECM is a key component of
the microenvironment that strongly influences cell behavior, which led us to investigate the composition
of ccRCC ECM.
3.3.2. Differences in ECM composition between ccRCC and neighboring healthy cortex
Considering its major constituents, Matrigel quite accurately represents epithelial basement
membrane, and we hypothesized that cells isolated from tumors may require a tumor-matched ECM in
order to grow out in proportions representative of the tumor of origin. To compare ECM composition
between ccRCC tumor and healthy neighboring cortex, we performed mass spectrometry analysis of
patient tumor samples. Kidney tumor samples were obtained from surgical nephrectomies, stored on ice
at the time of surgery, dissected and flash frozen within 24 hours of collection.
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Figure 3.1. Identification and culture of fibroblasts from ccRCC tumors. (A) Representative flow
cytometry cell marker analysis of ccRCC tumors can allow distinction of stromal populations (low
side scatter) from cancer cells (high side scatter). (B) Summary of marker analysis of different cell
types from 4 different patient tumors. Viability determined by propidium iodide exclusion. (C)
Identification of fibroblasts using PDGFRα/β, showing distinction from CA9+ tumor cells. (D)
Standard monolayer culture of isolated tumor cells showing lack of PGFRα/β+ stromal cells. Green =
vimentin, magenta = CK18, red = PDGFRα/β, gray = DAPI. (E-F) Subsets of cells from primary tumor
digests are viable when cultured in Matrigel Domes (E) but no evidence of PDGFRα/β + stromal cells
could be found (F). Green = vimentin, red = PDGFRα/β, blue = DAPI.
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Tumors with healthy margins used in this analysis were all stage 3, as determined by a pathologist, and
are listed in Table 3.1. Exploratory SWATH mass spectrometry, conducted using a kidney sample-derived
ion library [164], as previously described [152, 153], was used for this analysis since previous studies
have demonstrated its utility in quantitative profiling of the matrisome in unenriched tissues [165].
Unsupervised clustering of normalized proteomic data, presented as a principal component analysis
(PCA) [156], shows separation between the tumor and adjacent normal cortex tissue primarily on the
first principal component (Figure 3.2A).
SWATH analysis provided relative protein differences between grouped stage 3 ccRCC tumors
and adjacent healthy kidney cortex using Sciex MarkerView. To determine which biological pathways
differ between ccRCC and neighboring healthy cortex, we performed Gene Ontology (GO) analysis
(Figure 3.2B). Mitochondrial metabolism, including oxireductases, metabolite interconversion enzymes,
and dehydrogenases were the most downregulated pathways. This provides a degree of confirmation of
our approach since these pathways are predicted to be downregulated in ccRCC due to the heavily
glycolytic profile of the tumor [166]. Interestingly, the most significant upregulated class was PC00102:
Extracellular Matrix. Confirmatory analyses using GSEA and DAVID were performed, showing similar
results such as clustering of pathways related to ECM signaling (Figure 3.3A, Table B.3) and significant
enrichment of ECM (Figure B.3B, Table B.4) respectively.
To define the specific differences in ECM composition between ccRCC and neighboring healthy
cortex, we used the matrisome database MatrisomeDB [157] to identify ECM proteins from each
proteomic profile. Since we were interested in structural changes between ccRCC and the healthy
cortex, we narrowed our analysis to components of the “kidney cortex matrisome” i.e. glycoproteins,
collagens, and proteoglycans [167]. Substantial differences between tumor and neighboring healthy
cortex were found in both interstitial matrix proteins, such as collagen 6 (COL6A1, COL6A2, COL6A3),
and basement membrane components such as collagen 4 (COL4A1, COL4A2) and laminins (LAMA5,
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LAMA4, LAMB1, LAMB2, LAMC1) (Figure B.2C). While it revealed significant relative changes in protein
abundance, SWATH analysis did not have the sensitivity to accurately measure the abundance of each
protein. Using the same samples, we performed data dependent acquisition (DDA) mass spectrometry,
selecting for the 50 most intense ions. Due to its superior sensitivity, a DDA approach allowed for
accurate quantitation ECM proteins using Maxquant [168]. The most abundant proteins, based on a
normal distribution, were selected and segregated for further analysis (Figure 3.2D). Using both the
SWATH and DDA data, a combined dataset was produced that compares both the differential expression
and quantity of proteins between stage 3 ccRCC tumors and adjacent health cortex (Figure 3.2E).
3.3.3. Transcriptional analysis indicates that tumor fibroblasts are major contributors to ccRCC ECM
Stromal populations are commonly associated with tumor ECM remodeling, and contribute
significantly to tumor growth [169-171]. To determine if these cells could be the source of ECM in
ccRCCs, we analyzed scRNA-seq data from Young et al. [160] for transcripts related to the top ECM
targets we identified. First, we categorized clustered data into tumor and stromal populations using a
panel of markers for each (epithelial: AQP1, AQP2, EPCAM; endothelial: PLVAP, CD31, CD34; fibroblast:
PDGFRα, PDGFRb; immune: CD45; tumor cell: CXCR4, VIM, KRT18, PAX8, PAX2, CA9, CD10) (Figure 3.3A,
Table B.4). Then, we stratified the expression of each ECM component for mean expression and scored
clusters for high and low expression (Figure 3.3B). Two clusters of cells were identified as fibroblasts,
and interestingly these showed the highest expression of a number of genes encoding ECM proteins that
are abundant in ccRCC such as collagen VI isoforms, fibronectin, lumican and collagen XII. Fibroblast
cluster 23 was the most predominant ECM-expressing subset of all cells in the analysis.
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Figure 3.2. ECM protein upregulation in ccRCC. (A) Principal component analysis of mass
spectrometry data from stage 3 ccRCC tumors and matched adjacent healthy cortex shows
separation between tumor and normal. (B) Gene Ontology (GO) analysis of identified proteins shows
highest upregulation of the protein class PC00102: extracellular matrix protein. (C) Analysis of
highest upregulated and downregulated ECM proteins identified by mass spectrometry data and
cross-referenced with the Matrisome database (Matrisomedb). (D) Summary of DDA mass
spectrometry analysis, indicating inclusion of only the most abundant ECM proteins. (E) Combined
SWATH and DDA analyses to visually represent most significant ECM protein changes between
tumor and adjacent normal kidney.
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We hypothesized that this subpopulation of PDGFRα/b+ fibroblasts may be a cancer associated
fibroblast (CAF) population, and we analyzed it further to determine if it expressed a characteristic
transcriptome profile. ACTA2, IGFBP7, TAGLN, MYL9, and MYLK are significantly overexpressed in cluster
23 compared with other PDGFRα/b+ cells, suggesting that this subpopulation may indeed be a ccRCC
CAF population (Figure 3.3C, Table B.6)[172-174].
To spatially identify putative CAFs within tumor tissue, we immunostained patient tumors with
PDGFRα/ to label fibroblasts and pericytes, and ACTA2 to label activated tumor fibroblasts (Figure
3.3D, E). Reflecting the single cell data, there is an extensive PDGFRα/b population within the stroma of
the tumor tissue (Figure 3.3D). The ACTA2-expressing population is a small subset of these cells that is
disseminated within the stroma (Figure 3.3E). The scRNA-seq analysis also revealed that the ACTA2-high
putative CAF population shows high expression of REN (Figure 3.3C, Table B.6), suggesting that it
overlaps with the renin-producing cell population identified within the ccRCC stroma by other
investigators [175].
3.3.4. Binding of tumor and stromal cells to ccRCC ECM components
In healthy tissue of the cortex, ECM is organized into basal lamina on which epithelial cells sit,
and interstitial ECM which provides structural integrity and conduits for vasculature and nerves. A
representative section from adjacent healthy cortex stained for the basal lamina component laminin and
the interstitial component collagen VI is shown in Figure 4A. Healthy proximal tubule epithelia are
characterized by basal localization of laminin, which separates them from interstitial ECM components.
In contrast, ccRCC tissue shows a breakdown of this stereotypical arrangement with mixing of basal
lamina and interstitial ECM components (Figure 3.4B). Based on this analysis, we conclude that cells
within tumors are exposed to a mixture of basal lamina and interstitial ECM components, in contrast to
healthy proximal tubule epithelial cells which are only exposed to the basal lamina. Using the relative

54

abundances of ECM proteins characterized in our proteomic analysis, we generated an ECM blend
characteristic for ccRCC (Figure 3.4C). This blend is based on the nine most abundant components
identified in our analysis and includes approximately 80% of all components identified in tumor ECM. To
define the binding profiles of tumor and stromal cells to individual proteins that are most abundant in
tumor ECM, we measured the binding capacity of cell lines representative for each cell type to ECM
components using a monolayer attachment assay. Tumor cells (786-O), fibroblasts (NRK-49F),
endothelial cells (MS1), and macrophages (RAW 264.7, abbreviated to RAW) were used to represent the
common cell populations found in tumors. Single cell suspensions were given 2 hours to attach to ECMcoated or uncoated wells before quantification of bound cells (Figure B.4). This time-point was chosen
as it precedes non-specific attachment of cells to uncoated polystyrene (data not shown). As a
comparator we included Matrigel, which is commonly used to model tumor ECM and enhance
attachment of tumor cells. Attachment to Matrigel was seen with endothelial cells and fibroblasts, while
tumor cells and macrophages attached poorly. In contrast, all cell types attached efficiently to the 2
most abundant ECM molecules that we identified in tumors by mass spectrometry: collagen VI and
fibronectin. We found that the cell lines analyzed shared common preferences to our chosen ECM
components (Figure 3.4D). Fibronectin (FN1), collagen VI (COL6), collagen XII (COL12) and heparan
sulfate proteoglycan 2/perlecan (HSPG2) showed the strongest binding across all cell types. Some
components repelled certain cell types, for example TGFBI which decreased cell attachment of
fibroblasts, and lumican and tenascin C, which reduced attachment of tumor cells.
To validate if these findings could be applied more broadly to ccRCC tumor cells, we isolated
primary tumor cell cultures from three patient tumors as described in [151]. Cell lines S108, S109, and
S114 express characteristic markers of ccRCC tumor cells, but show distinct morphologies (Figure B.5).
The cell binding study was repeated using these primary tumor cell lines and showed a binding profile
very similar to 786-O, with strong binding to fibronectin, collagen VI and collagen XII, and inefficient
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binding to or repulsion by periostin, lumican and tenascin C (Figure 3.4D). Results from these
experiments suggest that a core group of ECM molecules promotes attachment of diverse ccRCC tumor
cells.

Figure 3.3. Prediction of cellular sources of matrix molecules based on scRNA-seq. (A) scRNA-seq
analysis of ccRCC tumors from Young et al. [160]. Unbiased clustering was performed and clusters
were identified using cell-type-representative transcripts. Distinct fibroblast subclusters are
indicated and outlined in red. (B) Differential ECM gene expression analysis of clusters identified as
discrete cell populations. Endo. = endothelial cells, Fibro. = fibroblast cells (C) Comparative transcript
analysis between fibroblast sub-clusters 23 and 14 shows differential expression of cancer
associated fibroblast markers. (D-E) Representative IHC from patient ccRCCs for PDGFRa/b+ (D).
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Figure 3.4. ECM effects on tumor and stromal cell attachment. (A) Immunofluorescence staining of
healthy human kidney showing structured tubule basement membrane separating CD10+ proximal
tubule epithelium from interstitial collagens (white arrowheads). Blue = DAPI, green = laminin, Red
= collagen 6 alpha 1, cyan = CD10 (B) Immunofluorescence staining of ccRCC tumor for ECM
components showing loss of the tubule basement membrane and mixing of laminin and interstitial
collagens (white arrowheads). Blue = DAPI, green = laminin, red = collagen 6 alpha 1, cyan = CD10
(C) Pie chart summarizing major components of ccRCC ECM from mass spectrometry analysis. (D)
Analysis of attachment of cell cultures to ECM components identified by mass spectrometry. Cell
attachment to 2 µg/ml of indicated ECM-coated wells was determined after 2 hours. Heatmap
indicates increased cell attachment (red) and decreased attachment (blue) relative to no coating
condition ("None"). (E) Cell attachment to coated dishes in the presence of all proteins or lacking
one component, indicated by "-" sign. Analysis was done relative to complete blend condition "All".
Total percentage each individual component takes up in the total blend (2 µg/ml total protein) is
indicated in the "%" column. (F) Freshly digested tumor tissue 72 hours after plating on ccRCC ECM
or noncoated plates. Scale bar = 20 µm. Blue = DAPI, green = CD34, red = PDGFRα/β, cyan = CD45.
(G) Cluster analysis comparing cultures grown on coated or uncoated chamber slides to initial cell
input.
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We were interested in understanding if there could be synergistic activities between ECM
molecules identified in our study, and we next asked how the effects of the single components would
compare to a combination of all molecules in our ECM blend. We found that all cell types adhered more
efficiently to our ccRCC ECM blend compared to Matrigel with the exception of endothelial cells (Figure
3.4E). To understand the contribution of each component of the blend, we subtracted them individually
and compared the binding efficiency of cells to the complete blend (Figure 3.4E). Although removal of
certain components could increase the binding efficiency of individual populations, removal of no one
individual component promoted attachment of all.
3.3.5. ccRCC ECM blend binds diverse cell types isolated from patient tumors
Based on the results of our cell binding experiments with immortalized and primary cell lines,
we predicted that the ccRCC ECM blend could capture discrete cell populations directly from patient
tumors. Utilizing previously published techniques [151], we dispersed ccRCC patient tumor samples into
single cell suspensions which we gave 2 to 72 hours to attach to ECM-coated or uncoated chamber
slides. Due to the poor attachment of cells to Matrigel, we did not include this coating as a comparator.
The following markers were used to identify stromal cell populations: fibroblasts (PDGFRα/β),
endothelia (CD34), and immune cells (CD45) (Figure 3.4F). At each time point analyzed, the percentage
of each cell type was compared to the percentage of original input cells determined from a smear of the
cell suspension isolated from each tumor. Cluster analysis based on cell composition was performed to
identify the culture condition that best matched the repertoire of original input cells derived from the
tumor (Figure 3.4G). While showing an increased preference for fibroblasts and tumor cells, the ccRCC
ECM blend after 2 hours was the closest match to the input. Following 72 hours, while no longer
accurately reflecting the initial input, the ccRCC ECM blend better maintained the distribution between
fibroblast and immune cells when compared to no ECM. Additionally, endothelial cells were also better
maintained, although at reduced abundance compared to earlier time points. To understand if the
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change in cell distribution after 72 hours was due to differences in cell growth, primary cell mixes were
cultured on ccRCC ECM coated chamber slides in the presence of the thymidine analog EdU, which is
incorporated into DNA of cycling cells. EdU was supplemented for the first week of culture (“pulse”), and
subsequently removed for one week (“chase”) to label dividing cells. 2 out of 3 samples analyzed had
viable cells by the end of this time course. Although the distribution of fibroblasts was better maintained
on ccRCC ECM compared to no ECM, little EdU labeling was found on these cells, indicating that ccRCC
ECM promoted survival but not proliferation (Figure B.6).
In conclusion, the use of ccRCC ECM can improve the capture of unique cell populations from a
tumor sample and can better maintain different cell identities from 2 to 72 hours when compared to
conventional monolayer tissue culture conditions. However, the monolayer culture system was unable
to promote outgrowth of fibroblast populations, regardless of ECM coating.
3.3.6. Design of a 3D model of ccRCC with native ECM environment
Although the inclusion of ccRCC ECM in monolayer culture showed improved cell representation
from tumors over Matrigel- and non-coated conditions, poor viability after extended culture was
problematic. The use of 3D organoid culture systems for in vitro tumor modeling has gained traction
over the past decade due in part to the ability to maintain characteristics of the tumor of origin [176179]. However, attempts to establish 3D organoid cultures from ccRCC tissue have shown a low rate of
success [151]. The basis for many 3D organoid model systems is generally Matrigel, which poorly
matches the ECM environment of ccRCC (Figure 3.2B-E). We postulated that utilization of ccRCC ECM in
a 3D culture system would improve both viability of tumor cells and representation of stromal
populations from ccRCC tumors. Fibrinogen is an attractive hydrogel substrate due to its tunability and
fibrin gels have been used in wound healing, drug delivery, cell differentiation, and cancer modeling
[180]. Fibrinogen is abundantly represented in tumors and can therefore be considered a component of
the tumor microenvironment, making it a particularly attractive candidate matrix for in vitro modeling.
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Differential analysis of tumor versus normal mass spectrometry data from this study showed increases
in fibrinogen components FIBA, FIBB, and FIBG in tumors relative to healthy cortex, making up a
significant percentage of total protein identified in ccRCC tumor samples (FIBA = 4.00%, FIBB = 4.83%,
FIBG = 6.79%). Additionally, analysis of the Renal Cancer subset of The Cancer Genome Atlas (TCGA)
database identifies fibrinogen genes as highly upregulated in kidney cancer tissue (fibrinogen-High >60%
of samples), indicating that it is locally expressed and not simply deposited by the circulation (Figure
B.7). From these observations we conclude that fibrinogen is a native ccRCC tumor component that can
be used as a versatile matrix to mimic the tumor ECM environment by mixing with ECM components
identified in this study.
Fibrin 3D cultures were established by mixing single cell suspensions with fibrinogen and
thrombin and spotting onto glass coverslips. The surface tension of the glass maintains a dome of cellfibrinogen mixture that gelates at 37˚C. Dome volumes up to 20 µl gelated within 10 minutes and were
subsequently submerged in medium for the duration of the culture period. Growth of tumor cells in
domes was monitored by microscopy throughout the culture period. Fibrinogen concentration
determines viscosity of the hydrogel, which determines growth properties of tumor cells. Spheroidal and
branching tumor cell aggregates have been identified in previous studies of 3D tumor cell growth. While
the spheroidal conformation has been associated with growth of colonies from tumor stem cells [181,
182], branching growth patterns have been associated with invasive behaviors of tumors [183, 184]. To
define a concentration for use in our studies, we analyzed 3D growth patterns of 786-O ccRCC cells in
fibrin domes at 3 concentrations of fibrinogen: 2 mg/ml, 4 mg/ml, and 10 mg/ml. Cells were grown in
Matrigel domes as a comparator. One hundred 786-O cells were seeded per 5 µl dome and
subsequently cultured for 2 weeks to ensure that the fibrin remained polymerized over an extended
culture period (Figure 3.5A-C). Fibrin dome integrity and tumor cell growth were observed in all
conditions, but variations in fibrinogen concentration drastically changed 3D growth patterns.
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Figure 3.5. 3D culture of 786-O utilizing tumor-specific ECM. (A-C) Modification of fibrinogen
concentrations, 2 µg/ml, 4 µg/ml, and 10 µg/ml changes morphology of cell structures formed by
786-O cells. Yellow dotted line outlines region containing 3D dome. Red dotted line indicates region
of magnified inset. (D-F) Live-dead analysis of cell structures found in fibrin domes with 4 mg/ml
fibrinogen shows viable elongated structures (E) as well as ones with necrotic cores (F). Arrowhead
indicates viable cells. Arrow indicates dead cells. Blue = Hoechst33342, green = calcein-AM, red =
ethidium homodimer 2. (G) Analysis of spheroids in Matrigel or fibrin with or without added ccRCC
ECM proteins showing changes in number of spheroids and size. (H-I) Example of 786-O growth in
Matrigel versus fibrin mixed with collagen VI (additional single ECM component blends with fibrin
are shown in Figure S6). Yellow dotted line outlines region containing 3D dome.3.7 3D ccRCC ECM
model maintains ccRCC fibroblast representation
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At 2 mg/ml, cells grew predominantly in branching structures (Figure 3.5A), while a mix of
spheroid and branching structures was seen at 4 mg/ml (Figure 3.5B). At 10 mg/ml, cells grew in
spheroids (Figure 3.5C). Both branched and spheroidal structures contained viable cells (Figure 3.5D-F).
Necrotic centers were observed in spheres larger than 40 microns diameter (Figure 3.5F). We reasoned
that an intermediate concentration would be best for maintaining heterogeneity in patient derived
samples since it promoted both growth patterns. To verify this, we studied growth patterns of three
primary tumor cell lines in fibrin dome cultures at 4 mg/ml fibrinogen concentration and confirmed that
we can generate viable multicellular structures with a variety of morphologies (Figure B.8).
We next asked if we could incorporate ccRCC ECM components into the 3D culture system, and
if this would enable analysis of 3D cell growth. 786-O cells were grown in Matrigel or 4 mg/ml fibrin
domes containing 4 µg/ml ECM proteins (Figure 3.5G, H, B.9). Nine days after seeding, cultures were
analyzed for the presence of multicellular spheroid structures (Figure 3.5I). While larger spheroids were
formed in Matrigel, the total number of structures was small, and many cells spread in a monolayer on
the glass instead of growing in the 3D gel (Figure 3.5H). In comparison, cells grown in fibrin generated
more multicellular structures (Figure 3.5I, B.9). The incorporation of ECM components into fibrin
significantly increased the size of structures (Figure 3.5G). Interestingly the inclusion of laminin, a
primary component of Matrigel, to fibrin increased spheroid size when compared to fibrin alone while
also maintaining a greater number of clusters when compared to Matrigel (Figure 3.5G). This suggests
that other components of Matrigel limit abundance of multicellular structures. In conclusion, we show
that fibrin is an appropriate carrier for ccRCC ECM components, can be used to culture both
immortalized and primary cell lines, and can be a useful tool for studying the effects that the ECM has
on ccRCC growth.
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Figure 3.6. Fibrin/ccRCC ECM 3D culture maintains viable ccRCC fibroblasts. (A) 3D cultures of
primary tumor digests culture either in Matrigel or fibrin/ccRCC ECM domes. * p <= 0.05. (B)
Viability analysis of structures based on calcein-AM/ethidium homodimer 2 staining. * p <= 0.05. (C)
Representative example of viable multicellular structures from patient derived ccRCC tumor digests
cultured in fibrin/ccRCC ECM domes. Green = calcein-AM, red = ethidium homodimer 2, blue =
Hoechst33342 (D-E) Presence of VIM+/CXCR4+ in both Matrigel and ccRCC ECM cultured ccRCC
primary digests. Arrowhead indicates CXCR4+ cells and arrow indicates CXCR4- cells. Green =
vimentin, red = CXCR4, blue = DAPI. (F) Quantification of VIM+ cells in Matrigel versus fibrin/ccRCC
ECM shows significantly more positive cells in cultures from fibrin/ccRCC ECM compared to Matrigel.
However, significantly more VIM+/CXCR4+ are found in Matrigel compared to fibrin/ccRCC ECM * p
<= 0.05 (G-G’) Multicellular structures show expression of fibroblast markers PDGFRα/β (red) and
vimentin (green), as well as presumed ccRCC CAF marker ACTA2 (cyan). Blue = DAPI. Arrowhead
indicates presence of PDGFRα/β+/ACTA2- cells. (G”) Some VIM+ structures do not express
PDGFRα/β. Green = vimentin, red = PDGFRα/β, blue = DAPI. (H-K) Fibrin/ccRCC ECM cultures were
maintained for 90 days (H) or passaged 1:4 into fibrin/ccRCC ECM (I), at which point EdU was
incorporated for 48 hours. Cultures were immunostained (J-K) for EdU (green), PDGFRα/β (red), and
ACTA2 (cyan). Blue = DAPI. (L-M) Cultures were immunostained additionally for renin (red).
Arrowheads indicate renin+ cells. Green = EdU, cyan = ACTA2, blue = DAPI. White staining is overlap
between red and cyan. Arrowheads indicate renin+ cells.
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Having established both that ccRCC ECM supports attachment of diverse cell types isolated from
primary tumors, and that these factors can be mixed into a fibrin hydrogel matrix that supports 3D
tumor cell growth, we wanted to know how this tumor-mimicking 3D environment affects growth of
primary tumor isolates compared to the current standard Matrigel. We digested 5 different patient
tumor samples into single cells using previously described methods [151]. We then seeded 750-1,000
viable cells into replicate 3D domes of either Matrigel or fibrin/ccRCC ECM. 3D cultures were maintained
for 19 days, at which point we analyzed the number of multicellular structures and cell viability using
Calcein-AM and Ethidium Homodimer-2 (Figure B.10). As expected, significant variation was observed
between patient samples. For all samples, multicellular structures were seen in both fibrin/ccRCC ECM
and Matrigel domes. However, for samples S215 and S145, significantly more 3D structures were seen in
ccRCC ECM compared with Matrigel (Figure 3.6A). Approximately half of the structures seen in all
samples were comprised of viable cells in both fibrin/ccRCC ECM and Matrigel, and S145 displayed
significantly more viable cells in Matrigel (Figure 3.6B-C). Interestingly, the lowest viability was seen in
the samples with most abundant 3D structures. From these studies we conclude that fibrin/ccRCC ECM
can be used to propagate 3D structures from primary tumor isolates with a similar efficiency to Matrigel.
To understand which cell types are represented in 3D cultures from primary tumor isolates grown using
ccRCC ECM versus Matrigel, we immunostained them for molecular markers on day 19 of culture.
Vimentin and CXCR4 are widely used to identify cell types within tumor cultures; co-staining
differentiates vimentin-positive CXCR4-negative (VIM+/CXCR4-) presumptive fibroblasts from vimentin
and CXCR4 co-expressing (VIM+/CXCR4+) presumptive cancer stem cells that have previously been
reported to grow out in 3D Matrigel cultures [185, 186]. As expected, clusters of VIM+ tumor cells were
prevalent throughout cultures established in both Matrigel domes (Figure 3.6D, B.11) and fibrin/ccRCC
ECM cultures (Figure 3.6E, B.11). Quantification revealed that 66% of cells in Matrigel were VIM+
whereas over 90% of cells in fibrin/ccRCC ECM were VIM+. (Figure 3.6F). Comparison of CXCR4
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expression within the VIM+ cell populations showed that CXCR4 was expressed in over 80% of cells in
Matrigel domes, as expected (Figure 3.6F). However, only in 41% of VIM+ cells were CXCR4+ in
fibrin/ccRCC ECM (Figure 3.6F). From this we conclude that approximately 55% of cells in 3D Matrigel
cultures are VIM+/CXCR4+ presumptive tumor cells and approximately 10% are VIM+/CXCR4presumptive fibroblasts. In fibrin/ccRCC ECM cultures approximately 37% of cells are VIM+/CXCR4+
presumptive tumor cells, and 53% are VIM+/CXCR4- presumptive fibroblasts. Our previous studies and
published reports have shown that fibroblasts fail to thrive in Matrigel, and we were therefore
interested in understanding the identities and growth properties of the VIM+/CXCR4- presumptive
primary fibroblasts in Matrigel versus fibrin/ccRCC ECM cultures.
To compare fibroblast representation, cultures were stained for the fibroblast marker PDGFRα/β
and, as previously observed in this study, few PDGFRα/β+ fibroblasts were found in Matrigel cultures
(less than 3% of cells in the culture) (Figure 3.1F, B.12). However, abundant clusters of fibroblasts were
observed in the fibrin/ccRCC ECM cultures (more than 33% of cells in the culture) (Figure 3.6G-G’, B.12).
Interestingly, we also found expression of ACTA2 in many PDGFRα/β+ clusters in fibrin/ccRCC ECM
cultures (Figure 3.6G, arrowhead; 16.5% ACTA2+ in the culture). In contrast to Matrigel, the fibrin/ccRCC
ECM 3D culture method maintains robust representation of ccRCC fibroblast populations from primary
tumor isolates.
To understand if ccRCC fibroblasts can be maintained in fibrin/ccRCC ECM 3D culture, we took
two separate approaches. First, we extended the culture period to 90 days to understand if fibroblasts
remained viable over longer periods in this culture system (Figure 3.6H). Second, we subcultured ccRCC
ECM domes into fibrin/ccRCC ECM domes to determine if it was possible to propagate fibroblasts
(Figure 3.6I). EdU was incorporated into the culture medium to assay for proliferation in both
experiments (Figure 3.6J-M). Following long term culture, 28.5% of cells were PDGFRα/β+/ACTA2+ and
showed EdU incorporation (Figure 3.6J, B.13), revealing very little decline in fibroblast number from the
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33% proportion quantified at 19 days and suggesting that they continue to proliferate to maintain their
proportion of the total culture. Following subculture, 63.6% of cells in the second passage were
PDGFRα/β+/ACTA2+ fibroblasts with EdU incorporation (Figure 3.6K), showing that these cells can be
propagated in these conditions without losing marker expression and indicating that their proportion of
the total culture can be expanded by passaging.
Although the renin expressing subset of fibroblasts is small in patient ccRCCs, transcriptome
analysis indicates that it may be a significant contributor of ECM proteins (Figure 3.3B). To understand if
this cell type is maintained following extended culture or subculture we co-stained samples for ACTA2
and renin. Following 90 days of culture, analysis of ACTA2+ cells show that 29.2% are renin+, and
following subculture, 27.7% are renin+ (Figure 3.6L-M, 3.13). In both cases, ACTA2+/renin+ were labeled
with EdU indicating that they are proliferative (90 day culture = 21.42% EdU+; subculture = 31.8% EdU+).
Thus, the unique and poorly understood ccRCC CAF population is maintained and propagated in
fibrin/ccRCC ECM with maintenance of the distinct tumor fibroblast repertoire.
3.4.

Discussion
Neoplastic transformation of an epithelial cell initiates tumor formation, but the interaction of

the transformed cell with non-transformed cells in its environment controls tumor formation. Numerous
studies have shown that the reciprocal interactions between transformed cells and their untransformed
environments are highly complex and should be considered an aberrant form of organogenesis [187].
Genetic evidence supports inactivation of the oxygen sensor VHL as the initiating event in ccRCC, with
the resulting pseudo-hypoxia promoting a persistent state of angiogenic recruitment in the transformed
cell [188]. The axis of communication between tumor cells and endothelium has been a major research
focus that has yielded effective therapies [189]. How tumor cells interact with surrounding cells to
control the immunological environment and escape lymphocyte attack has also become a major
research question given the success of immunotherapies [190].
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Studies in tumor biology and developmental biology support an essential role for fibroblasts in
regulating both angiogenesis and the local immune environment [191-193]. Our study reveals the
complex requirements required for growth of these cells and provides a strategy to culture them that
may be used to answer basic questions regarding their influence on tumor cell growth and
immunomodulation.
ECM governs cell behaviors through complex mechanisms including acting as a sink for growth
factors and controlling tissue stiffness and elasticity. For this series of experiments, the cell attachment
properties of ECM are of particular interest. Cells associate with ECM molecules such as collagens,
laminin and fibronectin through receptors at the cell surface that include integrins, the laminin receptor,
syndecans and dystroglycan. These have different affinities for distinct ECM components and are
generally redundantly expressed, forming a cell-specific ECM-binding signature. Interactions between
these surface proteins and ECM components are the basis of physical association of cells with the tissue
scaffold. For this reason, it is important to accurately reproduce the ECM protein repertoire in culture so
that the combination of ECM molecules required for the attachment of diverse cell types liberated from
dissociated tumors are represented. Our analysis defined specific differences in ECM-binding affinities
between the predominant cell types found in tumors. However, we showed that by generating a blend
of the most abundant tumor ECM components with proportions reflecting those in the ccRCC tumors we
could promote binding of all cell types. Capturing the cells within the culture system is an essential first
step towards establishing long-term cultures of patient tumors, and further investigations of metabolite
composition and oxygenation of medium will guide efforts to grow cells in 3D matrix to a density similar
to that seen in tumors.
In addition to their role in cellular adhesion, ECM-binding cell surface receptors control
cytoskeletal contacts with the surroundings. Our study identified an interesting contrast between the
ECM of healthy neighboring kidney cortex and tumors. In the healthy kidney, epithelial cells sit on
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basement membranes and stromal cells are embedded within the adjacent interstitial ECM which
functions as a scaffold for the organ. The compositions of basement membranes and interstitial ECM are
highly distinct, but ccRCC appears to consist of a mixture of components, with interstitial ECM
components most highly represented. Thus, tumor cells and stromal cells are embedded in a single
ccRCC ECM and this unique structural arrangement is anticipated to have profound effects on cell
behaviors. We speculate that the mismatch in ECM profile between Matrigel, which mimics basement
membrane, and fibrin/ccRCC ECM, which largely contains interstitial ECM components, may be the
reason that the few fibroblasts that do adhere to Matrigel are rapidly lost in culture. The rounded
structure of fibroblasts in Matrigel suggests aberrant cytoskeletal arrangement consistent with a lack of
ECM interaction. Fibroblasts in ccRCC ECM display characteristic morphology and are maintained in
culture.
A defining feature of the ccRCC ECM composition characterized in this work is its qualitative
similarity to healthy kidney cortex ECM. Within the detection limits of our analysis, neoplastic
transformation does not lead to de novo expression of matrix molecules, but rather alters the relative
abundances of components. In contrast to healthy cortex, ccRCC ECM is highly enriched in collagen VI,
fibronectin, tenascin C, TGFBI and periostin. The role of each of these components has been studied in
tumor cell biology. Collagen VI is abundantly expressed in tumors from several organs including breast
[194], colon and lung [195]. It promotes survival of tumor cells [196] and fibroblasts [197] and has been
shown to stimulate tumor angiogenesis [198]. Fibronectin promotes tumor growth through activation of
PI3K/AKT signaling in tumor cells [199, 200]. Tenascin C closely resembles fibronectin and shares
receptor-binding properties, promoting proliferation [201] and migration [202] of tumor cells. Similarly,
TGFBI promotes proliferation and migration of cancer cells [203]. Periostin promotes tumor cell growth
through increased survival [204]. All of these ECM proteins may activate multiple signal transduction
pathways through their cell surface receptor interactions, including PI3K, TGFβ, ERK and STAT.
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In many tumors the alteration in ECM content results in a more rigid matrix that promotes malignancy
[205], but in ccRCC we have found that this is not the case; modulus testing of tumors versus adjacent
healthy cortex revealed a lower modulus in tumors [206]. This suggests that the ECM profile of ccRCCs
defined in our analysis reduces tissue rigidity in comparison with the healthy surrounding tissue,
perhaps contributing to the indolent progression of ccRCC tumors, which genetic analysis has revealed
generally develop over decades [102].
Our reanalysis of published single cell data from ccRCCs indicates that tumor fibroblasts serve as
a major source of ECM. This is certainly in line with observations from tumors that develop in other
organ systems [207], where myofibroblast-derived ECM has been identified as a major determinant of
the tumor microenvironment. Interestingly we found that PDGFRα/β-expressing fibroblasts identified in
the Young et al. single cell dataset [160] segregated into two distinct clusters; the less abundant subset
of these had high expression of ACTA2 (smooth muscle actin), identifying them as the putative
myofibroblast population. In agreement with published reports on myofibroblast production of ECM,
this subset of cells displayed strong expression of ECM components identified by mass spectrometry;
collagen VI, HSPG2/perlecan, fibronectin, lumican, laminin and collagen 12. Thus, we propose that these
cells play a major role in forming the ECM environment of ccRCC. Immunostaining reveals that ACTA2expressing cells surround clusters of clear cells in ccRCC tissue, indicating that they deposit their matrix
within the network of stroma that contains vessels and immune cells. Our study indicates that these
ccRCC myofibroblasts express renin, an angiotensinogen protease that promotes vasoconstriction
through the renin-angiotensin (RAS) cascade. The presence of a renin expressing cell in ccRCC stroma
has previously been reported [175] and subsequent work has identified it as a cancer stem cell [208].
However, based on our findings we propose that it is a myofibroblast subpopulation of CAFs in ccRCC. In
the healthy kidney, renin is expressed in a specialized subpopulation of cells within vessel walls [209]
that are essential for maintaining blood pressure by secreting renin in response to neural and chemical
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cues [210]. Clinical observations support a role for the RAS system in ccRCC progression, with patients
treated with angiotensin inhibitors displaying improved survival in metastatic ccRCC [211]. A recent
study showed that RAS inhibition prevents ccRCC tumor colony formation, indicating direct effects of
this pathway on tumor tissue [212]. Contribution of the ccRCC myofibroblast to activation of the RAS
system in ccRCC is therefore an intriguing possibility. Our demonstration that the renin expressing
myofibroblast can be propagated in culture provides a novel and unique tool to investigate specific roles
of the ccRCC CAF in tumor biology.
In conclusion, proteomic analysis identified drastic changes in the ECM environment of ccRCC
compared with healthy neighboring kidney cortex tissue, including structural changes such as loss of
tubule basal lamina and alterations in the composition of ECM. scRNA-seq analysis identified a subset of
CAFs with a strong transcriptomic profile for ECM expression, identifying them as the source of
increased matrix deposition. We were unable to culture these ACTA2 and renin expressing CAFs using
conventional cell culture techniques, including monolayer and Matrigel domes. To isolate and propagate
these cells we devised a ccRCC specific ECM combination (ccRCC ECM) based on the proteomic profiles
of patient ccRCCs. Cell types representative of the tumor showed efficient attachment to this substrate
and incorporation of this ccRCC-characteristic ECM mix into fibrin gels enabled creation of a tunable 3D
ccRCC environment (fibrin/ccRCC ECM). Patient tumor-derive primary ccRCC cell isolates grew out in this
3D tumor culture, and molecular marker analysis revealed representation of both tumor cells and
fibroblasts. The fibroblast repertoire found in tumors was preserved with subsets of cells showing high
expression of ACTA2 and renin. In conclusion, we found that the use of ccRCC specific ECM components
in a fibrin-based 3D culture system allows for robust culture of ccRCC fibroblasts for use in studying
tumor-CAF-ECM interactions, as well as further exploration of different fibroblast subtypes within ccRCC
tumors.
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CHAPTER 4
UNCOVERNG THE FUNCTION OF FOXD1 REGULATION OF CCRCC CELL CYCLE PROGRESSION USING A
NOVEL TRANSCRIPTION FACTOR FOCUSED ANALYSIS PIPELINES

4.1.

Introduction
The transcription factor FOXD1 has been reported to having an oncogenic role in many cancers.

In clear cell renal cell carcinoma (ccRCC), we have previously shown that FOXD1 regulates cell cycle
progression through the G2/M phase, with its loss preventing tumor growth in vivo. The direct pathways
regulated by FOXD1 to cause this phenotype remain elusive. In this series of investigations, we explore
the functions of FOXD1 in regulating the cell cycle using a novel analysis pipeline that utilizes RNAsequencing, transcription factor binding site analysis, and phenotype validation. This protype pipeline
has broad applicability to drug discovery of similar datasets, with power to uncover novel therapeutic
targets. In tandem, we utilize a novel fibrin-based 3D ccRCC tumor avatar model to measure tumor
growth in response to drug treatment as a proof-of-principle concept. This study uncovers novel targets
involved in ccRCC growth including FOXM1, PME1, and TMEM167A.
4.2.

Materials and Methods

4.2.1. Cell Line Culture
786-O (ATCC CRL-1932) and 786-OFOXD1null cells were maintained in RPMI-1640 containing 10%
FBS, 1% GlutaMax (ThermoFisher), and 1% Penicillin-Streptomycin and grown to 70-80% confluency on
tissue culture treated plates before experiments. Cells were detached from plates using TrypLE Express
(ThermoFisher).
4.2.2. RNA-sequencing and data acquisition
RNA from 70% confluent plates of 786-O and 786-OFOXD1null cells was extracted using Qiagen
RNeasy Microkit and analyzed for RNA purity by analyzing the 260/280 ratio using ThermoFisher
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Nanodrop and for quality by running an RNA gel and analyzing the ratio between 28S and 18s. Samples
with pure RNA (260/280 ratio > 2.0) and good quality (28s/18s > 2.0) were submitted for RNA
sequencing through Genewiz. Pre-made total RNA libraries were prepared and sequenced using HiSeq at
2x150 bp sequencing mode. Quality was assessed by base sequence, and mean quality was assessed.
Quality scores greater than 30 were deemed acceptable for further downstream analysis. Reads were
trimmed using Trimmomatic v.0.36, and only high-quality reads with >= 30 bp were accepted. Reads
were aligned to the human genome build hg38 using STAR aligner v.2.5.2b. Unique gene hit counts were
calculated using the featureCounts function from the Subread RNA-seq package v.1.5.2.
4.2.3. RNA-seq data analysis
Unique reads were analyzed for differential gene expression using DESeq2, comparing 786-O
and 786-OFOXD1null. Fold change and p-values were calculated using the Wald test. Only p-values less than
or equal to 0.05 were considered “differentially expressed”. Genes without p-values were deemed
“Uninterpretable” and discarded from further analysis. All other genes were labeled “equally
expressed”. Differential genes were analyzed using the schematic featured in Figure 4.1. Dƒifferentially
expressed genes were divided into upregulated (foldchange > 1) or downregulated (foldchange <1) and
the top 100 most up or downregulated genes were set aside for scoring. In parallel, the entire list of
differentially expressed genes was analyzed for transcription factor binding sites using CiiiDER [214]. In
brief, transcription factor matrices from the JASPAR2020 database were mapped to the input gene list,
with the gene look-up manager (GLM) from the human genome atlas build hg3, using a deficit cutoff of
ether 0.5 (5%) or 0.15 (15%). From the 5% cutoff group, genes with FOXD1 motifs were further analyzed
for “clustered FOXD1” or FOXD1 binding motifs within 100bp from each other. These “clustered FOXD1”
targets were separated for further druggability analysis. From the 15% cutoff group, all genes, both
clustered and unclustered genes with FOXD1 motifs were scored for druggability.
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4.2.4. Gene Set Enrichment Analysis
Differentially expressed genes from RNA-sequencing were ranked for fold change and analyzed
using Gene Set Enrichment Analysis (GSEA), mapping pathway interactions using the Reactome database
[102]. Pathways and interactors were mapped using Cytoscape [103].
4.2.5. Target drug selection
Drug selection is outlined in Figure 4.3. Genes set aside for scoring (Top 100 up and
downregulated genes, genes with FOXD1 motifs from 15% cutoff analysis) were cross-referenced with
the following databases: Mitotic G2-G2/M phases (Reactome R-HAS-453274) [215], Human kinome
(Kinbase) [216], Matrisome [217], and Cell Adhesion (GO: 0007155) [218]. Scores were weighted as
follows: Mitotic G2-G2/M phases = +2, Human kinome = +1, Matrisome = +0.5, Cell Adhesion = +0.5.
Genes that scored greater than or equal to a final score of 2 were assessed further for druggability. All
candidates were divided into requiring either “inhibition” (log fold change > 0) or “activation” (log fold
change < 0). Targets requiring inhibition were first searched online as follows: “Protein Name” +
(“Inhibitor” OR “Antagonist”). If a specific inhibitor exists, the search ended and the drug was added to
the panel list. For targets requiring “activation”, the Uniprot protein description was reviewed to
identify if the protein is secreted or not. If yes, and a recombinant exists, it was added to the candidate
panel. If not, an online search was conducted: as follows: “Protein Name” + (“Activator” OR “Agonist”). If
a specific activator or agonist exists, then it was added to the candidate drug panel. The final panel was
further refined to remove secreted growth factors, extracellular matrix components, and targets with
known or contradictory effects based on the literature (data not shown). All other targets from this
analysis were not explored further in this study.
4.2.6. Conditioned Media Growth Rate Analysis
786-O and 786-OFOXD1null cells were seeded into 15 cm dishes and allowed to grow to confluency.
At confluency, culture media was replaced and cultured for an additional 48 hours. Conditioned media
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was collected, centrifuged at 14,000xg for 20 minutes at 4˚C to pellet any cell debris. Supernatant was
collected and stored at 4˚C. For growth assay, 786-O and 786-OFOXD1null cells were seeded into 24-well
tissue culture plates at a concentration of 5,000 cells per well, in either conditioned media from 786-O
or 786-OFOXD1null. Every day after seeding, cells from triplicate wells were collected and counted. Media
for remaining wells was changed daily. This was done until day 7 and graphed using Excel.
4.2.7. Native ECM Growth Rate analysis
Plates covered in native ECM from 786-O and 786-OFOXD1null were derived following the protocol
from Harris et al. [219]. In brief, 786-O or 786-OFOXD1null were seeded at confluency into 24-well plates,
then cultured for 5 days. Plates were washed with twice with DPBS, followed by three times with Wash
Buffer 1 (100 mM Na2PO4, 2 mM MgCl2, 2 mM EGTA, pH 9.6). Cells were lysed two rounds with Lysis
Buffer (8 mM Na2PO4, 1% NP-40, pH 9.6) for a total of 1 hour and 30 minutes at 37˚C. Plates were then
washed three times with Wash Buffer 2 (10 mM Na2PO4, 300 mM KCl, pH 7.5) and final wash four times
with sterile DI water. Plates were stored filled with DPBS at 4˚C until beginning the assay. At the
beginning of the assay, 70% confluent plates of 786-O and 786-OFOXD1null were detached using TrypLE
express, counted, and seeded onto plates containing native ECM from 786-O or 786-OFOXD1null at 5x104
cells per well. Every 24 hours after seeding, triplicate wells were imaged, detached, and counted. All
other wells media was changed daily. This was done until day 7 and graphed using Excel.
4.2.8. Drug Toxicity Screening
786-O cells were seeded into 96-well plates at 2x104 cells per well and cultured for 2 hours at
37˚C. 5 to 6 points doses were determined based on the following: 1. IC50 (1x, 2x, 3x, 4x, 5x, and 50100x) 2. ED50 (1x, 2x, 3x, 4x, 5x, and 50-100x), or 3. From reported working concentrations. Exact drug
titrations are summarized in Table C.1. Selected target drugs were prepared according to manufacturer
specifications, and diluted to selected dose ranges in culture media and added to wells in triplicate.
Untreated controls were included in each plate. After three days, wells were stained with Hoechst
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33342 and Ethidium Homodimer-1 for 30 minutes at room temperature in the dark. Wells were imaged
using Thermo Fisher EVOS. Images were quantified for number of cells per well (# Hoechst 33342
stained nuclei) and number of dead cells (# Ethidium Homodimer-1 stained nuclei). Percent growth
inhibition was calculated based on the average number of cells per well compared to untreated wells.
Percent viability was calculated based on the average number of Ethidium Homodimer-1 negative cells
to average total number of cells. Pairwise comparisons between treatments and untreated wells were
conducted using Students’ T-test, with p-values less than 0.05 designated as significant. Optimal dose
per drug was chosen based on the greatest amount of inhibition without toxicity.
4.2.9. Synchronized Cell Cycle Analysis
786-O and 786-OFOXD1null were seeded to culture treated dishes at 10.5x103 per cm2 and cultured
overnight at 37˚C. Cells were then treated with 2.5mM thymidine in culture media for 16h, followed by a
media change and retreatment with 2.5mM thymidine for an additional 9-12h. One plate was left
untreated for a control. Plates were the washed with DPBS two times before adding culture media. One
synchronized plate was collected and fixed at this point as a control. For drug treatments, media
containing optimal drug dose was added instead. Cells were cultured for 11h at 37˚C. After, cells were
lifted off plates with TrypLE, centrifuged, and resuspended in 100µl of culture media. 900µl of freezing
100% Methanol was then added drop-wise and transferred to -20˚C freezer and fixed for at least 2h.
Afterwards, cells were washed with MACS flow buffer three times, then resuspended in 1mL MACS flow
buffer containing 50 µg/ml DAPI, and incubated at 4˚C on a nutator overnight. Cells were washed three
times with MACS flow buffer, resuspended in 400 µl of MACS flow buffer and analyzed using
MACSquant VYB flow cytometer. The G1 phase was determined by analyzing synchronized control, in
which all cells are in G1. The G2 phase was determined by doubling the value of suspected G1, while S
phase was all values in-between.
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4.2.10. 3D cultures
Fibrin domes were created following modifications to protocol by Liu et al. [159]. In summary,
fibrin domes were generated by combining fibrinogen (Sigma cat#F8630) at a 1:1 ratio with cells
suspended in culture media with or without addition of ECM proteins. Thrombin (Sigma
cat#10602370001) at a concentration of 0.002 U/µl was added at a volume equal to 10% of total to cellfibrinogen mix, then immediately spotted onto glass coverslips at 5 µl per replicate. Domes were
immediately placed into a 37˚C cell culture incubator for 30 minutes to facilitate gelation. Pre-warmed
cell culture media, with or without drug treatments, was carefully added to wells and allowed to culture
in cell culture incubator.
4.2.11. Live/Dead and Structure Analysis
After 3 days of culture, media was replaced with Live/Dead staining solution containing 2 μM
Calcein-AM and 4 μM Ethidium homodimer-1 (Etd1) in culture media (Thermo cat#L3224) and incubated
for 30 minutes in culture incubator. In last remaining 8 minutes, Hoechst 33342 (Thermo cat# H3570) at
a final concentration of 5 µg/ml was added to each sample. Images were collected on EVOS imaging
system. images were analyzed for Calcein-AM positivity to identify number of cellular structures. Each
structure was designated as either live (Calcein+) or dead (Ethd2+). Higher magnifications were taken to
analyze nuclear structure stained with Hoechst 33342. Comparisons between culture conditions were
done via Z-test.
4.2.12. Tissue Sample Processing
Samples were processed as previously discussed. Fresh tumor and adjacent normal tissue
samples were diced and weighed. 100 mg of tissue was was digested in 20x volume DMEM containing
250 U/mL Collagenase IV (Gibco) + 0.02% Trypsin-EDTA at 37˚C in a shaking incubator set to 200 RPM for
up to 2 hours or until media became cloudy. Digest was stopped by adding equal volume of ice cold
DMEM containing 10% FBS. Any undigested material was filtered with 100 µM filter and placed in vessel
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containing 5x volume TrypLE Express (ThermoFisher) and returned to the 37˚C shaking incubator set to
220RPM for an additional 15 minutes. Samples were pooled if necessary and centrifuged at 500xg for 7
minutes 30 seconds at 4°C. Cells were washed with ice cold DMEM, counted and viability determined
using Trypan Blue exclusion, and utilized for downstream assays or frozen in Nutrifreeze (Sartorius)
freezing media. Summary of patient sample used in this study is summarized in Table 4.1.

Table 4.1. Isolated tissue samples used in drug study. NA = not applicable.

Tp17-S322
Tp17-s438
Tp18-S453
Tp18-s109
Tp18-s114
Tp20-s199
Tp20-s277

Diagnosis
Unclassified
renal neoplasm
Unclassified
renal neoplasm
Clear cell renal
cell carcinoma
Clear cell renal
cell carcinoma
Clear cell renal
cell carcinoma
Clear cell renal
cell carcinoma
Leiomyosarcoma

Stage
NA

Grade
NA

Race
White

Gender/Age
F/70-79

2

3

White

F/30-39

1

3

White

M/80-86

3

2

White

M/60-60

3

3

White

M/80-89

3

2

NA

M/74

3

NA

White

M/69

4.2.13. Primary Cell Culture
Adapted from Williams et.al [108]. Digested tumor cells were washed and resuspended in 1x106
cells/5 mL High Glucose DMEM containing 10% FBS, 1% GlutaMax (ThermoFisher), 1% PenicillinStreptomycin, 1% Non-Essential Amino Acids (Gibco), and 1% Sodium Pyruvate, and plated onto 5 cm
tissue culture treated plates. Plates were incubated at 37˚C for 24 hours before media change and
imaging. Cells were monitored with media change every 72 hours After reaching 70-80% confluency,
cells were expanded into a 10 cm tissue culture treated dish. Upon reaching 70-80% confluency,
passaged cells were either frozen in FBS/DMSO freeze media or further expanded for downstream
applications.
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4.2.14. qPCR analysis of predicted FOXD1 targets
RNA was extracted from primary cell cultures using Qiagen RNeasy Minikit (Qiagen Cat#74134)
with DNase step included. cDNA was generated using BioRad iScript Synthesis kit (BioRad Cat#1708891).
qPCR was performed using SsoAdvanced Universal SYBR Green Supermix using the manufacturer’s
protocol, and selection of appropriate reference genes was performed using BioRad CFX Maestro
software Reference Gene Selector Tool. Reference genes RPLPPO and HBB were used for analysis. qPCR
for FOXD1 was assayed and fold changes were calculated using BioRad CFX Maestro software using
parental 786-O as reference. All assays were performed on CFX96 Touch Real-Time PCR Detection
Systems, in triplicates.
4.2.15. Western blot analysis
Protein was collected from cell lines using 1x Laemelli Buffer. Western Blotting was performed
following manufacturer guidelines using the BioRad Western Blotting system. Blots were stained for
beta-tubulin, VHL, and HIF1α. Molecular weight and densitometry analysis were performed using BioRad
Imagelab software and normalized to beta-actin density.
4.3.

Results

4.3.1.

FOXD1 mutants have 3D growth defects
Previously, we reported the creation of a FOXD1-null renal cell carcinoma based on the 786-O

cell line, the 786-OFOXD1null [128]. This cell line is known to have growth inhibition and fails to form tumors
reliably in vivo. We identified defects in DNA repair and transition through G2/M in vitro. However, we
were unable to resolve if these cells are unable to form tumors due to this defect. To determine if 786OFOXD1null could form tumors in vitro, we grew 786-O and 786-OFOXD1null in ultralow attachment plates.
Under these conditions, cells with the capacity to aggregate and grow under attachment free conditions,
such as after xenograft injection, can be assessed.
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Figure 4.1. FOXD1 regulates 3D growth and multiple related signaling pathways. (A) 786-O and 786OFOXD1null plates grown in ultralow attachment plates for two days, 200 cells per well. (B) Volcano plot
summary of RNA-sequencing data comparing 786-O and 786-OFOXD1null. (C) GSEA analysis identifies
several signaling pathway modules differentially expressed between 786-O and 786-OFOXD1null. (D)
Growth rate analysis of 786-O and 786-OFOXD1null grown in conditioned media from 786-O or 786OFOXD1null. (E) Growth rate analysis of 786-O and 786-OFOXD1null grown on native decellularized matrix
from 786-O or 786-OFOXD1null. * = p-value <0.05 by Student’s T-test at end-point.
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What we observed is that 786-O cells could aggregate, form spheres, and could rapidly expand.
In contrast, the 786-OFOXD1null could aggregate, but failed to form dense spheres (Figure 4.1A). Growth
was also limited in comparison. To assess if defects in cell cycle progression could account for this
phenotype, we treated 786-O with Mitomycin C (MMC), an irreversible DNA crosslinker, and repeated
the assay. 786-O cells treated with MMC showed similar growth to 786-OFOXD1null, confirming the
possibility this is due to cell cycle defects (Figure C.1).
4.3.2.

Loss of FOXD1 shows defects in growth, not secreted signaling
The exact downstream signals that drive FOXD1-dependent growth remain elusive. To identify

potential candidates that explain this phenotype, we performed RNA-seq comparing 786-O with 786OFOXD1null (Figure 4.1B). Differential gene expression analysis identified that 34.5% (5828/16855) of genes
were significantly different with loss of FOXD1. Gene set enrichment analysis (GSEA) of the differential
gene targets identified several potential pathways including: organelle regulation, metabolism, receptor
mediated signaling, Notch signaling, RTK signaling, senescence, transcription regulation, necrosis, and
apoptotic signaling (Figure 4.1C) [220]. Since several pathways included secreted signaling (TNF, ILK,
Notch, and RTK signaling), we predicted that secreted factor autocrine signaling was modified with the
loss of FOXD1. To test this, we collected and purified conditioned media from both 786-O and 786OFOXD1null and performed a growth rate analysis of cells grown in their own conditioned media or in the
media of their opposing line (Figure 4.1D). This analysis revealed that replacement of conditioned media
had no effect of the growth of either cell line, indicating that even if changes in secreted factor signaling
occur, this is not the cause of the growth inhibition caused by loss of FOXD1.
4.3.3.

Changes in extracellular matrix deposition and interaction between 786-O and 786-OFOXD1
An additional pathway revealed by GSEA is collagen formation and modification. Laying down

the proper attachment substrates is essential for cells to not only attach, but also properly orient
themselves for cell division [221].
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To test if this reason could account for the growth delay experienced due to the loss of FOXD1, we
coated plates with “native” 786-O ECM or 786-OFOXD1null ECM by decellularizing confluent plates of 786-O
or 786-OFOXD1null following the protocol by Harris et al. [219].
Interestingly, we found that the 786-O was unaffected in growth through change in ECM
substrate. The 786-OFOXD1null in contrast was greatly growth inhibited when cultured on 786-O native
ECM (Figure 4.1E). The viability of 786-OFOXD1null cells on 786-O native ECM was low with a lot of
detachment within the first few days after plating. Due to the large amount of death, we infer that the
interaction these cells have with specific ECM, either through receptor mediated interaction or
downstream signaling, is controlled by FOXD1.
Since interaction between cells and their local ECM may be controlled by FOXD1, we sought to
understand if changes in the ECM environment could account for challenges growing in vivo. Previously,
we developed a 3D growth assay using a fibrin-based hydrogel [213]. By including components of the
interstitial extracellular matrix, such as fibronectin, collagen 6, and tenascin C, we could model the
microenvironment the cells would be exposed to within the adult kidney. By culturing cells in this
system, we could assess the ability for tumor cells to grow and invade. We cultured 786-O and 786OFOXD1null in fibrin domes with or without the inclusion of kidney interstitial ECM (Figure D.2). While 786O could form tumors in fibrin alone, they formed a more invasive phenotype with the inclusion of ECM.
The 786-OFOXD1null however where unable to grow in fibrin alone and showed a stressed morphology.
With the inclusion of ECM, 786-OFOXD1null were able to grow, but did not have an invasive phenotype but
instead grew in loose circular sheets. As observed in both a 2D native deposited ECM assay and in a 3D
model containing kidney ECM, the 786-OFOXD1null was dependent on ECM for growth, while the 786-O
showed more flexibility. The exact composition of ECM, ECM interacting receptors, and signaling
modifications as a result of loss of FOXD1 needs further investigation.
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Figure 4.2. RNA-sequencing analysis and drug discovery pipeline.
4.3.4.

RNA-seq analysis identifies novel targets downstream of FOXD1
Our previous work identified effects of FOXD1 on machinery controlling cell cycle progression.

The next step to identify direct targets causing this cell cycle effect was to expand the analysis of the
sequencing data using a novel analysis pipeline (Figure 4.2). Since FOXD1 is a transcription factor with a
known DNA binding motif, we chose to identify direct FOXD1 targets based on predicted DNA binding.
The FOXD1 motif was mapped on identified differentially expressed genes using the CiiiDER tool [214].
Based on the binding motif of FOXD1, we predicted that a 5% deficit would find genes with a high
likelihood of having a true FOXD1 binding site (1054/5828 genes). We further analyzed the presence of
multiple FOXD1 binding motifs clustered together, which is predictive for having higher transcription
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activity [222]. In parallel, we broadened the analysis to a 15% deficit, which we predict to include genes
with Forkhead binding domains that may allow binding of FOXD1 (4298/5828 genes). These genes were
then analyzed for cross-reference in other important databases we identified as being pertinent to the
phenotypes we have previously described; Mitotic G2-G2/M phase, Human Kinome, Matrsiome, and
Cell Adhesion. Using these annotations, we scored potential gene targets as summarized in Figure 4.3.
An enrichment analysis was further performed, using the remaining genes as the background list. We
found no enrichment in FOXD1, indicating that FOXD1 binding sites alone did not have predictive value
(data not shown). Knowing this, we also analyzed the differentially expressed data without a bias for
FOXD1 binding motifs by annotating and scoring the top 100 upregulated and top 100 downregulated
transcripts based on fold change. This gave us a list of 73 gene targets for drug target identification. To
refine our candidate list, we focused on identifying target genes with known treatments. We did this by
manually reviewing each target for the existence of specific inhibitors, activators, or recombinant
proteins. Our final list was narrowed to a selection of 12 inhibitors and 9 activators that may be under
the influence of FOXD1 to control ccRCC cells progression through the cell cycle (Table 4.2).
4.3.5.

Candidate drug targets inhibit cell growth, induce cell cycle arrest
To assess if any of these targets can account for the growth reduction phenotype assessed in

786-OFOXD1null, we screened all drug candidates in a toxicity screen. Doses were chosen based on IC50,
EC50, or literature reported concentrations and summarized in Table C.1. Cells were treated for 3 days
to assess growth inhibition and toxicity. At the end-point, wells were stained for the nuclear marker
Hoechst33342 and dead cell marker Ethidium homodimer-1, and assessed for number of cells per well
and percent viability. Of the tested drugs, 10 showed significant reduction in cell growth compared to
untreated controls, with minimal toxicity (Table 4.3.).
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Figure 4.3. Drug screening pipeline for toxicity screening. Only candidates from “Tier 1” were used in
this study.
To determine if growth reduction is due to our predicted mechanism of growth arrest at G2/M,
we synchronized cells using the double thymidine block method. We previously showed that after
synchronization, it took 786-O cells 12 hours to complete the cell cycle, while 786-OFOXD1null required 14
hours [128]. After synchronizing cells, we allowed them to proceed through the cell cycle exposed to the
maximal tolerated dose of each chosen drug based on the toxicity screen and cultured them for 10
hours, at which point we can assess if drug exposure induced growth arrest at G2/M (Figure 4.4.). Only
three drugs showed an increase in distribution of cells at G2/M; AMZ30, FDI-6, and Silbinin. Other
targets showed effects of G1/S transition (recombinant ANGPTL4, APE inhibitor III) and S/G2 transition
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(BITC, recombinant SHH), but were excluded from further analysis due to no known effects of FOXD1 on
these stages.
Table 4.2. Drug targets identified using drug discovery analysis pipeline.
#
SUBSET 1
SUBSET 1
SUBSET 2
SUBSET 2
SUBSET 2
SUBSET 2
SUBSET 2
SUBSET 2
SUBSET 2
SUBSET 2
SUBSET 2
SUBSET 2
SUBSET 2

1
2
3
4
5
6
7
8
9
10
11
12
13

Drug
WAY 170523
EED226
APE1 Inhibitor III
Silbinin
Recombinant Netrin
CINPA 1
BITC
AMZ-30
FDI-6
CPI-637
Anti-Galectin-9 Antibody
Recombinant Sonic Hedgehog/Shh
C5OH

SUBSET 2
SUBSET 2
SUBSET 2
SUBSET 2
SUBSET 2

14
15
16
17
18

Recombinant C1qTNF1
Recombinant Angiopoietin-like 4
Recombinant CXCL5/ENA-7
Recombinant Semaphorin 3C
Recombinant LTBP1

4.3.6.

Target
MMP13
SUZ12
APEX1
TMEM167A
UNC5B
CXADR
AGPS
PPME1
FOXM1
EP300
LGALS9
HHIP
S100P

Action
INHIBIT
INHIBIT
INHIBIT
INHIBIT
ACTIVATE
INHIBIT
INHIBIT
INHIBIT
INHIBIT
INHIBIT
INHIBIT
INHIBIT
INHIBIT

Reference
[223, 224]
[225, 226]
[227]
[228]
[229]
[230]
[231]
[232]
[233, 234]
[235]
[236, 237]
[238, 239]
[240]

C1QTNF1
ANGPTL4
CXCL5
SEMA3C
LTBP1

ACTIVATE
ACTIVATE
ACTIVATE
ACTIVATE
ACTIVATE

[241]
[242]
[243]
[244]

Drug induced growth delay effects 3D growth, nuclear structure
After identifying drugs that effect the G2/M phase of the cell cycle, we wanted to know if this

inhibition would affect 3D growth that parallels growth in vivo. 786-O and 786-OFOXD1null cells were
seeded into fibrin domes containing interstitial ECM, as previously described. After seeding cells into 3D
domes, multicellular structures could be analyzed and compared after 3 days. 3D cultures were treated
with drugs identified in the cell cycle analysis; AMZ30, FDI-6, and Silbinin. At the end-point, domes were
stained with the nuclear dye Hoechst33342, live-cell dye Calcein-AM, and dead cell marker Ethidium
homodimer-1. Untreated 786-O and 786-OFOXD1null grew as predicted (Figure C.2.), with 786-O forming
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dense interconnected structures with invasive-like morphological features (Figure 4.5A) while 786OFOXD1null forming independent loose sheet-like circular structures (Figure 4.5B). Drug treated domes all
showed no observable toxicity using Ethidium homodimer-1, as predicted. Morphologically, drug
treated domes had different morphological characteristics. Domes treated with AMZ30 and Silibinin
showed a distribution of cells more similar to the 786-OFOXD1null structures (Figure 4.5C).
Table 4.3. Drug toxicity screening on 786-O cultured for three days. Cells exposed to drug at doses
specified in Table C.3. % Inhibition was calculated based on average number of Hoechst33342+ cells in
each condition compared untreated controls. % Viability was calculated based on average number of
Ethidium Homodimer-1 positive nuclei no negative nuclei. Blue text indicates significant (p<0.05)
inhibition, as determined by Student’s T-test. Green text indicates high viability similar to controls. Red
text indicates some level of toxicity at associated concentration.

AMZ30
ANGPTL4
APE1
inhibitor
III
BITC
CINPA1
CPI-637
CTRP1
CXCL5
C5OH
EED226
FDI-6
Galectin
mAb
LTPB1
Netrin1
Semapho
rin
Silbinin
SHH
WAY170
523

Dose 1
%
%
Inhibi Viab
t
le
38% 96%
8%
96%

Dose 2
%
%
Inhibi Viab
t
le
37% 96%
8%
96%

Dose 3
%
%
Inhibi Viab
t
le
22% 95%
12% 95%

Dose 4
%
%
Inhibi Viab
t
le
21% 97%
23% 94%

Dose 5
%
%
Inhibi Viab
t
le
32% 97%
7%
97%

Dose 6
%
%
Inhibi Viab
t
le
22% 97%
15% 95%

14%

94%

2%

95%

23%

93%

41%

94%

67%

86%

-

-

20%
15%
-13%
14%
14%
7%
22%
2%

94%
94%
99%
95%
93%
93%
96%
99%

16%
19%
-15%
17%
15%
8%
19%
-18%

94%
94%
99%
93%
94%
93%
95%
98%

13%
-4%
1%
21%
-1%
15%
-2%
13%

93%
95%
98%
95%
95%
96%
97%
99%

18%
27%
3%
33%
11%
8%
29%
19%

93%
94%
98%
91%
94%
94%
94%
98%

13%
20%
4%
29%
13%
12%
28%
2%

93%
95%
99%
94%
95%
94%
94%
98%

56%
21%
-18%
13%
7%
13%
48%

82%
94%
99%
96%
95%
93%
88%

5%

97%

-2%

97%

10%

96%

2%

96%

-4%

97%

-

-

12%
12%

98%
94%

3%
15%

98%
95%

20%
18%

98%
96%

11%
5%

99%
96%

12%
3%

97%
96%

-

-

1%

94%

-1%

94%

-2%

97%

10%

92%

1%

93%

1%

94%

6%
9%

94%
94%

12%
1%

92%
93%

13%
-1%

93%
96%

28%
24%

94%
94%

22%
10%

93%
94%

52%
10%

92%
94%

7%

95%

2%

95%

7%

96%

1%

95%

4%

95%

-2%

95%
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Figure 4.4. Synchronized cell cycle analysis identifies targets that inhibit G2/M progression. (A-D)
Untreated controls were compared to non-synchronized cells to confirm blocking and lifting strategy
worked as predicted. (E-N) Synchronized cells were treated with indicated drug upon removal from
block and allowed to grow 11h. Fixed cells were analyzed for cell cycle distribution using DAPI and
distribution of cells at G2/M was compared to untreated controls. * = significant increase in
distribution of cells at G2/M compared to untreated control.
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Figure 4.5. 786-O 3D tumor growth is effected by identified drugs. (A-E) 786-O 3D cultures were
untreated or treated with specified inhibitors and allowed to grow out for 3 days. Domes were then
stained for Hoechst 33342 (blue), Calcein-AM (green), and Ethidium homodimer-1 (magenta). (F)
Average number of Calcein-AM+ structures were quantified. * = p-value < 0.05 calculated by Z-test.
Treatment with FDI-6 had a severe effect, with much smaller and rounder structures compared
to untreated (Figure 4.5D). The number of structures in each dome were quantified, and a significant
number of structures were found with treatment with FDI-6 and Silbinin, and paralleled the increase in
number with 786-OFOXD1null (Figure 4.5F). The apparent increase in the number of structures appears to
be due to less interconnections associated with the invasive morphology of the untreated 786-O.
To further characterize the effects drug treatments had on cell growth, we analyzed the nuclear
morphology of structures within each group (Figure 4.6A-F). Previously, we showed that loss of FOXD1
led to not only an increase in cells at G2 (increased nuclear size), but also an increase in mitotic defects
(nuclear fragmentation and small size). Analyzing this in 3D space shows a similar distribution between
786-O and 786-OFOXD1null, with a skew towards larger nuclei with loss of FOXD1 (Figure 4.6A, E, F).
Similarly, increased nuclear size or “swelling” was found with treatment with silbinin. In contrast to this,
we saw a reduction of nuclear size with treatment of 786-O domes with AMZ30 and FDI-6 (Figure 4.6B,
C, F). In both these treatments, nuclear mitotic defects were apparent in subsets of cells. Interestingly,
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we observed many anuclear cells with darkened, protruding cell bodies (Figure 4.6C). Previous reports
show that loss of FOXM1 can lead to mitotic decline and senescence [245], which is likely what is
observed in this context. We can conclude from the tested drugs, 3D growth and nuclear morphology of
the 786-O was highly effected by targeting PME-1 (AMZ30), FOXM1 (FDI-6), and TMEM16A (Silbinin), all
which may be downstream of FOXD1.
4.3.7.

Characterization of FOXD1 and drug response in primary ccRCC tumor lines
To understand if the drugs we discovered have broad applicability to RCC treatment, or only can

influence a subset of FOXD1+ cells, we isolated several cell lines from patients following previously
reported protocol [22]. Lines were grown to at least passage 3, at which point protein was collected to
assess VHL status. Previous reports indicate that the majority of lines grown out from patient tumor
samples do not harbor VHL mutations [246]. Western blot analysis showed that of the 7 isolated lines,
three appeared to lack VHL (S109, S114, S438) with increased expression of HIF1α, as compared to the
control line 786-O which has a known mutation in VHL (Figure 4.7A). Two lines with high VHL levels
showed degradation of HIF1α (S322, S453), while the last two were in-between (S199, S277), either due
to being polyclonal or through incomplete repression of VHL. To assess if there was an association
between VHL status and FOXD1 expression levels, we performed qPCR analysis for FOXD1 in all lines.
Fascinatingly, the 786-O line, which we characterized previously as having protein level expression of
FOXD1, had the lowest levels of detectable FOXD1 (Figure 4.7B). Of the VHL-null lines, two had no
detectable transcription of FOXD1 (S109, S114), while the last (S438) had moderate expression. The
remaining lines, while all higher in expression compared to 786-O, had variable expression of FOXD1,
with the highest having 25-fold more relative expression compared to 786-O. We can conclude that VHL
status may influence FOXD1 expression, but alone is not the only factor for determining FOXD1
expression.
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Figure 4.6. Nuclear defects of 3D 786-O cultures analyzed from drug treatments. (A-F) High
magnification images of stained domes were taken and analyzed for nuclear morphology
(Hoechst33342) with each drug condition. Inlays show positive Calcein-AM staining (green) of
structures. Hyphened figures show Hoechst staining of region. (F) Box-and-whisker plot of quantified
nuclear sizes from each condition. * = p-value < 0.05 by Z-test.
We next asked if these cell lines could form 3D structures, and if this growth could be impeded
by the drugs selected from the analysis of FOXD1 in 786-O cells. To assess this, we seeded cells from
each line into fibrin domes containing Tumor ECM, which we previously have used to promote tumor
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growth in vitro, and grown for three days with or without treatment with drugs. Interestingly, there may
appear to be an anti-correlation between FOXD1 expression and 3D formation capacity; the highest
FOXD1 expressing lines, S277 and S453, failed to form multicellular structures after 3 days (Figure C.3).
Of the two lines with no detectable FOXD1 expression, both formed large and plentiful multicellular
structures. All other lines showed intermediate growth in 3D domes, allowing us to assess how
expression levels between low-FOXD1 and medium-FOXD1 expression levels are influenced by drug
treatments.
Performing a similar analysis of what was done on the 786-O cells, domes were stained with
Hoechst33342, Calcein-AM, and Ethidium homodimer-1 and analyzed for the number of structures and
compared between treatment conditions (Figure 4.7C-D). Three lines responded to AMZ30 (S114, S199,
S438). For FDI-6, four lines showed a strong response (S109, S114, S199, S438). Lastly, silbinin showed a
strong effect in two lines (S109, S438). In taking a look at nuclear structure, we see that AMZ30 only
effects nuclear size in S199. FDI-6, as seen in the 786-O line, causes nuclear dissolution, with all lines
effected either through complete loss of nuclei of reduction of nuclear content (Figure 4.7F). The effect
of silbinin was cell line dependent, with an increase in nuclear content in S109 but drastic reduction in
S199.
The results of these inquiry indicate that is no simple correlation between VHL status, FOXD1
expression level, and response to the drugs AMZ30 and Silbinin. However, all lines were heavily affected
by FDI-6, indicating a general dependence on FOXM1 on growth in these cells. In conclusion, we show
that FOXD1 may effect transcription and regulation of FOXM1, which is required for nuclear stability
through the cell cycle.
4.4.

Discussion

We have shown that FOXD1 regulates the G2/M phase of the cell cycle, however, the exact
mechanism of action has yet to be uncovered. In order to delineate this elusive mechanism, we
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designed an analysis pipeline of RNA sequencing comparing 786-O and 786-OFOXD1null data designed with
the specific intent to uncover novel pathways downstream of FOXD1 that regulates the cell cycle. Using
standard pathway analysis pointed towards changes in secreted factor signaling and extracellular matrix
interactions. However, investigations into these did not reveal any connections with the cell cycle delays
previously observed. While pathway analysis has been key to discovering the mechanism of action for
many targets, pursuit of the pathways identified proved unsubstantial. A better method for analyzing
the transcript data was necessary for uncovering the signaling mechanism used by FOXD1 to regulate
the cell cycle. Here, we present an analysis method designed specifically for uncovering this elusive
mechanism, but may also have broader applicability for other transcription factors.
Our method to analyze uncharacterized transcription factors relies on the following: 1. The
binding domain of the transcription factor, 2. Differential gene expression (DGE) analysis from RNAsequencing data comparing mutant and wild type cells, and 3. Characterization of the phenotypes.
Analysis of DGE, instead of relying on unbiased pathway analysis, instead focuses on mapping the
transcription factor of interest to the gene list, and then scoring genes based on their inclusion in
databases related to their known phenotype. In our case, we had characterized the mutant as having a
delay at in G2/M, extracellular matrix interactions, and an attachment phenotype. With this
information, we could narrow a list of genes to those with putative transcription factor binding sites
associated with the observed phenotypes. From this point, we could identify drug targets from the
discreet list through literature review, with further scoring based on specificity of the targets. Using this
method, we created a narrow list of 18 druggable targets at which to analyze.
We additionally developed a drug analysis pipeline to characterize the identified drugs on our
cells to see if they replicate the mutation phenotypes we previously characterized. While specific for our
phenotype, the outline of this pipeline can be applied to any other target with a known phenotype. It
would follow the following scheme: 1. Dose response and toxicity screen for each target, 2. Analysis of
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maximal tolerable dose on phenotype(s) of interest, and 3. Confirmation that drugs influences growth in
a pre-clinical model system. In this case, by knowing of a G2/M growth delay, we were able to analyze if
the drugs caused a growth delay in 2D culture, cause G2/M arrest, and influence growth in our 3D
kidney ECM model. Lastly, any identified targets that recapitulate the known phenotype can be applied
to multiple clones or lines to analyze the conditionality of the targeting. In our scenario, our list of 18
drugs were narrowed to a modest 3 that replicate the G2/M arrest phenotype. When applied to isolated
primary ccRCC lines, only one drug, FDI-6, was able to uniformly effect all samples tested.
Several limitations exist in this pipeline that can be improved on. First is that we used a single
ccRCC cell line to define the action of our transcription factor of interest, FOXD1. This cell line has
limitations, including not forming clear cells in vivo and having a mutation in HIF2α. By expanding this
analysis to more cell lines, there may be a stronger applicability to patient derived samples. A second
limitation regards the druggability of the targets. Many are uncharacterized or do not have specific
activators or inhibitors. To address this, we began testing a new delivery method using AAV. We show
that we can target primary lines established in this study, as well as freshly digested tissue samples
(Figure 4.8). By enabling the targeting of genes with no specific activator or inhibitor using a method
with applicability to patients would give more power to this type of analysis. Lastly, focusing the RNAsequencing on the observed phenotypes would also give more power to this analysis. For example, one
way to improve this analysis may have been to analyze the transcription profile of cells at each stage of
the cell cycle (G1, S, G2/M). We established that the 786-OFOXD1null have an increased distribution of cells
at G2/M compared to the 786-O; total RNA-seq on an unsynchronized population would give a falsepositive identification of genes involved in G2/M. Applying this logic to future studies would improve the
power and applicability of this type of analysis.
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Figure 4.7. Drug treatment analysis of primary tumor cell lines. (A) Patient-derived tumor lines were
assessed for VHL mutation and HIF1 protein accumulation. (B) Tumor lines were analyzed for FOXD1
expression through qPCR analysis. Bars were scaled to lowest detectable Cq value (786-O). (C)
Representative images of 3D cultures after 3 days with low-FOXD1 expression and high-FOXD1
expression treated with inhibitors. Domes were stained with Hoechst33342 (blue), Calcein-AM
(green), and Ethidium homodimer-1 (magenta). (D) Structure quantification of 3D cultures exposed
to drugs. Cells without multicellular structures in untreated controls at 3 days were labeled “No
growth”. (E) Represnetative images of multicellular structures analyzed for nuclear morphology. Inlay images show positive staining for live-cell marker calcein-AM. (F) Quantification of nuclei size of
cells in cultures with multicellular structures exposed to different drug treatments. * = p-value <
0.05 calculated by Z-test.
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The analysis revealed interesting targets downstream of FOXD1. FOXM1 is known to a master
regulator of the cell cycle and regulates passage of cells through S and G2/M [247]. It has been
implicated in several cancer subtypes and is highly prognostic, including in RCC [234]. Loss of FOXM1 has
been shown to lead to mitotic decline, senescence, and necrosis in both aging and cancer treatment
with FDI-6 [245, 248]. FDI-6 has been shown to cause nuclear fragmentation and subsequent dissolution
in cancer cells. We report this effect occurring in an immortal cell line, as well as in primary tumor cells
lines. As of current, no investigations have reported an effect of targeting FOXM1 in RCC, leading this
discovery to be of valuable therapeutic interest. Revisiting the initial RNA-seq DGE pathway analysis, we
identified a cluster of pathways related to cell senescence, necrosis, and apoptosis that are upregulated
with loss of FOXD1 (Figure 4.1C). Induction of senescence in tumors is an attractive therapeutic strategy,
especially in an organ like the kidney where therapeutic options are limited. If FDI-6 can cause
senescence in vivo, it would be an exciting treatment strategy to explore.

Figure 4.8. Primary tumor cells can be targeted using AAV delivery system. (A-B) Primary tumor
cultures used in this study show high targeting efficiency using AAVDJ to deliver GFP expression
construct. (C) Freshly digested, uncultured tumor samples plated onto 2D and immediately treated
with AAVDJ shows delivery to subsets of cells.
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PME-1 is a specific methylesterase for that binds to the active site of protein phosphatase 2A
(PP2A), resulting in demethylation and inactivation. It has been shown to influence formation and
elongation of the mitotic spindle, with its inhibition by AMZ-30 resulting in mitotic crises and cell death
[249]. In this analysis, we see that inhibition of PME-1 did not completely inhibit the ability of cells to
create structures, but did result in increased mitotic defects similar to the loss of FOXD1. Long-term
inhibition of PME-1 would likely result in gradual growth inhibition with the accumulation of mitotic
defects. It’s utility to specifically inhibit rapidly dividing cells makes it an attractive drug, especially with
its low toxicity. Further exploration of the utility of AMZ-30 to treat RCC, as well as the role of PME-1
and PP2A in FOXD1 mediated cell cycle progression should have further exploration.
Little is known about TMEM167A, but it has been implicated as has prognostic significance in
lung cancer and glioma [250, 251]. TMEM167A regulates vesicular trafficking, TNF and EGF signaling,
and p53 transcription [228]. The drug silibinin has been shown to inhibit the TMEM family of receptors
[250, 251]. While being the least characterized drug, it’s antitumor effects have been well established
[252]. It’s specificity in regulating TMEM receptor activity implicates this as its primary role. The specific
effects of TMEM167A, and how that relates to FOXD1, is not known. Further definition of the function of
TMEM167A needs investigation, but the use of silibinin as a cancer treatment remains attractive.
Several aspects are interesting in the analysis of FOXD1 in tumor cell lines. VHL mutant cells,
which are believed to hold the mutation that results in tumor formation, showed no detectable levels of
FOXD1. We previously tested total RNA from tumors and have been able to identify high levels of
FOXD1. This can imply several important aspects of FOXD1; first, that FOXD1 levels can be exacerbated
substantially beyond the predicted levels from previous experience. Second, FOXD1 must have specific
transcriptional activation to allow for its elevation, and this signaling is not known. Lastly, FOXD1
expression is independent or in counter to VHL action. We propose two possible scenarios; the first is
that FOXD1 is regulated in a context specific way, likely dependent on the tumor microenvironment.
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Secondly, FOXD1 may be upregulated not in tumor cells, but non-mutated VHL+ adjacent epithelium.
Epithelium from the kidney is highly susceptible to EMT and, with the right signaling ques, can rapidly
divide and forms cysts [253]. Single cell RNA-seq analysis has shown that normal kidney epithelium
significantly contributes to landscape of kidney tumors [213]. Exploration as to the identity of cells
containing high FOXD1 expression levels would be exciting and prognostically important.
In conclusion, this presents a methodology for analyzing downstream targets of transcription
factors, in this case FOXD1, that can be used for quick and simple drug discovery. Using this
methodology, we identified three unique pathways that are targetable in RCC and may prevent tumor
growth. While the direct mechanism of action of FOXD1 still needs more work, focusing on the target
genes we identified brings may bring insight into how to best treat patients suffering from RCC with high
FOXD1 expression.
4.5.
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CHAPTER 5
CONCLUSIONS AND RECOMMENDATIONS

A growing interest in FOXD1 in cancer has become more apparent over the last few years,
having been identified in several different solid tumors with increased risk of metastasis. Historically,
FOXD1 has been a difficult transcription factor to analyze due to difficulty in targeting the locus. Utilizing
CRISPR/Cas9 has allowed us to overcome this hurdle to generate the first reported knockout model
lacking FOXD1, which we used to characterize the null-phenotype in ccRCC. As predicted, we found
reduced growth rates and inability to form tumors in vivo parallel the prognostic significance of FOXD1
in ccRCC. However, many challenges still exist in understanding the regulation of FOXD1 and its contextdependent nature.
Our main observations regarding FOXD1 implicate its role in regulating the G2/M phase of the
cell cycle. Several aspects of this phase are modified with loss of FOXD1, including increased time spent
at G2, increased overall DNA damage, and genomic crises during mitosis. The broad number of effects at
this phase indicates either a broad role of FOXD1 directly throughout this phase, or control over a
master regulatory element. Utilizing a novel drug screening approach identified FOXM1 as a target of
FOXD1, with many of the effects of its inhibition paralleling that of the FOXD1 mutant. Forkhead
transcription factors are intimately linked with one another, many of which share the same binding
domains and are different only base on their associated DNA binding partners. However, analysis of
Forkhead promoter regions commonly show forkhead-box binding motifs, indicating that these forkeads
may have a complex regulatory network amongst themselves. For example, we have previously
identified a putative FOXD1 binding domain on the promoter of FOXP1. While FOXP1 was not found to
be regulated in our studies, the context of which FOXD1 could bind to the promoters of FOXP1 and
FOXM1, as well as other forkheads, is in need of further investigation.
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This body of work also presents a model for studying and analyzing 3D tumor growth in vitro in
order to overcome the limitations of in vivo xenografts, which the RCC field is currently dependent on.
Because murine genetic models do not develop ccRCC as humans do, there is a strong likelihood that
only a humanized in vitro model could properly recapitulate the human kidney environment necessary
to allow RCC growth. The model developed here recapitulates the identities of the human kidney tumor
extracellular matrix, and shows improvements over other currently used tumor model systems, such as
Matrigel, which is non-human and has an incorrect ECM composition to the patient tumors.
Several additional aspects can be used to improve this model system. First, the media and
culture formulations may be further modified to promote maintenance of multiple different cell
populations. Identifying the growth factor requirements, as well as the availability of other essential
nutrients, may improve the outcomes in deriving models from a wider range of patients. Second, these
models can be scaled up for expansion cultures. An advantage of other model systems is that they allow
for continual passaging to gather cell numbers necessary to do large scale drug and genetic experiments.
Our system has been optimized for high throughput, low scale experimentation on non-passaged
patient material. While this has advantages in terms of being closer to the original patient material,
certain expectations based on scale may not be met. Modifying this system for scale may expand the
functionality. Lastly, modification of the ECM composition to match metastatic sites may be of great
importance in understanding which tumor samples have the propensity to metastasize and grow in
different microenvironments, placing patients at risk of metastasis. By generating ECM environments for
common RCC metastatic sites, such as bone and lung, can further expand the utility of this model
beyond analysis of primary tumors.
Lastly, we presented an analysis pipeline to take a knockout of a target transcription factor, in
this case FOXD1, through to discovering potential drug candidates that may explain observed
phenotypes. Many aspects of this can be broadly applied to other transcription factors, and further
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improvement of this system by increasing the RNA-sequencing depth and expanding on the analysis can
create a potential analysis pipeline to identify the function of many different transcription factors in
cancer. Using a strategy such as this circumvents many issues regarding pathway analysis that may
otherwise lead many chasing after endless leads. A leap forward to this type of analysis that we begun
exploring is the utility of an AAV based delivery system. Primary tumor lines and digests were
susceptible to AAV targeting, and thus may us to target factors without a known inhibitor or activator.
In conclusion, this body of work expanded upon our understanding of FOXD1, as well as
presenting a model system by which to study its growth effects. We identified several characteristics of
a FOXD1-null ccRCC cell line, and identified drug targets with therapeutic potential. Expansion on these
techniques and findings may lead to improved identification of RCC drug targets, and hopefully to new
treatments for patients suffering from this disease.

101

REFERENCES
1.

Lam, E. W.; Brosens, J. J.; Gomes, A. R.; Koo, C. Y., Forkhead box proteins: tuning forks for
transcriptional harmony. Nat Rev Cancer 2013, 13 (7), 482-95.

2.

Hannenhalli, S.; Kaestner, K. H., The evolution of Fox genes and their role in development and
disease. Nature reviews. Genetics 2009, 10 (4), 233-40.

3.

Larsson, C.; Hellqvist, M.; Pierrou, S.; White, I.; Enerbäck, S.; Carlsson, P., Chromosomal
localization of six human forkhead genes, freac-1 (FKHL5), -3 (FKHL7), -4 (FKHL8), -5 (FKHL9), -6
(FKHL10), and -8 (FKHL12). Genomics 1995, 30 (3), 464-9.

4.

Lim, W. J.; Kim, K. H.; Kim, J. Y.; Jeong, S.; Kim, N., Identification of DNA-Methylated CpG
Islands Associated With Gene Silencing in the Adult Body Tissues of the Ogye Chicken Using
RNA-Seq and Reduced Representation Bisulfite Sequencing. Frontiers in genetics 2019, 10, 346.

5.

Morris, G.; Fanucchi, S., A Key Evolutionary Mutation Enhances DNA Binding of the FOXP2
Forkhead Domain. Biochemistry 2016, 55 (13), 1959-67.

6.

Quintero-Ronderos, P.; Jiménez, K. M.; Esteban-Pérez, C.; Ojeda, D. A.; Bello, S.; Fonseca, D.
J.; Coronel, M. A.; Moreno-Ortiz, H.; Sierra-Díaz, D. C.; Lucena, E.; Barbaux, S.; Vaiman, D.;
Laissue, P., FOXD1 mutations are related to repeated implantation failure, intra-uterine growth
restriction and preeclampsia. Molecular medicine (Cambridge, Mass.) 2019, 25 (1), 37.

7.

Tufarelli, C.; Stanley, J. A.; Garrick, D.; Sharpe, J. A.; Ayyub, H.; Wood, W. G.; Higgs, D. R.,
Transcription of antisense RNA leading to gene silencing and methylation as a novel cause of
human genetic disease. Nature genetics 2003, 34 (2), 157-65.

8.

Harrow, J.; Frankish, A.; Gonzalez, J. M.; Tapanari, E.; Diekhans, M.; Kokocinski, F.; Aken, B. L.;
Barrell, D.; Zadissa, A.; Searle, S.; Barnes, I.; Bignell, A.; Boychenko, V.; Hunt, T.; Kay, M.;
Mukherjee, G.; Rajan, J.; Despacio-Reyes, G.; Saunders, G.; Steward, C.; Harte, R.; Lin, M.;
Howald, C.; Tanzer, A.; Derrien, T.; Chrast, J.; Walters, N.; Balasubramanian, S.; Pei, B.; Tress,
M.; Rodriguez, J. M.; Ezkurdia, I.; van Baren, J.; Brent, M.; Haussler, D.; Kellis, M.; Valencia,
A.; Reymond, A.; Gerstein, M.; Guigó, R.; Hubbard, T. J., GENCODE: the reference human
genome annotation for The ENCODE Project. Genome research 2012, 22 (9), 1760-1774.

9.

Hubisz, M. J.; Pollard, K. S.; Siepel, A., PHAST and RPHAST: phylogenetic analysis with
space/time models. Briefings in bioinformatics 2011, 12 (1), 41-51.

102

10.

Laissue, P.; Lakhal, B.; Vatin, M.; Batista, F.; Burgio, G.; Mercier, E.; Santos, E. D.; Buffat, C.;
Sierra-Diaz, D. C.; Renault, G.; Montagutelli, X.; Salmon, J.; Monget, P.; Veitia, R. A.; Méhats,
C.; Fellous, M.; Gris, J. C.; Cocquet, J.; Vaiman, D., Association of FOXD1 variants with adverse
pregnancy outcomes in mice and humans. Open biology 2016, 6 (10).

11.

Cerami, E.; Gao, J.; Dogrusoz, U.; Gross, B. E.; Sumer, S. O.; Aksoy, B. A.; Jacobsen, A.; Byrne,
C. J.; Heuer, M. L.; Larsson, E.; Antipin, Y.; Reva, B.; Goldberg, A. P.; Sander, C.; Schultz, N.,
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer
genomics data. Cancer discovery 2012, 2 (5), 401-4.

12.

Clark, K. L.; Halay, E. D.; Lai, E.; Burley, S. K., Co-crystal structure of the HNF-3/fork head DNArecognition motif resembles histone H5. Nature 1993, 364 (6436), 412-20.

13.

Wu, H.; Larribère, L.; Sun, Q.; Novak, D.; Sachindra, S.; Granados, K.; Umansky, V.; Utikal, J.,
Loss of neural crest-associated gene FOXD1 impairs melanoma invasion and migration via RAC1B
downregulation. International journal of cancer 2018, 143 (11), 2962-2972.

14.

Bernhofer, M.; Goldberg, T.; Wolf, S.; Ahmed, M.; Zaugg, J.; Boden, M.; Rost, B., NLSdb-major
update for database of nuclear localization signals and nuclear export signals. Nucleic acids
research 2018, 46 (D1), D503-d508.

15.

Ernstsson, S.; Pierrou, S.; Hulander, M.; Cederberg, A.; Hellqvist, M.; Carlsson, P.; Enerbäck, S.,
Characterization of the human forkhead gene FREAC-4. Evidence for regulation by Wilms' tumor
suppressor gene (WT-1) and p53. The Journal of biological chemistry 1996, 271 (35), 21094-9.

16.

Verginelli, F.; Perin, A.; Dali, R.; Fung, K. H.; Lo, R.; Longatti, P.; Guiot, M. C.; Del Maestro, R.
F.; Rossi, S.; di Porzio, U.; Stechishin, O.; Weiss, S.; Stifani, S., Transcription factors FOXG1 and
Groucho/TLE promote glioblastoma growth. Nature communications 2013, 4, 2956.

17.

Ramaswamy, S.; Nakamura, N.; Sansal, I.; Bergeron, L.; Sellers, W. R., A novel mechanism of
gene regulation and tumor suppression by the transcription factor FKHR. Cancer cell 2002, 2 (1),
81-91.

18.

Fetting, J. L.; Guay, J. A.; Karolak, M. J.; Iozzo, R. V.; Adams, D. C.; Maridas, D. E.; Brown, A. C.;
Oxburgh, L., FOXD1 promotes nephron progenitor differentiation by repressing decorin in the
embryonic kidney. Development (Cambridge, England) 2014, 141 (1), 17-27.

19.

Auguste, G.; Gurha, P.; Lombardi, R.; Coarfa, C.; Willerson, J. T.; Marian, A. J., Suppression of
Activated FOXO Transcription Factors in the Heart Prolongs Survival in a Mouse Model of
Laminopathies. Circulation research 2018, 122 (5), 678-692.

103

20.

Xiang, Q.; Tan, G.; Jiang, X.; Wu, K.; Tan, W.; Tan, Y., Suppression of FOXM1 Transcriptional
Activities via a Single-Stranded DNA Aptamer Generated by SELEX. Scientific reports 2017, 7,
45377.

21.

Quintero-Ronderos, P.; Laissue, P., The multisystemic functions of FOXD1 in development and
disease. Journal of molecular medicine (Berlin, Germany) 2018, 96 (8), 725-739.

22.

Fanni, D.; Gerosa, C.; Vinci, L.; Ambu, R.; Dessì, A.; Eyken, P. V.; Fanos, V.; Faa, G., Interstitial
stromal progenitors during kidney development: here, there and everywhere. The journal of
maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal
Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of
Perinatal Obstet 2016, 29 (23), 3815-20.

23.

Hatini, V.; Huh, S. O.; Herzlinger, D.; Soares, V. C.; Lai, E., Essential role of stromal mesenchyme
in kidney morphogenesis revealed by targeted disruption of Winged Helix transcription factor
BF-2. Genes & development 1996, 10 (12), 1467-78.

24.

Boivin, F. J.; Sarin, S.; Lim, J.; Javidan, A.; Svajger, B.; Khalili, H.; Bridgewater, D., Stromally
Expressed β-Catenin Modulates Wnt9b Signaling in the Ureteric Epithelium. PloS one 2015, 10
(3), e0120347.

25.

Levinson, R. S.; Batourina, E.; Choi, C.; Vorontchikhina, M.; Kitajewski, J.; Mendelsohn, C. L.,
Foxd1-dependent signals control cellularity in the renal capsule, a structure required for normal
renal development. 2005.

26.

Lindström, N. O.; Guo, J.; Kim, A. D.; Tran, T.; Guo, Q.; De Sena Brandine, G.; Ransick, A.;
Parvez, R. K.; Thornton, M. E.; Baskin, L.; Grubbs, B.; McMahon, J. A.; Smith, A. D.; McMahon,
A. P., Conserved and Divergent Features of Mesenchymal Progenitor Cell Types within the
Cortical Nephrogenic Niche of the Human and Mouse Kidney. Journal of the American Society of
Nephrology : JASN 2018, 29 (3), 806-824.

27.

Das, A.; Tanigawa, S.; Karner, C. M.; Xin, M.; Lum, L.; Chen, C.; Olson, E. N.; Perantoni, A. O.;
Carroll, T. J., Stromal-epithelial crosstalk regulates kidney progenitor cell differentiation. Nature
cell biology 2013, 15 (9), 1035-44.

28.

Vidal, V. P.; Jian-Motamedi, F.; Rekima, S.; Gregoire, E. P.; Szenker-Ravi, E.; Leushacke, M.;
Reversade, B.; Chaboissier, M. C.; Schedl, A., R-spondin signalling is essential for the
maintenance and differentiation of mouse nephron progenitors. eLife 2020, 9.

104

29.

Rowan, C. J.; Li, W.; Martirosyan, H.; Erwood, S.; Hu, D.; Kim, Y.-K.; Sheybani-Deloui, S.;
Mulder, J.; Blake, J.; Chen, L. J. D., Hedgehog-GLI signaling in Foxd1-positive stromal cells
promotes murine nephrogenesis via TGFβ signaling. 2018, 145 (13), dev159947.

30.

Gerl, K.; Steppan, D.; Fuchs, M.; Wagner, C.; Willam, C.; Kurtz, A.; Kurt, B., Activation of
Hypoxia Signaling in Stromal Progenitors Impairs Kidney Development. Am J Pathol 2017, 187
(7), 1496-1511.

31.

Ohmori, T.; Tanigawa, S.; Kaku, Y.; Fujimura, S.; Nishinakamura, R., Sall1 in renal stromal
progenitors non-cell autonomously restricts the excessive expansion of nephron progenitors.
Scientific reports 2015, 5, 15676.

32.

Song, R.; Lopez, M.; Yosypiv, I. V., Foxd1 is an upstream regulator of the renin-angiotensin
system during metanephric kidney development. Pediatric research 2017, 82 (5), 855-862.

33.

Fink, D. M.; Sun, M. R.; Heyne, G. W.; Everson, J. L.; Chung, H. M.; Park, S.; Sheets, M. D.;
Lipinski, R. J., Coordinated d-cyclin/Foxd1 activation drives mitogenic activity of the Sonic
Hedgehog signaling pathway. Cellular signalling 2018, 44, 1-9.

34.

Liu, J.; Zhou, Y.; Liu, Y.; Li, L.; Chen, Y.; Liu, Y.; Feng, Y.; Yosypiv, I. V.; Song, R.; Peng, H.,
(Pro)renin receptor regulates lung development via the Wnt/β-catenin signaling pathway.
American journal of physiology. Lung cellular and molecular physiology 2019, 317 (2), L202-l211.

35.

Falke, L. L.; He, N.; Chuva de Sousa Lopes, S. M.; Broekhuizen, R.; Lyons, K.; Nguyen, T. Q.;
Goldschmeding, R., FoxD1-driven CCN2 deletion causes axial skeletal deformities, pulmonary
hypoplasia, and neonatal asphyctic death. Journal of cell communication and signaling 2020.

36.

Yu, X.; Yuan, Y.; Qiao, L.; Gong, Y.; Feng, Y., The Sertoli cell marker FOXD1 regulates testis
development and function in the chicken. Reproduction, fertility, and development 2019, 31 (5),
867-874.

37.

Bedoui, Y.; Lebeau, G.; Guillot, X.; Dargai, F.; Guiraud, P.; Neal, J. W.; Ralandison, S.; Gasque,
P., Emerging Roles of Perivascular Mesenchymal Stem Cells in Synovial Joint Inflammation.
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune
Pharmacology 2020, 15 (4), 838-851.

38.

Herrera, E.; Marcus, R.; Li, S.; Williams, S. E.; Erskine, L.; Lai, E.; Mason, C., Foxd1 is required
for proper formation of the optic chiasm. Development (Cambridge, England) 2004, 131 (22),
5727-39.

105

39.

Takahashi, H.; Sakuta, H.; Shintani, T.; Noda, M., Functional mode of FoxD1/CBF2 for the
establishment of temporal retinal specificity in the developing chick retina. Developmental
biology 2009, 331 (2), 300-10.

40.

Thackray, V. G., Fox tales: regulation of gonadotropin gene expression by forkhead transcription
factors. Molecular and cellular endocrinology 2014, 385 (1-2), 62-70.

41.

Dahle, M. K.; Grønning, L. M.; Cederberg, A.; Blomhoff, H. K.; Miura, N.; Enerbäck, S.; Taskén,
K. A.; Taskén, K., Mechanisms of FOXC2- and FOXD1-mediated regulation of the RI alpha subunit
of cAMP-dependent protein kinase include release of transcriptional repression and activation
by protein kinase B alpha and cAMP. The Journal of biological chemistry 2002, 277 (25), 22902-8.

42.

Zhang, H.; Palmer, R.; Gao, X.; Kreidberg, J.; Gerald, W.; Hsiao, L.; Jensen, R. V.; Gullans, S. R.;
Haber, D. A., Transcriptional activation of placental growth factor by the forkhead/winged helix
transcription factor FoxD1. Current biology : CB 2003, 13 (18), 1625-9.

43.

Berg, D. T.; Myers, L. J.; Richardson, M. A.; Sandusky, G.; Grinnell, B. W., Smad6s regulates
plasminogen activator inhibitor-1 through a protein kinase C-beta-dependent up-regulation of
transforming growth factor-beta. The Journal of biological chemistry 2005, 280 (15), 14943-7.

44.

Nam, S. A.; Kim, W. Y.; Kim, J. W.; Kang, M. G.; Park, S. H.; Lee, M. S.; Kim, H. W.; Yang, C. W.;
Kim, J.; Kim, Y. K., Autophagy in FOXD1 stroma-derived cells regulates renal fibrosis through
TGF-β and NLRP3 inflammasome pathway. Biochemical and biophysical research
communications 2019, 508 (3), 965-972.

45.

Gomez, I. G.; Duffield, J. S., The FOXD1 lineage of kidney perivascular cells and myofibroblasts:
functions and responses to injury. Kidney international supplements 2014, 4 (1), 26-33.

46.

Meng, F.; Liu, Y.; Chen, Q.; Ma, Q.; Gu, S.; Cui, R.; Cao, R.; Zhao, M., METTL3 contributes to
renal ischemia-reperfusion injury by regulating Foxd1 methylation. American journal of
physiology. Renal physiology 2020, 319 (5), F839-f847.

47.

Lin, L.; Peng, S. L., Coordination of NF-kappaB and NFAT antagonism by the forkhead
transcription factor Foxd1. Journal of immunology (Baltimore, Md. : 1950) 2006, 176 (8), 4793803.

48.

Huang, J.; Liang, B.; Wang, T., FOXD1 expression in head and neck squamous carcinoma: a study
based on TCGA, GEO and meta-analysis. Bioscience reports 2021, 41 (7).

106

49.

Liang, H.; Zhang, C.; Li, C.; Li, C.; Wang, Y.; Lin, H., FOXD1 is a prognostic biomarker and
correlated with macrophages infiltration in head and neck squamous cell carcinoma. Bioscience
reports 2021, 41 (7).

50.

Mu, L.; Zhang, J.; Wu, Z.; Huang, J.; Cui, Y., FOXD1 Regulates the Sensitivity of Cetuximab by
Regulating the Expression of EGFR in Head and Neck Squamous Cell Cancer. Journal of
healthcare engineering 2022, 2022, 6108241.

51.

Li, J.; Yan, T.; Wu, X.; Ke, X.; Li, X.; Zhu, Y.; Yang, J.; Li, Z., Aberrant overexpression of
transcription factor Forkhead box D1 predicts poor prognosis and promotes cancer progression
in HNSCC. BMC cancer 2021, 21 (1), 1205.

52.

Qiu, S.; Li, D.; Shen, Z.; Li, Q.; Shen, Y.; Deng, H.; Wu, Y.; Zhou, C., Diagnostic and prognostic
value of FOXD1 expression in head and neck squamous cell carcinoma. Journal of Cancer 2021,
12 (3), 693-702.

53.

Chen, C.; Xu, Z. Q.; Zong, Y. P.; Ou, B. C.; Shen, X. H.; Feng, H.; Zheng, M. H.; Zhao, J. K.; Lu, A.
G., CXCL5 induces tumor angiogenesis via enhancing the expression of FOXD1 mediated by the
AKT/NF-κB pathway in colorectal cancer. Cell death & disease 2019, 10 (3), 178.

54.

Han, T.; Lin, J.; Wang, Y.; Fan, Q.; Sun, H.; Tao, Y.; Sun, C., Forkhead box D1 promotes
proliferation and suppresses apoptosis via regulating polo-like kinase 2 in colorectal cancer.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018, 103, 1369-1375.

55.

Pan, F.; Li, M.; Chen, W., FOXD1 predicts prognosis of colorectal cancer patients and promotes
colorectal cancer progression via the ERK 1/2 pathway. Am J Transl Res 2018, 10 (5), 1522-1530.

56.

Marra, G., An "expressionistic" look at serrated precancerous colorectal lesions. Diagnostic
pathology 2021, 16 (1), 4.

57.

Liang, W. L.; Xiao, T. B.; Yuan, F.; Cao, Y. B.; Yan, D. G., [Effects of microRNA95 targeting FOXD1
gene on radiosensitivity of colorectal cancer loVo cells and its mechanism]. Zhongguo ying yong
sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology
2020, 36 (2), 148-151.

58.

Zuo, S.; Dai, G.; Ren, X., Identification of a 6-gene signature predicting prognosis for colorectal
cancer. Cancer cell international 2019, 19, 6.

107

59.

Zhang, Y.; Zhang, W., FOXD1, negatively regulated by miR-186, promotes the proliferation,
metastasis and radioresistance of nasopharyngeal carcinoma cells. Cancer biomarkers : section A
of Disease markers 2020, 28 (4), 511-521.

60.

Wang, Z.; Cheng, Y.; Zhu, Y.; Hu, X.; Jin, Y.; Gong, L.; Xiao, M.; Xiang, L.; Zeng, Q.; Liu, J.;
Chen, X.; Zhang, Y.; Liu, X.; Deng, L.; He, D.; Cao, K., Long non-coding RNA FOXD1-AS1
promotes the progression and glycolysis of nasopharyngeal carcinoma by sustaining FOXD1
expression. American journal of cancer research 2020, 10 (11), 3686-3704.

61.

Ren, D.; Lu, J.; Han, X.; Xiong, W.; Jiang, H.; Wei, Y.; Wang, Y., LINC00641 contributes to
nasopharyngeal carcinoma cell malignancy through FOXD1 upregulation at the posttranscriptional level. Biochemistry and cell biology = Biochimie et biologie cellulaire 2021, 99 (6),
750-758.

62.

Li, C. H.; Chang, Y. C.; Hsiao, M.; Liang, S. M., FOXD1 and Gal-3 Form a Positive Regulatory Loop
to Regulate Lung Cancer Aggressiveness. Cancers 2019, 11 (12).

63.

Li, D.; Fan, S.; Yu, F.; Zhu, X.; Song, Y.; Ye, M.; Fan, L.; Lv, Z., FOXD1 Promotes Cell Growth and
Metastasis by Activation of Vimentin in NSCLC. Cellular physiology and biochemistry :
international journal of experimental cellular physiology, biochemistry, and pharmacology 2018,
51 (6), 2716-2731.

64.

Nakayama, S.; Soejima, K.; Yasuda, H.; Yoda, S.; Satomi, R.; Ikemura, S.; Terai, H.; Sato, T.;
Yamaguchi, N.; Hamamoto, J.; Arai, D.; Ishioka, K.; Ohgino, K.; Naoki, K.; Betsuyaku, T., FOXD1
expression is associated with poor prognosis in non-small cell lung cancer. Anticancer research
2015, 35 (1), 261-8.

65.

Sun, Q.; Novak, D.; Hüser, L.; Poelchen, J.; Wu, H.; Granados, K.; Federico, A.; Liu, K.;
Steinfass, T.; Vierthaler, M.; Umansky, V.; Utikal, J., FOXD1 promotes dedifferentiation and
targeted therapy resistance in melanoma by regulating the expression of connective tissue
growth factor. International journal of cancer 2021, 149 (3), 657-674.

66.

Nemlich, Y.; Baruch, E. N.; Besser, M. J.; Shoshan, E.; Bar-Eli, M.; Anafi, L.; Barshack, I.;
Schachter, J.; Ortenberg, R.; Markel, G., ADAR1-mediated regulation of melanoma invasion.
Nature communications 2018, 9 (1), 2154.

67.

Li, C.; Nguyen, V.; Clark, K. N.; Zahed, T.; Sharkas, S.; Filipp, F. V.; Boiko, A. D., Downregulation of FZD3 receptor suppresses growth and metastasis of human melanoma
independently of canonical WNT signaling. Proc Natl Acad Sci U S A 2019, 116 (10), 4548-4557.

108

68.

Chen, Y.; Liang, W.; Liu, K.; Shang, Z., FOXD1 promotes EMT and cell stemness of oral squamous
cell carcinoma by transcriptional activation of SNAI2. Cell & bioscience 2021, 11 (1), 154.

69.

Chen, S.; Yang, M.; Wang, C.; Ouyang, Y.; Chen, X.; Bai, J.; Hu, Y.; Song, M.; Zhang, S.; Zhang,
Q., Forkhead box D1 promotes EMT and chemoresistance by upregulating lncRNA CYTOR in oral
squamous cell carcinoma. Cancer letters 2021, 503, 43-53.

70.

Li, Z.; Yan, T.; Wu, X.; Zhang, W.; Li, J.; Wang, L.; Yang, J., Increased expression of FOXD1 is
associated with cervical node metastasis and unfavorable prognosis in oral squamous cell
carcinoma. Journal of oral pathology & medicine : official publication of the International
Association of Oral Pathologists and the American Academy of Oral Pathology 2020, 49 (10),
1030-1036.

71.

Lin, C. H.; Lee, H. H.; Chang, W. M.; Lee, F. P.; Chen, L. C.; Lu, L. S.; Lin, Y. F., FOXD1 Repression
Potentiates Radiation Effectiveness by Downregulating G3BP2 Expression and Promoting the
Activation of TXNIP-Related Pathways in Oral Cancer. Cancers 2020, 12 (9).

72.

Wang, Y.; Qiu, C.; Lu, N.; Liu, Z.; Jin, C.; Sun, C.; Bu, H.; Yu, H.; Dongol, S.; Kong, B., FOXD1 is
targeted by miR-30a-5p and miR-200a-5p and suppresses the proliferation of human ovarian
carcinoma cells by promoting p21 expression in a p53-independent manner. International
journal of oncology 2018, 52 (6), 2130-2142.

73.

Ju, W.; Yoo, B. C.; Kim, I. J.; Kim, J. W.; Kim, S. C.; Lee, H. P., Identification of genes with
differential expression in chemoresistant epithelial ovarian cancer using high-density
oligonucleotide microarrays. Oncology research 2009, 18 (2-3), 47-56.

74.

Zhao, Y. F.; Zhao, J. Y.; Yue, H.; Hu, K. S.; Shen, H.; Guo, Z. G.; Su, X. J., FOXD1 promotes breast
cancer proliferation and chemotherapeutic drug resistance by targeting p27. Biochemical and
biophysical research communications 2015, 456 (1), 232-7.

75.

Zhang, Y.; Yang, W.; Li, D.; Yang, J. Y.; Guan, R.; Yang, M. Q., Toward the precision breast
cancer survival prediction utilizing combined whole genome-wide expression and somatic
mutation analysis. BMC medical genomics 2018, 11 (Suppl 5), 104.

76.

Bai, J.; Luo, Y.; Zhang, S., Microarray data analysis reveals gene expression changes in response
to ionizing radiation in MCF7 human breast cancer cells. Hereditas 2020, 157 (1), 37.

77.

Zhou, H.; Lv, Q.; Guo, Z., Transcriptomic signature predicts the distant relapse in patients with
ER+ breast cancer treated with tamoxifen for five years. Molecular medicine reports 2018, 17
(2), 3152-3157.

109

78.

Liu, Q.; Song, X.; Liu, Z.; Yu, Z., Investigation of Candidate Genes and Pathways in Basal/TNBC
Patients by Integrated Analysis. Technology in cancer research & treatment 2021, 20,
15330338211019506.

79.

Gao, Y. F.; Zhu, T.; Mao, X. Y.; Mao, C. X.; Li, L.; Yin, J. Y.; Zhou, H. H.; Liu, Z. Q., Silencing of
Forkhead box D1 inhibits proliferation and migration in glioma cells. Oncology reports 2017, 37
(2), 1196-1202.

80.

Cheng, P.; Wang, J.; Waghmare, I.; Sartini, S.; Coviello, V.; Zhang, Z.; Kim, S. H.; Mohyeldin,
A.; Pavlyukov, M. S.; Minata, M.; Valentim, C. L.; Chhipa, R. R.; Bhat, K. P.; Dasgupta, B.; La
Motta, C.; Kango-Singh, M.; Nakano, I., FOXD1-ALDH1A3 Signaling Is a Determinant for the SelfRenewal and Tumorigenicity of Mesenchymal Glioma Stem Cells. Cancer Res 2016, 76 (24),
7219-7230.

81.

Ma, X. L.; Shang, F.; Ni, W.; Zhu, J.; Luo, B.; Zhang, Y. Q., MicroRNA-338-5p plays a tumor
suppressor role in glioma through inhibition of the MAPK-signaling pathway by binding to
FOXD1. Journal of cancer research and clinical oncology 2018, 144 (12), 2351-2366.

82.

Ma, Q.; Yang, T., E2F transcription factor 1/small nucleolar RNA host gene 18/microRNA-3385p/forkhead box D1: an important regulatory axis in glioma progression. Bioengineered 2022, 13
(1), 418-430.

83.

Yan, Q.; Liu, L.; Yang, H.; Xu, C.; Wang, Z.; Wang, Q.; Wu, Z.; Wu, C.; Dong, L.; Wang, J.; Wu,
M., Long Non-Coding RNA OIP5-AS1 Inhibits the Proliferation and Migration of Esophageal
Squamous Carcinoma Cells by Targeting FOXD1/miR-30a-5p Axis and the Effect of Micro- and
Nano-Particles on Targeting Transfection System. Journal of biomedical nanotechnology 2021,
17 (7), 1380-1391.

84.

Wu, L.; Liu, Y.; Guo, C.; Shao, Y., LncRNA OIP5-AS1 promotes the malignancy of pancreatic
ductal adenocarcinoma via regulating miR-429/FOXD1/ERK pathway. Cancer cell international
2020, 20, 296.

85.

Zhou, L.; Jia, S.; Ding, G.; Zhang, M.; Yu, W.; Wu, Z.; Cao, L., Down-regulation of miR-30a-5p is
Associated with Poor Prognosis and Promotes Chemoresistance of Gemcitabine in Pancreatic
Ductal Adenocarcinoma. Journal of Cancer 2019, 10 (21), 5031-5040.

86.

Zhang, D.; Zhang, Y.; Sun, X., LINC01133 promotes the progression of cervical cancer via
regulating miR-30a-5p/FOXD1. Asia-Pacific journal of clinical oncology 2021, 17 (3), 253-263.

110

87.

Chang, S.; Sun, L.; Feng, G., SP1-mediated long noncoding RNA POU3F3 accelerates the cervical
cancer through miR-127-5p/FOXD1. Biomedicine & pharmacotherapy = Biomedecine &
pharmacotherapie 2019, 117, 109133.

88.

Sun, D. S.; Guan, C. H.; Wang, W. N.; Hu, Z. T.; Zhao, Y. Q.; Jiang, X. M., LncRNA NORAD
promotes proliferation, migration and angiogenesis of hepatocellular carcinoma cells through
targeting miR-211-5p/FOXD1/VEGF-A axis. Microvascular research 2021, 134, 104120.

89.

Chen, J.; Qian, Z.; Li, F.; Li, J.; Lu, Y., Integrative Analysis of Microarray Data to Reveal
Regulation Patterns in the Pathogenesis of Hepatocellular Carcinoma. Gut and liver 2017, 11 (1),
112-120.

90.

Li, X.; Jiao, M.; Hu, J.; Qi, M.; Zhang, J.; Zhao, M.; Liu, H.; Xiong, X.; Dong, X.; Han, B., miR-30a
inhibits androgen-independent growth of prostate cancer via targeting MYBL2, FOXD1, and
SOX4. The Prostate 2020, 80 (9), 674-686.

91.

van der Heul-Nieuwenhuijsen, L.; Dits, N. F.; Jenster, G., Gene expression of forkhead
transcription factors in the normal and diseased human prostate. BJU international 2009, 103
(11), 1574-80.

92.

Fang, G.; Fan, J.; Ding, Z.; Li, R.; Lin, K.; Fu, J.; Huang, Q.; Zeng, Y.; Liu, J., Prognostic and
Predictive Value of Transcription Factors Panel for Digestive System Carcinoma. Frontiers in
oncology 2021, 11, 670129.

93.

Nagel, S.; Meyer, C.; Kaufmann, M.; Drexler, H. G.; MacLeod, R. A., Deregulated FOX genes in
Hodgkin lymphoma. Genes, chromosomes & cancer 2014, 53 (11), 917-33.

94.

Zhang, Y.; Wang, T.; Wang, S.; Xiong, Y.; Zhang, R.; Zhang, X.; Zhao, J.; Yang, A. G.; Wang, L.;
Jia, L., Nkx2-2as Suppression Contributes to the Pathogenesis of Sonic Hedgehog
Medulloblastoma. Cancer Res 2018, 78 (4), 962-973.

95.

Jia, Z.; Wan, F.; Zhu, Y.; Shi, G.; Zhang, H.; Dai, B.; Ye, D., Forkhead-box series expression
network is associated with outcome of clear-cell renal cell carcinoma. Oncology letters 2018, 15
(6), 8669-8680.

96.

Xu, G.; Li, K.; Zhang, N.; Zhu, B.; Feng, G., Screening Driving Transcription Factors in the
Processing of Gastric Cancer. Gastroenterology research and practice 2016, 2016, 8431480.

111

97.

Feng, D.; Ye, X.; Zhu, Z.; Wei, Z.; Cai, Q.; Wang, Y., Comparative transcriptome analysis
between metastatic and non-metastatic gastric cancer reveals potential biomarkers. Molecular
medicine reports 2015, 11 (1), 386-92.

98.

Fan, L.; Wang, J.; Deng, P.; Wang, Y.; Zhang, A.; Yang, M.; Zeng, G., Foxhead box D1 promotes
the partial epithelial-to-mesenchymal transition of laryngeal squamous cell carcinoma cells via
transcriptionally activating the expression of zinc finger protein 532. Bioengineered 2022, 13 (2),
3057-3069.

99.

O'Brien, J.; Hayder, H.; Zayed, Y.; Peng, C., Overview of MicroRNA Biogenesis, Mechanisms of
Actions, and Circulation. Frontiers in endocrinology 2018, 9, 402.

100.

Chung, Y. H.; Li, S. C.; Kao, Y. H.; Luo, H. L.; Cheng, Y. T.; Lin, P. R.; Tai, M. H.; Chiang, P. H.,
MiR-30a-5p Inhibits Epithelial-to-Mesenchymal Transition and Upregulates Expression of Tight
Junction Protein Claudin-5 in Human Upper Tract Urothelial Carcinoma Cells. International
journal of molecular sciences 2017, 18 (8).

101.

Jaju, R. J.; Haas, O. A.; Neat, M.; Harbott, J.; Saha, V.; Boultwood, J.; Brown, J. M.; PircDanoewinata, H.; Krings, B. W.; Müller, U.; Morris, S. W.; Wainscoat, J. S.; Kearney, L., A new
recurrent translocation, t(5;11)(q35;p15.5), associated with del(5q) in childhood acute myeloid
leukemia. The UK Cancer Cytogenetics Group (UKCCG). Blood 1999, 94 (2), 773-80.

102.

Mitchell, T. J.; Turajlic, S.; Rowan, A.; Nicol, D.; Farmery, J. H. R.; O'Brien, T.; Martincorena, I.;
Tarpey, P.; Angelopoulos, N.; Yates, L. R.; Butler, A. P.; Raine, K.; Stewart, G. D.; Challacombe,
B.; Fernando, A.; Lopez, J. I.; Hazell, S.; Chandra, A.; Chowdhury, S.; Rudman, S.; Soultati, A.;
Stamp, G.; Fotiadis, N.; Pickering, L.; Au, L.; Spain, L.; Lynch, J.; Stares, M.; Teague, J.; Maura,
F.; Wedge, D. C.; Horswell, S.; Chambers, T.; Litchfield, K.; Xu, H.; Stewart, A.; Elaidi, R.;
Oudard, S.; McGranahan, N.; Csabai, I.; Gore, M.; Futreal, P. A.; Larkin, J.; Lynch, A. G.;
Szallasi, Z.; Swanton, C.; Campbell, P. J., Timing the Landmark Events in the Evolution of Clear
Cell Renal Cell Cancer: TRACERx Renal. Cell 2018, 173 (3), 611-623.e17.

103.

Petty, E. M.; Bolognia, J. L.; Bale, A. E.; Yang-Feng, T., Cutaneous malignant melanoma and
atypical moles associated with a constitutional rearrangement of chromosomes 5 and 9.
American journal of medical genetics 1993, 45 (1), 77-80.

104.

Bruno, S.; Bussolati, B.; Grange, C.; Collino, F.; Graziano, M. E.; Ferrando, U.; Camussi, G.,
CD133+ renal progenitor cells contribute to tumor angiogenesis. Am J Pathol 2006, 169 (6),
2223-35.

105.

Qian, C. N.; Huang, D.; Wondergem, B.; Teh, B. T., Complexity of tumor vasculature in clear cell
renal cell carcinoma. Cancer 2009, 115 (10 Suppl), 2282-9.

112

106.

Jassal, B.; Matthews, L.; Viteri, G.; Gong, C.; Lorente, P.; Fabregat, A.; Sidiropoulos, K.; Cook,
J.; Gillespie, M.; Haw, R.; Loney, F.; May, B.; Milacic, M.; Rothfels, K.; Sevilla, C.; Shamovsky,
V.; Shorser, S.; Varusai, T.; Weiser, J.; Wu, G.; Stein, L.; Hermjakob, H.; D'Eustachio, P., The
reactome pathway knowledgebase. Nucleic acids research 2020, 48 (D1), D498-d503.

107.

Shannon, P.; Markiel, A.; Ozier, O.; Baliga, N. S.; Wang, J. T.; Ramage, D.; Amin, N.;
Schwikowski, B.; Ideker, T., Cytoscape: a software environment for integrated models of
biomolecular interaction networks. Genome research 2003, 13 (11), 2498-504.

108.

Williams, R. D.; Elliott, A. Y.; Stein, N.; Fraley, E. E., In vitro cultivation of human renal cell
cancer. II. Characterization of cell lines. In Vitro 1978, 14 (9), 779-86.

109.

Shanmughapriya, S.; Tomar, D.; Dong, Z.; Slovik, K. J.; Nemani, N.; Natarajaseenivasan, K.;
Carvalho, E.; Lu, C.; Corrigan, K.; Garikipati, V. N. S.; Ibetti, J.; Rajan, S.; Barrero, C.; Chuprun,
K.; Kishore, R.; Merali, S.; Tian, Y.; Yang, W.; Madesh, M., FOXD1-dependent MICU1 expression
regulates mitochondrial activity and cell differentiation. Nature communications 2018, 9 (1),
3449.

110.

Briston, T.; Stephen, J. M.; Thomas, L. W.; Esposito, C.; Chung, Y. L.; Syafruddin, S. E.;
Turmaine, M.; Maddalena, L. A.; Greef, B.; Szabadkai, G.; Maxwell, P. H.; Vanharanta, S.;
Ashcroft, M., VHL-Mediated Regulation of CHCHD4 and Mitochondrial Function. Frontiers in
oncology 2018, 8, 388.

111.

Kim, J. W.; Tchernyshyov, I.; Semenza, G. L.; Dang, C. V., HIF-1-mediated expression of pyruvate
dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell
metabolism 2006, 3 (3), 177-85.

112.

Wang, X.; Zhang, L.; O'Neill, A.; Bahamon, B.; Alsop, D. C.; Mier, J. W.; Goldberg, S. N.;
Signoretti, S.; Atkins, M. B.; Wood, C. G.; Bhatt, R. S., Cox-2 inhibition enhances the activity of
sunitinib in human renal cell carcinoma xenografts. Br J Cancer 2013, 108 (2), 319-26.

113.

Bhatt, R. S.; Wang, X.; Zhang, L.; Collins, M. P.; Signoretti, S.; Alsop, D. C.; Goldberg, S. N.;
Atkins, M. B.; Mier, J. W., Renal cancer resistance to antiangiogenic therapy is delayed by
restoration of angiostatic signaling. Mol Cancer Ther 2010, 9 (10), 2793-802.

114.

Lindqvist, A.; Rodríguez-Bravo, V.; Medema, R. H., The decision to enter mitosis: feedback and
redundancy in the mitotic entry network. The Journal of cell biology 2009, 185 (2), 193-202.

115.

Strelkov, I. S.; Davie, J. R., Ser-10 phosphorylation of histone H3 and immediate early gene
expression in oncogene-transformed mouse fibroblasts. Cancer Res 2002, 62 (1), 75-8.

113

116.

Oktay, K.; Buyuk, E.; Oktem, O.; Oktay, M.; Giancotti, F. G., The c-Jun N-terminal kinase JNK
functions upstream of Aurora B to promote entry into mitosis. Cell Cycle 2008, 7 (4), 533-41.

117.

Hendzel, M. J.; Wei, Y.; Mancini, M. A.; Van Hooser, A.; Ranalli, T.; Brinkley, B. R.; BazettJones, D. P.; Allis, C. D., Mitosis-specific phosphorylation of histone H3 initiates primarily within
pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with
mitotic chromosome condensation. Chromosoma 1997, 106 (6), 348-60.

118.

Wei, Y.; Yu, L.; Bowen, J.; Gorovsky, M. A.; Allis, C. D., Phosphorylation of histone H3 is
required for proper chromosome condensation and segregation. Cell 1999, 97 (1), 99-109.

119.

Cancer_Genome_Atlas_Research_Network, Comprehensive molecular characterization of clear
cell renal cell carcinoma. Nature 2013, 499 (7456), 43-9.

120.

Lunt, S. Y.; Vander Heiden, M. G., Aerobic glycolysis: meeting the metabolic requirements of cell
proliferation. Annual review of cell and developmental biology 2011, 27, 441-64.

121.

Yoda, K.; Ando, S.; Morishita, S.; Houmura, K.; Hashimoto, K.; Takeyasu, K.; Okazaki, T.,
Human centromere protein A (CENP-A) can replace histone H3 in nucleosome reconstitution in
vitro. Proc Natl Acad Sci U S A 2000, 97 (13), 7266-71.

122.

Dimitriadis, E. K.; Weber, C.; Gill, R. K.; Diekmann, S.; Dalal, Y., Tetrameric organization of
vertebrate centromeric nucleosomes. Proc Natl Acad Sci U S A 2010, 107 (47), 20317-22.

123.

Bui, M.; Dimitriadis, E. K.; Hoischen, C.; An, E.; Quénet, D.; Giebe, S.; Nita-Lazar, A.;
Diekmann, S.; Dalal, Y., Cell-cycle-dependent structural transitions in the human CENP-A
nucleosome in vivo. Cell 2012, 150 (2), 317-26.

124.

Frew, I. J.; Moch, H., A clearer view of the molecular complexity of clear cell renal cell
carcinoma. Annu Rev Pathol 2015, 10, 263-89.

125.

Kobayashi, A.; Mugford, J. W.; Krautzberger, A. M.; Naiman, N.; Liao, J.; McMahon, A. P.,
Identification of a multipotent self-renewing stromal progenitor population during mammalian
kidney organogenesis. Stem cell reports 2014, 3 (4), 650-62.

126.

Lindstrom, N. O.; Guo, J.; Kim, A. D.; Tran, T.; Guo, Q.; De Sena Brandine, G.; Ransick, A.;
Parvez, R. K.; Thornton, M. E.; Basking, L.; Grubbs, B.; McMahon, J. A.; Smith, A. D.;
McMahon, A. P., Conserved and Divergent Features of Mesenchymal Progenitor Cell Types
within the Cortical Nephrogenic Niche of the Human and Mouse Kidney. Journal of the American
Society of Nephrology : JASN 2018.

114

127.

Liu, J.; Edgington-Giordano, F.; Dugas, C.; Abrams, A.; Katakam, P.; Satou, R.; Saifudeen, Z.,
Regulation of Nephron Progenitor Cell Self-Renewal by Intermediary Metabolism. Journal of the
American Society of Nephrology : JASN 2017, 28 (11), 3323-3335.

128.

Bond, K. H.; Fetting, J. L.; Lary, C. W.; Emery, I. F.; Oxburgh, L., FOXD1 regulates cell division in
clear cell renal cell carcinoma. BMC cancer 2021, 21 (1), 312.

129.

Siegel, R. L.; Miller, K. D.; Jemal, A., Cancer statistics, 2020. CA Cancer J Clin 2020, 70 (1), 7-30.

130.

Haake, S. M.; Rathmell, W. K., Renal cancer subtypes: Should we be lumping or splitting for
therapeutic decision making? Cancer 2017, 123 (2), 200-209.

131.

Nickerson, M. L.; Jaeger, E.; Shi, Y.; Durocher, J. A.; Mahurkar, S.; Zaridze, D.; Matveev, V.;
Janout, V.; Kollarova, H.; Bencko, V.; Navratilova, M.; Szeszenia-Dabrowska, N.; Mates, D.;
Mukeria, A.; Holcatova, I.; Schmidt, L. S.; Toro, J. R.; Karami, S.; Hung, R.; Gerard, G. F.;
Linehan, W. M.; Merino, M.; Zbar, B.; Boffetta, P.; Brennan, P.; Rothman, N.; Chow, W. H.;
Waldman, F. M.; Moore, L. E., Improved identification of von Hippel-Lindau gene alterations in
clear cell renal tumors. Clin Cancer Res 2008, 14 (15), 4726-34.

132.

Iliopoulos, O.; Levy, A. P.; Jiang, C.; Kaelin, W. G., Jr.; Goldberg, M. A., Negative regulation of
hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 1996, 93
(20), 10595-9.

133.

Choueiri, T. K.; Kaelin, W. G., Jr., Targeting the HIF2-VEGF axis in renal cell carcinoma. Nat Med
2020, 26 (10), 1519-1530.

134.

Lindgren, D.; Sjölund, J.; Axelson, H., Tracing Renal Cell Carcinomas back to the Nephron. Trends
Cancer 2018, 4 (7), 472-484.

135.

Delahunt, B.; Srigley, J. R., The evolving classification of renal cell neoplasia. Semin Diagn Pathol
2015, 32 (2), 90-102.

136.

Weaver, V. M.; Petersen, O. W.; Wang, F.; Larabell, C. A.; Briand, P.; Damsky, C.; Bissell, M. J.,
Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in
vivo by integrin blocking antibodies. J Cell Biol 1997, 137 (1), 231-45.

137.

Mettouchi, A.; Klein, S.; Guo, W.; Lopez-Lago, M.; Lemichez, E.; Westwick, J. K.; Giancotti, F.
G., Integrin-specific activation of Rac controls progression through the G(1) phase of the cell
cycle. Mol Cell 2001, 8 (1), 115-27.

115

138.

Brooks, P. C.; Clark, R. A.; Cheresh, D. A., Requirement of vascular integrin alpha v beta 3 for
angiogenesis. Science 1994, 264 (5158), 569-71.

139.

Brooks, P. C.; Montgomery, A. M.; Rosenfeld, M.; Reisfeld, R. A.; Hu, T.; Klier, G.; Cheresh, D.
A., Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of
angiogenic blood vessels. Cell 1994, 79 (7), 1157-64.

140.

Wang, Y.; McNiven, M. A., Invasive matrix degradation at focal adhesions occurs via protease
recruitment by a FAK-p130Cas complex. J Cell Biol 2012, 196 (3), 375-85.

141.

Paszek, M. J.; Zahir, N.; Johnson, K. R.; Lakins, J. N.; Rozenberg, G. I.; Gefen, A.; Reinhart-King,
C. A.; Margulies, S. S.; Dembo, M.; Boettiger, D.; Hammer, D. A.; Weaver, V. M., Tensional
homeostasis and the malignant phenotype. Cancer Cell 2005, 8 (3), 241-54.

142.

Guo, W.; Pylayeva, Y.; Pepe, A.; Yoshioka, T.; Muller, W. J.; Inghirami, G.; Giancotti, F. G., Beta
4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell 2006, 126 (3),
489-502.

143.

Naba, A.; Clauser, K. R.; Ding, H.; Whittaker, C. A.; Carr, S. A.; Hynes, R. O., The extracellular
matrix: Tools and insights for the "omics" era. Matrix Biol 2016, 49, 10-24.

144.

Tian, C.; Clauser, K. R.; Öhlund, D.; Rickelt, S.; Huang, Y.; Gupta, M.; Mani, D. R.; Carr, S. A.;
Tuveson, D. A.; Hynes, R. O., Proteomic analyses of ECM during pancreatic ductal
adenocarcinoma progression reveal different contributions by tumor and stromal cells. Proc Natl
Acad Sci U S A 2019, 116 (39), 19609-19618.

145.

Avery, D.; Govindaraju, P.; Jacob, M.; Todd, L.; Monslow, J.; Puré, E., Extracellular matrix
directs phenotypic heterogeneity of activated fibroblasts. Matrix Biol 2018, 67, 90-106.

146.

Neal, J. T.; Li, X.; Zhu, J.; Giangarra, V.; Grzeskowiak, C. L.; Ju, J.; Liu, I. H.; Chiou, S. H.;
Salahudeen, A. A.; Smith, A. R.; Deutsch, B. C.; Liao, L.; Zemek, A. J.; Zhao, F.; Karlsson, K.;
Schultz, L. M.; Metzner, T. J.; Nadauld, L. D.; Tseng, Y. Y.; Alkhairy, S.; Oh, C.; Keskula, P.;
Mendoza-Villanueva, D.; De La Vega, F. M.; Kunz, P. L.; Liao, J. C.; Leppert, J. T.; Sunwoo, J. B.;
Sabatti, C.; Boehm, J. S.; Hahn, W. C.; Zheng, G. X. Y.; Davis, M. M.; Kuo, C. J., Organoid
Modeling of the Tumor Immune Microenvironment. Cell 2018, 175 (7), 1972-1988.e16.

147.

Driehuis, E.; Kretzschmar, K.; Clevers, H., Establishment of patient-derived cancer organoids for
drug-screening applications. Nat Protoc 2020, 15 (10), 3380-3409.

116

148.

Orkin, R. W.; Gehron, P.; McGoodwin, E. B.; Martin, G. R.; Valentine, T.; Swarm, R., A murine
tumor producing a matrix of basement membrane. J Exp Med 1977, 145 (1), 204-20.

149.

Sato, T.; Stange, D. E.; Ferrante, M.; Vries, R. G.; Van Es, J. H.; Van den Brink, S.; Van Houdt,
W. J.; Pronk, A.; Van Gorp, J.; Siersema, P. D.; Clevers, H., Long-term expansion of epithelial
organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium.
Gastroenterology 2011, 141 (5), 1762-72.

150.

Xia, X.; Li, F.; He, J.; Aji, R.; Gao, D., Organoid technology in cancer precision medicine. Cancer
Lett 2019, 457, 20-27.

151.

Pauli, C.; Hopkins, B. D.; Prandi, D.; Shaw, R.; Fedrizzi, T.; Sboner, A.; Sailer, V.; Augello, M.;
Puca, L.; Rosati, R.; McNary, T. J.; Churakova, Y.; Cheung, C.; Triscott, J.; Pisapia, D.; Rao, R.;
Mosquera, J. M.; Robinson, B.; Faltas, B. M.; Emerling, B. E.; Gadi, V. K.; Bernard, B.;
Elemento, O.; Beltran, H.; Demichelis, F.; Kemp, C. J.; Grandori, C.; Cantley, L. C.; Rubin, M. A.,
Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. Cancer Discov
2017, 7 (5), 462-477.

152.

Rostama, B.; Beauchemin, M.; Bouchard, C.; Bernier, E.; Vary, C. P. H.; May, M.; Houseknecht,
K. L., Understanding Mechanisms Underlying Non-Alcoholic Fatty Liver Disease (NAFLD) in
Mental Illness: Risperidone and Olanzapine Alter the Hepatic Proteomic Signature in Mice. Int J
Mol Sci 2020, 21 (24).

153.

Peterson, S. M.; Turner, J. E.; Harrington, A.; Davis-Knowlton, J.; Lindner, V.; Gridley, T.; Vary,
C. P. H.; Liaw, L., Notch2 and Proteomic Signatures in Mouse Neointimal Lesion Formation.
Arterioscler Thromb Vasc Biol 2018, 38 (7), 1576-1593.

154.

Kang, Y.; Burton, L.; Lau, A.; Tate, S., SWATH-ID: An instrument method which combines
identification and quantification in a single analysis. Proteomics 2017.

155.

Beauchemin, M.; Geguchadze, R.; Guntur, A. R.; Nevola, K.; Le, P. T.; Barlow, D.; Rue, M.;
Vary, C. P. H.; Lary, C. W.; Motyl, K. J.; Houseknecht, K. L., Exploring mechanisms of increased
cardiovascular disease risk with antipsychotic medications: Risperidone alters the cardiac
proteomic signature in mice. Pharmacol Res 2020, 152, 104589.

156.

Ivosev, G.; Burton, L.; Bonner, R., Dimensionality reduction and visualization in principal
component analysis. Analytical chemistry 2008, 80 (13), 4933-44.

157.

Shao, X.; Taha, I. N.; Clauser, K. R.; Gao, Y. T.; Naba, A., MatrisomeDB: the ECM-protein
knowledge database. Nucleic Acids Res 2020, 48 (D1), D1136-d1144.

117

158.

Hynes, R. O.; Naba, A., Overview of the matrisome--an inventory of extracellular matrix
constituents and functions. Cold Spring Harb Perspect Biol 2012, 4 (1), a004903.

159.

Liu, J.; Tan, Y.; Zhang, H.; Zhang, Y.; Xu, P.; Chen, J.; Poh, Y. C.; Tang, K.; Wang, N.; Huang, B.,
Soft fibrin gels promote selection and growth of tumorigenic cells. Nat Mater 2012, 11 (8), 73441.

160.

Young, M. D.; Mitchell, T. J.; Vieira Braga, F. A.; Tran, M. G. B.; Stewart, B. J.; Ferdinand, J. R.;
Collord, G.; Botting, R. A.; Popescu, D. M.; Loudon, K. W.; Vento-Tormo, R.; Stephenson, E.;
Cagan, A.; Farndon, S. J.; Del Castillo Velasco-Herrera, M.; Guzzo, C.; Richoz, N.; Mamanova,
L.; Aho, T.; Armitage, J. N.; Riddick, A. C. P.; Mushtaq, I.; Farrell, S.; Rampling, D.; Nicholson,
J.; Filby, A.; Burge, J.; Lisgo, S.; Maxwell, P. H.; Lindsay, S.; Warren, A. Y.; Stewart, G. D.;
Sebire, N.; Coleman, N.; Haniffa, M.; Teichmann, S. A.; Clatworthy, M.; Behjati, S., Single-cell
transcriptomes from human kidneys reveal the cellular identity of renal tumors. Science 2018,
361 (6402), 594-599.

161.

Uhlén, M.; Fagerberg, L.; Hallström, B. M.; Lindskog, C.; Oksvold, P.; Mardinoglu, A.;
Sivertsson, Å.; Kampf, C.; Sjöstedt, E.; Asplund, A.; Olsson, I.; Edlund, K.; Lundberg, E.;
Navani, S.; Szigyarto, C. A.; Odeberg, J.; Djureinovic, D.; Takanen, J. O.; Hober, S.; Alm, T.;
Edqvist, P. H.; Berling, H.; Tegel, H.; Mulder, J.; Rockberg, J.; Nilsson, P.; Schwenk, J. M.;
Hamsten, M.; von Feilitzen, K.; Forsberg, M.; Persson, L.; Johansson, F.; Zwahlen, M.; von
Heijne, G.; Nielsen, J.; Pontén, F., Proteomics. Tissue-based map of the human proteome.
Science 2015, 347 (6220), 1260419.

162.

McKeehan, W. L.; Ham, R. G., Methods for reducing the serum requirement for growth in vitro
of nontransformed diploid fibroblasts. Dev Biol Stand 1976, 37, 97-8.

163.

Whateley, J. G.; Knox, P., Isolation of a serum component that stimulates the spreading of cells
in culture. Biochem J 1980, 185 (2), 349-54.

164.

Wu, J. X.; Song, X.; Pascovici, D.; Zaw, T.; Care, N.; Krisp, C.; Molloy, M. P., SWATH Mass
Spectrometry Performance Using Extended Peptide MS/MS Assay Libraries. Mol Cell Proteomics
2016, 15 (7), 2501-14.

165.

Krasny, L.; Bland, P.; Kogata, N.; Wai, P.; Howard, B. A.; Natrajan, R. C.; Huang, P. H., SWATH
mass spectrometry as a tool for quantitative profiling of the matrisome. J Proteomics 2018, 189,
11-22.

118

166.

Courtney, K. D.; Bezwada, D.; Mashimo, T.; Pichumani, K.; Vemireddy, V.; Funk, A. M.;
Wimberly, J.; McNeil, S. S.; Kapur, P.; Lotan, Y.; Margulis, V.; Cadeddu, J. A.; Pedrosa, I.;
DeBerardinis, R. J.; Malloy, C. R.; Bachoo, R. M.; Maher, E. A., Isotope Tracing of Human Clear
Cell Renal Cell Carcinomas Demonstrates Suppressed Glucose Oxidation In Vivo. Cell Metab
2018, 28 (5), 793-800.e2.

167.

Naba, A.; Clauser, K. R.; Hoersch, S.; Liu, H.; Carr, S. A.; Hynes, R. O., The matrisome: in silico
definition and in vivo characterization by proteomics of normal and tumor extracellular
matrices. Mol Cell Proteomics 2012, 11 (4), M111.014647.

168.

Gillet, L. C.; Navarro, P.; Tate, S.; Röst, H.; Selevsek, N.; Reiter, L.; Bonner, R.; Aebersold, R.,
Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a
new concept for consistent and accurate proteome analysis. Mol Cell Proteomics 2012, 11 (6),
O111.016717.

169.

Sahai, E.; Astsaturov, I.; Cukierman, E.; DeNardo, D. G.; Egeblad, M.; Evans, R. M.; Fearon, D.;
Greten, F. R.; Hingorani, S. R.; Hunter, T.; Hynes, R. O.; Jain, R. K.; Janowitz, T.; Jorgensen, C.;
Kimmelman, A. C.; Kolonin, M. G.; Maki, R. G.; Powers, R. S.; Puré, E.; Ramirez, D. C.; ScherzShouval, R.; Sherman, M. H.; Stewart, S.; Tlsty, T. D.; Tuveson, D. A.; Watt, F. M.; Weaver, V.;
Weeraratna, A. T.; Werb, Z., A framework for advancing our understanding of cancer-associated
fibroblasts. Nat Rev Cancer 2020, 20 (3), 174-186.

170.

Lin, Y.; Xu, J.; Lan, H., Tumor-associated macrophages in tumor metastasis: biological roles and
clinical therapeutic applications. J Hematol Oncol 2019, 12 (1), 76.

171.

Cornil, I.; Theodorescu, D.; Man, S.; Herlyn, M.; Jambrosic, J.; Kerbel, R. S., Fibroblast cell
interactions with human melanoma cells affect tumor cell growth as a function of tumor
progression. Proc Natl Acad Sci U S A 1991, 88 (14), 6028-32.

172.

Costa, A.; Kieffer, Y.; Scholer-Dahirel, A.; Pelon, F.; Bourachot, B.; Cardon, M.; Sirven, P.;
Magagna, I.; Fuhrmann, L.; Bernard, C.; Bonneau, C.; Kondratova, M.; Kuperstein, I.;
Zinovyev, A.; Givel, A. M.; Parrini, M. C.; Soumelis, V.; Vincent-Salomon, A.; Mechta-Grigoriou,
F., Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer.
Cancer Cell 2018, 33 (3), 463-479.e10.

173.

Torres, S.; Garcia-Palmero, I.; Herrera, M.; Bartolomé, R. A.; Peña, C.; Fernandez-Aceñero, M.
J.; Padilla, G.; Peláez-García, A.; Lopez-Lucendo, M.; Rodriguez-Merlo, R.; García de Herreros,
A.; Bonilla, F.; Casal, J. I., LOXL2 Is Highly Expressed in Cancer-Associated Fibroblasts and
Associates to Poor Colon Cancer Survival. Clin Cancer Res 2015, 21 (21), 4892-902.

119

174.

Rupp, C.; Scherzer, M.; Rudisch, A.; Unger, C.; Haslinger, C.; Schweifer, N.; Artaker, M.;
Nivarthi, H.; Moriggl, R.; Hengstschläger, M.; Kerjaschki, D.; Sommergruber, W.; Dolznig, H.;
Garin-Chesa, P., IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon
cancer through a paracrine tumor-stroma interaction. Oncogene 2015, 34 (7), 815-25.

175.

Lindop, G. B.; Fleming, S., Renin in renal cell carcinoma--an immunocytochemical study using an
antibody to pure human renin. J Clin Pathol 1984, 37 (1), 27-31.

176.

Bregenzer, M. E.; Horst, E. N.; Mehta, P.; Novak, C. M.; Raghavan, S.; Snyder, C. S.; Mehta, G.,
Integrated cancer tissue engineering models for precision medicine. PLoS One 2019, 14 (5),
e0216564.

177.

Puca, L.; Bareja, R.; Prandi, D.; Shaw, R.; Benelli, M.; Karthaus, W. R.; Hess, J.; Sigouros, M.;
Donoghue, A.; Kossai, M.; Gao, D.; Cyrta, J.; Sailer, V.; Vosoughi, A.; Pauli, C.; Churakova, Y.;
Cheung, C.; Deonarine, L. D.; McNary, T. J.; Rosati, R.; Tagawa, S. T.; Nanus, D. M.; Mosquera,
J. M.; Sawyers, C. L.; Chen, Y.; Inghirami, G.; Rao, R. A.; Grandori, C.; Elemento, O.; Sboner,
A.; Demichelis, F.; Rubin, M. A.; Beltran, H., Patient derived organoids to model rare prostate
cancer phenotypes. Nat Commun 2018, 9 (1), 2404.

178.

Kim, M.; Mun, H.; Sung, C. O.; Cho, E. J.; Jeon, H. J.; Chun, S. M.; Jung, D. J.; Shin, T. H.;
Jeong, G. S.; Kim, D. K.; Choi, E. K.; Jeong, S. Y.; Taylor, A. M.; Jain, S.; Meyerson, M.; Jang, S.
J., Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nat
Commun 2019, 10 (1), 3991.

179.

Yuki, K.; Cheng, N.; Nakano, M.; Kuo, C. J., Organoid Models of Tumor Immunology. Trends
Immunol 2020, 41 (8), 652-664.

180.

Janmey, P. A.; Winer, J. P.; Weisel, J. W., Fibrin gels and their clinical and bioengineering
applications. J R Soc Interface 2009, 6 (30), 1-10.

181.

Singh, S. K.; Clarke, I. D.; Terasaki, M.; Bonn, V. E.; Hawkins, C.; Squire, J.; Dirks, P. B.,
Identification of a cancer stem cell in human brain tumors. Cancer Res 2003, 63 (18), 5821-8.

182.

Gimona, M.; Buccione, R.; Courtneidge, S. A.; Linder, S., Assembly and biological role of
podosomes and invadopodia. Curr Opin Cell Biol 2008, 20 (2), 235-41.

183.

Friedl, P.; Alexander, S., Cancer invasion and the microenvironment: plasticity and reciprocity.
Cell 2011, 147 (5), 992-1009.

120

184.

Anderson, A. R.; Weaver, A. M.; Cummings, P. T.; Quaranta, V., Tumor morphology and
phenotypic evolution driven by selective pressure from the microenvironment. Cell 2006, 127
(5), 905-15.

185.

Miki, J.; Furusato, B.; Li, H.; Gu, Y.; Takahashi, H.; Egawa, S.; Sesterhenn, I. A.; McLeod, D. G.;
Srivastava, S.; Rhim, J. S., Identification of putative stem cell markers, CD133 and CXCR4, in
hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate
epithelial cell lines and in prostate cancer specimens. Cancer Res 2007, 67 (7), 3153-61.

186.

Fendler, A.; Bauer, D.; Busch, J.; Jung, K.; Wulf-Goldenberg, A.; Kunz, S.; Song, K.;
Myszczyszyn, A.; Elezkurtaj, S.; Erguen, B.; Jung, S.; Chen, W.; Birchmeier, W., Inhibiting WNT
and NOTCH in renal cancer stem cells and the implications for human patients. Nat Commun
2020, 11 (1), 929.

187.

Egeblad, M.; Nakasone, E. S.; Werb, Z., Tumors as organs: complex tissues that interface with
the entire organism. Dev Cell 2010, 18 (6), 884-901.

188.

Shen, C.; Kaelin, W. G., Jr., The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol
2013, 23 (1), 18-25.

189.

Wang, Z.; Dabrosin, C.; Yin, X.; Fuster, M. M.; Arreola, A.; Rathmell, W. K.; Generali, D.;
Nagaraju, G. P.; El-Rayes, B.; Ribatti, D.; Chen, Y. C.; Honoki, K.; Fujii, H.; Georgakilas, A. G.;
Nowsheen, S.; Amedei, A.; Niccolai, E.; Amin, A.; Ashraf, S. S.; Helferich, B.; Yang, X.; Guha,
G.; Bhakta, D.; Ciriolo, M. R.; Aquilano, K.; Chen, S.; Halicka, D.; Mohammed, S. I.; Azmi, A. S.;
Bilsland, A.; Keith, W. N.; Jensen, L. D., Broad targeting of angiogenesis for cancer prevention
and therapy. Semin Cancer Biol 2015, 35 Suppl (Suppl), S224-s243.

190.

Rini, B. I.; Battle, D.; Figlin, R. A.; George, D. J.; Hammers, H.; Hutson, T.; Jonasch, E.; Joseph,
R. W.; McDermott, D. F.; Motzer, R. J.; Pal, S. K.; Pantuck, A. J.; Quinn, D. I.; Seery, V.; Voss,
M. H.; Wood, C. G.; Wood, L. S.; Atkins, M. B., The society for immunotherapy of cancer
consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma
(RCC). J Immunother Cancer 2019, 7 (1), 354.

191.

De Palma, M.; Biziato, D.; Petrova, T. V., Microenvironmental regulation of tumour
angiogenesis. Nat Rev Cancer 2017, 17 (8), 457-474.

192.

Flavell, R. A.; Sanjabi, S.; Wrzesinski, S. H.; Licona-Limón, P., The polarization of immune cells in
the tumour environment by TGFbeta. Nat Rev Immunol 2010, 10 (8), 554-67.

121

193.

Yang, X.; Lin, Y.; Shi, Y.; Li, B.; Liu, W.; Yin, W.; Dang, Y.; Chu, Y.; Fan, J.; He, R., FAP Promotes
Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via
STAT3-CCL2 Signaling. Cancer Res 2016, 76 (14), 4124-35.

194.

Motrescu, E. R.; Blaise, S.; Etique, N.; Messaddeq, N.; Chenard, M. P.; Stoll, I.; Tomasetto, C.;
Rio, M. C., Matrix metalloproteinase-11/stromelysin-3 exhibits collagenolytic function against
collagen VI under normal and malignant conditions. Oncogene 2008, 27 (49), 6347-55.

195.

Nanda, A.; Carson-Walter, E. B.; Seaman, S.; Barber, T. D.; Stampfl, J.; Singh, S.; Vogelstein,
B.; Kinzler, K. W.; St Croix, B., TEM8 interacts with the cleaved C5 domain of collagen alpha
3(VI). Cancer Res 2004, 64 (3), 817-20.

196.

Iyengar, P.; Espina, V.; Williams, T. W.; Lin, Y.; Berry, D.; Jelicks, L. A.; Lee, H.; Temple, K.;
Graves, R.; Pollard, J.; Chopra, N.; Russell, R. G.; Sasisekharan, R.; Trock, B. J.; Lippman, M.;
Calvert, V. S.; Petricoin, E. F., 3rd; Liotta, L.; Dadachova, E.; Pestell, R. G.; Lisanti, M. P.;
Bonaldo, P.; Scherer, P. E., Adipocyte-derived collagen VI affects early mammary tumor
progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment.
J Clin Invest 2005, 115 (5), 1163-76.

197.

Rühl, M.; Sahin, E.; Johannsen, M.; Somasundaram, R.; Manski, D.; Riecken, E. O.; Schuppan,
D., Soluble collagen VI drives serum-starved fibroblasts through S phase and prevents apoptosis
via down-regulation of Bax. J Biol Chem 1999, 274 (48), 34361-8.

198.

You, W. K.; Bonaldo, P.; Stallcup, W. B., Collagen VI ablation retards brain tumor progression
due to deficits in assembly of the vascular basal lamina. Am J Pathol 2012, 180 (3), 1145-1158.

199.

Han, S. W.; Roman, J., Fibronectin induces cell proliferation and inhibits apoptosis in human
bronchial epithelial cells: pro-oncogenic effects mediated by PI3-kinase and NF-kappa B.
Oncogene 2006, 25 (31), 4341-9.

200.

Han, S.; Khuri, F. R.; Roman, J., Fibronectin stimulates non-small cell lung carcinoma cell growth
through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of
LKB1/AMP-activated protein kinase signal pathways. Cancer Res 2006, 66 (1), 315-23.

201.

Huang, W.; Chiquet-Ehrismann, R.; Moyano, J. V.; Garcia-Pardo, A.; Orend, G., Interference of
tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell
proliferation. Cancer Res 2001, 61 (23), 8586-94.

202.

Yoshida, T.; Yoshimura, E.; Numata, H.; Sakakura, Y.; Sakakura, T., Involvement of tenascin-C in
proliferation and migration of laryngeal carcinoma cells. Virchows Arch 1999, 435 (5), 496-500.

122

203.

Guo, S. K.; Shen, M. F.; Yao, H. W.; Liu, Y. S., Enhanced Expression of TGFBI Promotes the
Proliferation and Migration of Glioma Cells. Cell Physiol Biochem 2018, 49 (3), 1097-1109.

204.

Bao, S.; Ouyang, G.; Bai, X.; Huang, Z.; Ma, C.; Liu, M.; Shao, R.; Anderson, R. M.; Rich, J. N.;
Wang, X. F., Periostin potently promotes metastatic growth of colon cancer by augmenting cell
survival via the Akt/PKB pathway. Cancer Cell 2004, 5 (4), 329-39.

205.

Levental, K. R.; Yu, H.; Kass, L.; Lakins, J. N.; Egeblad, M.; Erler, J. T.; Fong, S. F.; Csiszar, K.;
Giaccia, A.; Weninger, W.; Yamauchi, M.; Gasser, D. L.; Weaver, V. M., Matrix crosslinking
forces tumor progression by enhancing integrin signaling. Cell 2009, 139 (5), 891-906.

206.

Abbott, A.; Bond, K.; Chiba, T.; Sims-Lucas, S.; Oxburgh, L.; Coburn, J. M., Development of a
mechanically matched silk scaffolded 3D clear cell renal cell carcinoma model. Mater Sci Eng C
Mater Biol Appl 2021, 126, 112141.

207.

De Wever, O.; Demetter, P.; Mareel, M.; Bracke, M., Stromal myofibroblasts are drivers of
invasive cancer growth. Int J Cancer 2008, 123 (10), 2229-38.

208.

Siljee, S.; Milne, B.; Brasch, H. D.; Bockett, N.; Patel, J.; Davis, P. F.; Kennedy-Smith, A.;
Itinteang, T.; Tan, S. T., Expression of Components of the Renin-Angiotensin System by Cancer
Stem Cells in Renal Clear Cell Carcinoma. Biomolecules 2021, 11 (4).

209.

Everett, A. D.; Carey, R. M.; Chevalier, R. L.; Peach, M. J.; Gomez, R. A., Renin release and gene
expression in intact rat kidney microvessels and single cells. J Clin Invest 1990, 86 (1), 169-75.

210.

Sequeira López, M. L.; Pentz, E. S.; Nomasa, T.; Smithies, O.; Gomez, R. A., Renin cells are
precursors for multiple cell types that switch to the renin phenotype when homeostasis is
threatened. Dev Cell 2004, 6 (5), 719-28.

211.

McKay, R. R.; Rodriguez, G. E.; Lin, X.; Kaymakcalan, M. D.; Hamnvik, O. P.; Sabbisetti, V. S.;
Bhatt, R. S.; Simantov, R.; Choueiri, T. K., Angiotensin system inhibitors and survival outcomes in
patients with metastatic renal cell carcinoma. Clin Cancer Res 2015, 21 (11), 2471-9.

212.

Khanna, P.; Soh, H. J.; Chen, C. H.; Saxena, R.; Amin, S.; Naughton, M.; Joslin, P. N.; Moore,
A.; Bakouny, Z.; O'Callaghan, C.; Catalano, P.; Signoretti, S.; McKay, R.; Choueiri, T. K.; Bhasin,
M.; Walther, T.; Bhatt, R. S., ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting
angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma. Sci Transl Med 2021, 13 (577).

123

213.

Bond, K. H.; Chiba, T.; Wynne, K. P. H.; Vary, C. P. H.; Sims-Lucas, S.; Coburn, J. M.; Oxburgh,
L., The Extracellular Matrix Environment of Clear Cell Renal Cell Carcinoma Determines Cancer
Associated Fibroblast Growth. Cancers 2021, 13 (23).

214.

Gearing, L. J.; Cumming, H. E.; Chapman, R.; Finkel, A. M.; Woodhouse, I. B.; Luu, K.; Gould, J.
A.; Forster, S. C.; Hertzog, P. J., CiiiDER: A tool for predicting and analysing transcription factor
binding sites. PloS one 2019, 14 (9), e0215495.

215.

Lorca, T., Manfredi, JJ., Orlic-Milacic, M., Mitotic G2-G2/M phases. Reactome: Reactome, 2018.

216.

Eid, S.; Turk, S.; Volkamer, A.; Rippmann, F.; Fulle, S., KinMap: a web-based tool for interactive
navigation through human kinome data. BMC Bioinformatics 2017, 18 (1), 16.

217.

Shao, X.; Taha, I. N.; Clauser, K. R.; Gao, Y.; Naba, A., MatrisomeDB: the ECM-protein
knowledge database. Nucleic acids research 2019, 48 (D1), D1136-D1144.

218.

Gaudet, P.; Livstone, M. S.; Lewis, S. E.; Thomas, P. D., Phylogenetic-based propagation of
functional annotations within the Gene Ontology consortium. Briefings in bioinformatics 2011,
12 (5), 449-62.

219.

Harris, G. M.; Raitman, I.; Schwarzbauer, J. E., Cell-derived decellularized extracellular matrices.
Methods in cell biology 2018, 143, 97-114.

220.

Subramanian, A.; Tamayo, P.; Mootha, V. K.; Mukherjee, S.; Ebert, B. L.; Gillette, M. A.;
Paulovich, A.; Pomeroy, S. L.; Golub, T. R.; Lander, E. S.; Mesirov, J. P., Gene set enrichment
analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc
Natl Acad Sci U S A 2005, 102 (43), 15545-50.

221.

Taneja, N.; Fenix, A. M.; Rathbun, L.; Millis, B. A.; Tyska, M. J.; Hehnly, H.; Burnette, D. T.,
Focal adhesions control cleavage furrow shape and spindle tilt during mitosis. Scientific reports
2016, 6 (1), 29846.

222.

Arnone, M. I.; Davidson, E. H., The hardwiring of development: organization and function of
genomic regulatory systems. Development (Cambridge, England) 1997, 124 (10), 1851-64.

223.

Meierjohann, S.; Hufnagel, A.; Wende, E.; Kleinschmidt, M. A.; Wolf, K.; Friedl, P.; Gaubatz,
S.; Schartl, M., MMP13 mediates cell cycle progression in melanocytes and melanoma cells: in
vitro studies of migration and proliferation. Molecular cancer 2010, 9, 201.

124

224.

Kominsky, S. L.; Doucet, M.; Thorpe, M.; Weber, K. L., MMP-13 is over-expressed in renal cell
carcinoma bone metastasis and is induced by TGF-beta1. Clinical & experimental metastasis
2008, 25 (8), 865-70.

225.

Cui, Y.; Chen, J.; He, Z.; Xiao, Y., SUZ12 depletion suppresses the proliferation of gastric cancer
cells. Cellular physiology and biochemistry : international journal of experimental cellular
physiology, biochemistry, and pharmacology 2013, 31 (6), 778-84.

226.

Pasini, D.; Bracken, A. P.; Jensen, M. R.; Lazzerini Denchi, E.; Helin, K., Suz12 is essential for
mouse development and for EZH2 histone methyltransferase activity. The EMBO journal 2004,
23 (20), 4061-71.

227.

Ströbel, T.; Madlener, S.; Tuna, S.; Vose, S.; Lagerweij, T.; Wurdinger, T.; Vierlinger, K.;
Wöhrer, A.; Price, B. D.; Demple, B.; Saydam, O.; Saydam, N., Ape1 guides DNA repair pathway
choice that is associated with drug tolerance in glioblastoma. Scientific reports 2017, 7 (1), 9674.

228.

Segura-Collar, B.; Gargini, R.; Tovar-Ambel, E.; Hernández-SanMiguel, E.; Epifano, C.; Pérez de
Castro, I.; Hernández-Laín, A.; Casas-Tintó, S.; Sánchez-Gómez, P., The EGFR-TMEM167A-p53
Axis Defines the Aggressiveness of Gliomas. Cancers 2020, 12 (1).

229.

Huang, Y.; Zhu, Y.; Zhang, Z.; Li, Z.; Kong, C., UNC5B mediates G2/M phase arrest of bladder
cancer cells by binding to CDC14A and P53. Cancer gene therapy 2020, 27 (12), 934-947.

230.

Wu, G.; Cheng Zhang, C., Membrane protein CAR promotes hematopoietic regeneration upon
stress. Haematologica 2021, 106 (8), 2180-2190.

231.

Zhu, Y.; Zhu, L.; Lu, L.; Zhang, L.; Zhang, G.; Wang, Q.; Yang, P., Role and mechanism of the
alkylglycerone phosphate synthase in suppressing the invasion potential of human glioma and
hepatic carcinoma cells in vitro. Oncology reports 2014, 32 (1), 431-6.

232.

Morita, K.; He, S.; Nowak, R. P.; Wang, J.; Zimmerman, M. W.; Fu, C.; Durbin, A. D.; Martel,
M. W.; Prutsch, N.; Gray, N. S.; Fischer, E. S.; Look, A. T., Allosteric Activators of Protein
Phosphatase 2A Display Broad Antitumor Activity Mediated by Dephosphorylation of MYBL2.
Cell 2020, 181 (3), 702-715.e20.

233.

Chen, X.; Müller, G. A.; Quaas, M.; Fischer, M.; Han, N.; Stutchbury, B.; Sharrocks, A. D.;
Engeland, K., The forkhead transcription factor FOXM1 controls cell cycle-dependent gene
expression through an atypical chromatin binding mechanism. Molecular and cellular biology
2013, 33 (2), 227-36.

125

234.

Xue, Y. J.; Xiao, R. H.; Long, D. Z.; Zou, X. F.; Wang, X. N.; Zhang, G. X.; Yuan, Y. H.; Wu, G. Q.;
Yang, J.; Wu, Y. T.; Xu, H.; Liu, F. L.; Liu, M., Overexpression of FoxM1 is associated with tumor
progression in patients with clear cell renal cell carcinoma. Journal of translational medicine
2012, 10, 200.

235.

Goodman, R. H.; Smolik, S., CBP/p300 in cell growth, transformation, and development. Genes &
development 2000, 14 (13), 1553-77.

236.

Akashi, E.; Fujihara, S.; Morishita, A.; Tadokoro, T.; Chiyo, T.; Fujikawa, K.; Kobara, H.; Mori,
H.; Iwama, H.; Okano, K.; Suzuki, Y.; Niki, T.; Hirashima, M.; Masaki, T., Effects of galectin-9 on
apoptosis, cell cycle and autophagy in human esophageal adenocarcinoma cells. Oncology
reports 2017, 38 (1), 506-514.

237.

Jikuya, R.; Kishida, T.; Sakaguchi, M.; Yokose, T.; Yasui, M.; Hashizume, A.; Tatenuma, T.;
Mizuno, N.; Muraoka, K.; Umemoto, S.; Kawai, M.; Yoshihara, M.; Nakamura, Y.; Miyagi, Y.;
Sasada, T., Galectin-9 expression as a poor prognostic factor in patients with renal cell
carcinoma. Cancer immunology, immunotherapy : CII 2020, 69 (10), 2041-2051.

238.

Taniguchi, H.; Yamamoto, H.; Akutsu, N.; Nosho, K.; Adachi, Y.; Imai, K.; Shinomura, Y.,
Transcriptional silencing of hedgehog-interacting protein by CpG hypermethylation and
chromatic structure in human gastrointestinal cancer. The Journal of pathology 2007, 213 (2),
131-9.

239.

Kotulak-Chrzaszcz, A.; Klacz, J.; Matuszewski, M.; Kmiec, Z.; Wierzbicki, P. M., Expression of the
Sonic Hedgehog pathway components in clear cell renal cell carcinoma. Oncology letters 2019,
18 (6), 5801-5810.

240.

Du, M.; Wang, G.; Barsukov, I. L.; Gross, S. R.; Smith, R.; Rudland, P. S., Direct interaction of
metastasis-inducing S100P protein with tubulin causes enhanced cell migration without changes
in cell adhesion. The Biochemical journal 2020, 477 (6), 1159-1178.

241.

Stojic, L.; Lun, A. T. L.; Mascalchi, P.; Ernst, C.; Redmond, A. M.; Mangei, J.; Barr, A. R.;
Bousgouni, V.; Bakal, C.; Marioni, J. C.; Odom, D. T.; Gergely, F., A high-content RNAi screen
reveals multiple roles for long noncoding RNAs in cell division. Nature communications 2020, 11
(1), 1851.

242.

Yang, L.; Wang, Y.; Sun, R.; Zhang, Y.; Fu, Y.; Zheng, Z.; Ji, Z.; Zhao, D., ANGPTL4 Promotes the
Proliferation of Papillary Thyroid Cancer via AKT Pathway. OncoTargets and therapy 2020, 13,
2299-2309.

126

243.

Cui, D.; Zhao, Y.; Xu, J., Activation of CXCL5-CXCR2 axis promotes proliferation and accelerates
G1 to S phase transition of papillary thyroid carcinoma cells and activates JNK and p38
pathways. Cancer biology & therapy 2019, 20 (5), 608-616.

244.

Tominaga, K.; Minato, H.; Murayama, T.; Sasahara, A.; Nishimura, T.; Kiyokawa, E.; Kanauchi,
H.; Shimizu, S.; Sato, A.; Nishioka, K.; Tsuji, E. I.; Yano, M.; Ogawa, T.; Ishii, H.; Mori, M.;
Akashi, K.; Okamoto, K.; Tanabe, M.; Tada, K. I.; Tojo, A.; Gotoh, N., Semaphorin signaling via
MICAL3 induces symmetric cell division to expand breast cancer stem-like cells. Proc Natl Acad
Sci U S A 2019, 116 (2), 625-630.

245.

Macedo, J. C.; Vaz, S.; Bakker, B.; Ribeiro, R.; Bakker, P. L.; Escandell, J. M.; Ferreira, M. G.;
Medema, R.; Foijer, F.; Logarinho, E., FoxM1 repression during human aging leads to mitotic
decline and aneuploidy-driven full senescence. Nature communications 2018, 9 (1), 2834.

246.

Sinha, R.; Winer, A. G.; Chevinsky, M.; Jakubowski, C.; Chen, Y. B.; Dong, Y.; Tickoo, S. K.;
Reuter, V. E.; Russo, P.; Coleman, J. A.; Sander, C.; Hsieh, J. J.; Hakimi, A. A., Analysis of renal
cancer cell lines from two major resources enables genomics-guided cell line selection. Nature
communications 2017, 8, 15165.

247.

Liao, G. B.; Li, X. Z.; Zeng, S.; Liu, C.; Yang, S. M.; Yang, L.; Hu, C. J.; Bai, J. Y., Regulation of the
master regulator FOXM1 in cancer. Cell communication and signaling : CCS 2018, 16 (1), 57.

248.

Wang, S. P.; Wu, S. Q.; Huang, S. H.; Tang, Y. X.; Meng, L. Q.; Liu, F.; Zhu, Q. H.; Xu, Y. G., FDI-6
inhibits the expression and function of FOXM1 to sensitize BRCA-proficient triple-negative
breast cancer cells to Olaparib by regulating cell cycle progression and DNA damage repair. Cell
death & disease 2021, 12 (12), 1138.

249.

Xia, X.; Gholkar, A.; Senese, S.; Torres, J. Z., A LCMT1-PME-1 methylation equilibrium controls
mitotic spindle size. Cell Cycle 2015, 14 (12), 1938-47.

250.

Guo, S.; Bai, X.; Liu, Y.; Shi, S.; Wang, X.; Zhan, Y.; Kang, X.; Chen, Y.; An, H., Inhibition of
TMEM16A by Natural Product Silibinin: Potential Lead Compounds for Treatment of Lung
Adenocarcinoma. Frontiers in pharmacology 2021, 12, 643489.

251.

Portela, M.; Segura-Collar, B.; Argudo, I.; Sáiz, A.; Gargini, R.; Sánchez-Gómez, P.; Casas-Tintó,
S., Oncogenic dependence of glioma cells on kish/TMEM167A regulation of vesicular trafficking.
Glia 2019, 67 (2), 404-417.

252.

Comelli, M. C.; Mengs, U.; Schneider, C.; Prosdocimi, M., Toward the definition of the
mechanism of action of silymarin: activities related to cellular protection from toxic damage
induced by chemotherapy. Integrative cancer therapies 2007, 6 (2), 120-9.

127

253.

Neufeld, T. K.; Douglass, D.; Grant, M.; Ye, M.; Silva, F.; Nadasdy, T.; Grantham, J. J., In vitro
formation and expansion of cysts derived from human renal cortex epithelial cells. Kidney
international 1992, 41 (5), 1222-36.

128

APPENDIX A
FOXD1 regulates cell division in clear cell renal cell carcinoma supplemental data
Table A.1 Summary of patient clinical data used for FOXD1 immunohistochemistry analysis.
Sex

Male

Female

All

Count

82 (57.7%)

60 (42.3%)

142

61.13

62.67

61.78

61

62

62

I

9

13

22

II

38

25

63

III

19

13

32

IV

4

5

9

11

4

15

1 39

38

77

2 9

10

19

3 22

9

31

4 9

3

12

3

0

3

Mean (S.D.)

67.02(±54.37)

77.12 (±54.35)

71.30(±53.75)

Median

51

65

58.5

Recurrence

6(8.5%)

3(5.0%)

10(7.0%)

Age
Mean
Median
Stage

Unknown
Grade

Unknown
Overall Survival
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Table A.2 Primers used for FOXD1 genotyping and off-target analysis. * Blue indicates primers used for
sequencing mismatch region. ** Red bases indicate mismatches from FOXD1.
Gene

Chr

Ploid

Cut Site

Sequence

PAM

Forward Primer

Reverse Primer

7344835

ATCGGACATCTCAG

GGG

GAGCTCTGTTCT

ATAGTGATGAGC

3

TGCTCA

TAGACTCTCACC

GCGATATACGAG

y
FOXD1

5

2N

*
CCR3

KCNMB2

KIAA093

3

3

22

4N

4N

3N

0
PRMT3

Chr1

11

1

2N

4N

1432384

4621226

ATCTCACATCTCTGT

4

GATCA**

1784909

ATCAGACATTTCAG

62

TGCTCT

4521685

CTCGGACAGCTCTG

8

TGCTCA

2045096

ATAGTACATCTTATT

3

GCTCA

1143238

CCTGGACATCAGTG

46

CTCT

1029438

AACCCACATCTCAG

7

TACTCA

1056579

ATGGTACTTCTCAG

61

TGCACA

CGG

TGG

CGG

GGG

GGG

TGGCCCTGTTTC

GGTGGAAAGAGA

TGGTTCTCCT

GGCTGGGGAA

ACATAGGTGGG

AGCTGCACTGTGA

TGCTCAACAGA

GCTGTTCTC

ACCTGCCTTAGC

AGGTTTTCCCCAC

GTTCCAAGGT

CCTCAAGCA

ATACCGACGTA

GCCACTACTGGTG

GAGTTGCCGGC

TCACAAATACGC

TGCAGCAGTAA

GAGGCTGTGGGT

GTGTAAGCCCT

GTTGAGGAGT

TGACTGCCTTTG

AGTGTTCTCCCCA

GTGGTCAGCT

CACACACAA

CCCATTTGCCTG

AGAGCCTAGCAG

TGTAAAAGTTG

ACTGTGTGGC

6
Chr2

2

4N

1414143

TGG

0
Chr10
1056579

10

3N

61

AGG

GG
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Table A.3 Primers for reference genes and FOXD1 targets.
Target

Forward Sequence

Reverse Sequence

Reference Gene Panel
RPLPPO

TGG TCA TCC AGC AGG TGT TCG A

ACA GAC ACT GGC AAC ATT GCG G

B2M

CCA CTG AAA AAG ATG AGT ATG

CCA ATC CAA ATG CGG CAT CTT CA

CCT
TFRC

ATC GGT TGG TGC CAC TGA ATG G

ACA ACA GTG GGC TGG CAG AAA C

HBB

CAC CTT TGC CAC ACT GAG TGA G

CCA CTT TCT GAT AGG CAG CCT G

PUM1

GCA TTT GGA CAA GGT CTG GCA G

GCT ACA AGT CGA ACA GGA GCT C

LDHA

GGA TCT CCA ACA TGG CAG CCT T

AGA CGG CTT TCT CCC TCT TGC T

ACTB

CAC CAT TGG CAA TGA GCG GTT C

AGG TCT TTG CGG ATG TCC ACG T

HSP90AB1

CTC TGT CAG AGT ATG TTT CTC GC

GTT TCC GCA CTC GCT CCA CAA A

CDKN1A

AGG TGG ACC TGG AGA CTC TCA G

TCC TCT TGG AGA AGA TCA GCC G

PPIA

GGC AAA TGC TGG ACC CAA CAC A

TGC TGG TCT TGC CAT TCC TGG A

IPO8

AGG ATC AGA GGA CAG CAC TGC A

AGG TGA AGC CTC CCT GTT GTT C

PGK1

CCG CTT TCA TGT GGA GGA AGA AG

CTC TGT GAG CAG TGC CAA AAG C

ALAS1

GAT GTC AGC CAC CTC AGA GAA C

CAT CCA CGA AGG TGA TTG CTC C

PPIH

CAC CTG CTC TAA GTG CGA TTG G

CGA GAT CAC CAC AGG TAG CTT G

RPL30

CCA GTC TGT TCT GGC ATG CTT C

CTG GTG TCC ATC ACT ACA GTG G

RPS18S

GCA GAA TCC ACG CCA GTA CAA G

GCT TGT TGT CCA GAC CAT TGG C

HMBS

ACG GCT CAG ATA GCA TAC AAG AG

GTT ACG AGC AGT GAT GCC TAC C

GAPDH

GTC TCC TCT GAC TTC AAC AGC G

ACC ACC CTG TTG CTG TAG CCA A

Table A.3 Continued.
HPRT1

CAT TAT GCT GAG GAT TTG GAA

CTT GAG CAC ACA GAG GGC TAC A

AGG
G6PD

CTG TTC CGT GAG GAC CAG ATC T

TGA AGG TGA GGA TAA CGC AGG C

NONO

CAT CAA GGA GGC TCG TGA GAA G

TGG TTG TGC AGC TCT TCC ATC C

TUBB

CTG GAC CGC ATC TCT GTG TAC T

GCC AAA AGG ACC TGA GCG AAC A

SDHA

GAG ATG TGG TGT CTC GGT CCA T

GCT GTC TCT GAA ATG CCA GGC A

TBP

TGT ATC CAC AGT GAA TCT TGG TTG

GGT TCG TGG CTC TCT TAT CCT C

FOXD1 Targets
CCNE1

TGT GTC CTG GAT GTT GAC TGC C

CTC TAT GTC GCA CCA CTG ATA CC

CDKN1A

AGG TGG ACC TGG AGA CTC TCA G

TCC TCT TGG AGA AGA TCA GCC G

CDKN1B

ATA AGG AAG CGA CCT GCA ACC G

TTC TTG GGC GTC TGC TCC ACA G

CDKN2A

CTC GTG CTG ATG CTA CTG AGG A

GGT CGG CGC AGT TGG GCT CC

FOXP2

TGG ATG ACC GAA GCA CTG CTC A

TGG GAG ATG GTT TGG GCT CTG A

PRC1

ATA GCC AGG AGC AGA GAC AAG C

AAC CGC ACA ATC TCA GCA TCG TG

WT1

CGA GAG CGA TAA CCA CAC AAC G

GTC TCA GAT GCC GAC CGT ACA A

TP53

CCT CAG CAT CTT ATC CGA GTG G

TGG ATG GTG GTA CAG TCA GAG C

CTNNB1

CAC AAG CAG AGT GCT GAA GGT G

GAT TCC TGA GAG TCC AAA GAC AG

DCN

GCT CTC CTA CAT CCG CAT TGC T

GTC CTT TCA GGC TAG CTG CAT C

ERK1

TGG CAA GCA CTA CCT GGA TCA G

GCA GAG ACT GTA GGT AGT TTC GG

MICU1

GAC AGT GGC TAA AGT GGA GCT C

CCT CTC ATC AGC CGT TGC TTC A

PGF

GGC GAT GAG AAT CTG CAC TGT G

ATT CGC AGC GAA CGT GCT GAG A

PUM1

GCA TTT GGA CAA GGT CTG GCA G

GCT ACA AGT CGA ACA GGA GCT C

SLIT2

CAG AGC TTC AGC AAC ATG ACC C

GAA AGC ACC TTC AGG CAC AAC AG
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Table A.3 Continued.
Mitochondrial Metabolism Components
ANT1

ATA AGC AGT TCT GGC GCT ACT

GTC CAG CGG GTA GAC AAA GC

ANT2

TGA TGG GAT TAA GGG CCT GTA

GAA GTA GGC GGC TCG GTA G

COXIV

CAG GGT ATT TAG CCT AGT TGG C

GCC GAT CCA TAT AAG CTG GGA

PDHA1

TGG TAG CAT CCC GTA ATT TTG

ATT CGG CGT ACA GTC TGC ATC

PDK1

GGA TTG CCC ATA TCA CGT CTT T

TCC CGT AAC CCT CTA GGG AAT A

PDP1

TGT GAA CTG AGC AGG ATC TAT GG

GGA ATG TAC GAT GAGA GAA CAA CA

NDUFB8

ACA GGA ACC GTG TGG ATA CAT

CCC CAC CCA GCA CAT GAA T

UQRC2

AAT TTC GTC GTT GGG AAG TAG C

ATG AGT CTG CGG ATT CTG AAA G

SDHB

ACC TTC CGA AGA TCA TGC AGA

GTG CAA GCT AGA GTG TTG CCT
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Table A.4 Nuclear morphology analysis of 786-O and 786-OFOXD1null. *Immunocytochemistry analysis of
cells in different phases of the cell cycle after low density plating, based on nuclear and actin
morphologies and localization. Percentage values are based on analysis of 100 cells per group across
several fields. **Defects panel indicates collection of possible mitotic defects including lack of
chromosome condensation (prophase), loss of spindle polarity (metaphase/anaphase), incomplete
sister chromosome separation (cytokinesis), and death of daughter cell (post-mitosis G1).
Phase of analyzed
cells

%Cells*

%pH3+

%yH2AX+

%Defects**

786-O

FOXD1-

786-O

FOXD1-

786-O

FOXD1-

786-O

FOXD1-

S

6.0

4.2

0

0

0

0

0

0

G2

21.4

12.9

100

11.1

20

40

0

0

Mitosis

60.7

62.9

60.0

0

5.3

9.1

23.5

59

Prophase

21.4

14.3

50

0

0

33.3

11.1

30

Metaphase

16.7

32.9

71.4

0

0

8.3

21.4

69.6

Anaphase

16.7

10.0

50

0

16.7

0

42.9

71.4

Cytokinesis

6.0

5.7

7.1

0

0

0

20

25

Post-mitosis G1

7.1

18.6

0

0

0

83.3

16.7

100

Dead/Apoptotic

4.7

1.4

-

-

-

-

-

-
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Figure A.1. FOXD1 grade and stage analyses (A) FOXD1 expression level comparisons at different
ccRCC tumor grades based on transcriptome data from The Cancer Genome Atlas (B) FOXD1
expression level comparisons at different ccRCC tumor stages based on transcriptome data from The
Cancer Genome Atlas. (C-D) Kaplan-Meier survival analyses for ccRCC patients with high versus low
tumor expression of FOXD1, analyzed based of tumor stage. *p<0.05.
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Figure A.2. FOXD1 antibody validation (A-D) Immunohistochemistry staining of human kidney tissue
(A, C) against normal E12.5 mouse kidney (not shown) and FOXD1-null E12.15 mouse kidney (B,D).
(E-F) TSA amplification staining for FOXD1 on E12.5 mouse kidneys on normal and FOXD1-null
backgrounds.
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Figure A.3. FOXD1 qPCR reference gene selection. (A) Stability scores generated by comparing
candidate reference gene assays (Table S3) on equivalent mRNA quantities of 786-O versus 786OFOXD1null analyzed using the BioRad Reference Gene Selector Tool. Colors of bars denote genes that
are over (green) or under the acceptable stability threshold between samples. (B-D) Standard curves
for reference genes selected for this study.

Figure A.4. FOXD1-null cells difficulty in tumor establishment (A) Xenograft of 786-O and 786OFOXD1null into flanks of 6-week old NCG mice. (B) Rapid tumor recession in 786-OFOXD1null engraftment
group, indicating low long-term viability of tumors.
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Figure A.5. Histone H3 Phosphorylation analysis (A-B) Full membranes used for Western Blot
analysis, with proteins visualized using the Bio-Rad Stain-Free gel system. Protein loading was
quantified in each lane for normalization). (C-F) Full protein blots for Histone H3 and Phosphorylated
Histone H3 (Ser10) of synchronized 786-O and 786-OFOXD1null cells at designated time points after
release from thymidine block. Blue boxes indicate areas used for quantification. (G) Densitometry
analysis (Ser10), normalized to total protein in well.
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Figure A.6 CDC2 Phosphorylation analysis Full membranes and quantification used for western blot
analysis of CDC2 (A-B) and phosphorylated forms at T161 (C-D) and Y15 (E-F). All protein levels were
normalized to total protein loaded.
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Figure A.7. Cyclin B1 and MICU1 protein analysis. Full membranes and quantification used for
western blot analysis of Cyclin B1 (A-B) Cyclin D1 and MICU1 (C-D). All protein levels were
normalized to total protein loaded.
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Figure A.8. EdU pulse-chase analysis (A) Labeling schematic of pulse-chase experiment. Cells in S
phase incorporate EdU and are labeled (yellow circles). After 8 hour EdU treatment, cells in G2 are
labeled with EdU. After 2 hours (2 hour chase), labeled cells in G2 progress into mitosis (M). After an
additional 2 hours (4 hour chase), labeled cells in M divide and enter G1. (B) Representative images
showing staining of pH3 and γH2AX at 2 hour intervals following EdU pulse of both 786-O and 786OFOXD1null. (C) Immunocytochemistry of pH3 and γH2AX at each chase time point for 6 hour and 8
hour EdU pulses.
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Figure A.9. FOXD1 correlated genes involved in cell cycle regulation. Leading edge analysis of FOXD1
correlated genes from TCGA and top scoring candidates. *indicates kinases linked to
phosphorylation of Histone H3.
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Figure B.1. Flow cytometry based cell type marker analysis of three tumors. (A) Patient R19-6200,
(B) patient Tp18-S601, and (C) patient R18-1453 were analyzed for cell type specific markers using
flow cytometry.
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Figure B.2. Loss of PDGFRα/β after passaging primary ccRCC cultures. (A) Representative images of
immunostained patient tumor line Tp18-S108 for tumor cell and fibroblast markers at sequential
passages. Green = CK18, red = PDGFRα/β, gray = DAPI. Scale bar = 50 µm. (B) Summary analysis of 5
patient derived primary RCC cultures over passages for expression of fibroblast marker PDGFRα/β,
tumor marker CK18, and vimentin.
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Figure B.3. Pathway analyses of ccRCC mass spectrometry dataset. (A) Gene Set Enrichment Analysis
(GSEA) using the Reactome reference pathway database visualized using Cytoscape. Blue =
upregulated in tumors, red = downregulated in tumors. Encircled node indicates increase in ECM
related pathways and interactions. (B) DAVID enriched analysis of only significantly modified
pathways. Red = upregulated, blue = downregulated.
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Figure B.4. Cell attachment on ECM. (A-K) Characteristic images of 786-O cell attachment after 2
hours to coated assay plates. Each well was coated with 2 µg/ml of designated recombinant protein.
Cell attachment was quantified morphologically (N = 3). Blue circle = sample of unattached cell. Red
circle= sample of attached cell. Scale bar = 100 µm.
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Figure B.5. ccRCC cell marker analysis of primary cell lines. Primary ccRCC tumor lines were
immunostained for common ccRCC and cancer stem cell markers. Left column; red = vimentin, green
= CK18, white = PAX2/8, blue = DAPI. Right column; red = CXCR4, green = CA9, Blue = DAPI. Scale bar
= 25 µm.

147

Figure B.6. EdU analysis of primary tumor isolates. (A-B) Representative immunostaining and EdU
detection on primary tumor digests cultured on ccRCC ECM coated slides or slides without any
coating. Green = EdU, red = PAX2/8, cyan = CD45, blue = DAPI. (C-F) Analysis of EdU intensity in each
cell, further defined by co-expression of other cell-type specific markers.
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Figure B.7. Analysis of fibrinogen transcripts from TCGA. Percentage of patients among each tumor
grouping for above median expression of fibrinogen transcripts.
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Figure B.8. Primary RCC cultures create viable structures in fibrin/ccRCC ECM after 3 weeks. Yellow
dotted line outlines region containing 3D domes. Green = calcein-AM, red = ethidium homodimer 2,
blue = Hoechstt33342. Stereoscope and 5x image scalebar = 100 µm. 63x image scalebar = 25 µm.
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Figure B.9. Incorporation of ECM into fibrin domes. Three dimensional growth of aggregates of 786O cells in fibrin with ECM protein additives after 7 days. Yellow dotted line outlines region
containing 3D dome.
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Figure B.10. ccRCC tumor isolate culture in Matrigel vs fibrin/ccRCC ECM (A-E) Viability staining of
primary tumor cells in Matrigel or fibrin/ccRCC ECM. Arrowhead indicates region containing inset
images. Green = calcein-AM, red = ethidium homodimer 2, blue = Hoechst33342. Scale bar = 100
µm. Yellow dotted line outlines region containing 3D dome.
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Figure B.11. Media formulation influences cell viability of 3D cultures. 3D cultures from tumor
sample S215 were created in either Matrigel (A-A’), Fibrinogen only (B-B’), or Fibrin/ccRCC ECM mix
(C-C’) and cultured in CHM media for 14 days and analyzed for cell viability using Calcein-AM and
Ethidium Homodimer-2. Yellow-dotted line indicates region magnified for cell viability. Green =
Calcein-AM, red = ethidium homodimer-2, blue = Hoechst 33342. D) Quantification of cell viability of
cultures grown in Matrigel, fibrin only, and fibrin/ccRCC ECM grown in either CHM media of DMEM
+ 10% FBS. * = p-value < 0.05.
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Figure B.12. Further characterization of 3D cultures. Primary tumor digests grown in either Matrigel
or fibrin/ccRCC ECM domes show staining for vimentin (green) in majority of cells. Subsets of
vimentin-positive cells show staining for CXCR4 (red), with or without expression of CD45 (cyan).
Blue = DAPI.
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Figure B.13. Immunostaining analysis of fibrin/ccRCC ECM cultures for fibroblast markers. (A)
Staining of primary tumor digests from two different patients grown in either Matrigel or
fibrin/ccRCC ECM. Arrows indicate location of magnified images below. Green = vimentin, red =
PDGFRα/β, cyan = ACTA2, blue = DAPI. Scale bar top panels = 100 µm. Scale bar bottom panels = 25
µm. (B) Quantification of vimentin positive structures for co-staining of fibroblast marker PDGFRα/β
and CAF marker ACTA2. * p <= 0.05 between percentage of PDGFRα/β+/ACTA2+ cells between
cultures grown in fibrin/ccRCC ECM compared to Matrigel.
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Figure B.14. Additional analysis of fibroblast markers after 90 days of culture. (A) Immunostaining
and EdU detection in sample S199 grown in fibrin/ccRCC ECM after 90 days. Yellow dotted line
outlines region containing fibrin dome. White arrowhead indicates magnified region in second
panel. Green = EdU, red = PDGFRα/β or renin, cyan = ACTA2, blue = DAPI. (B) Quantification of EdU
positivity among PDGFRα/β+ cells. Percentage of cells co-positive with ACTA2 or renin additionally
quantified.
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Figure B.15. Protein localization in ccRCC tissue. Expression patterns of ECM proteins identified in
this study analyzed using IHC from ProteinAtlas. Immunostaining patterns of ECM molecules in
healthy kidney tissue versus ccRCC. Healthy kidneys were investigated for staining around tubules
(first column) and glomeruli (second column).

157

APPENDIX C
Supplemental Material
Table C.1. Summary of drug titrations used for toxicity screen.
Drug

Targe
t

AMZ30

PPM
E1
SUZ1
2
CXAD
R
LGAL
S9
SEM
A3C

EED226
CINPA1
Galectin-9
mAb
Recombina
nt
Semaphorin
3C
Recombina
nt CXCL5
Recombina
nt ANGPTL4
Recombina
nt SHH
Recombina
nt CTRP1
Recombina
nt Netrin
WAY17015
23
C5OH
CPI-637
FDI-6
APE-1
Inhibitor III
Benezyl
Isocyanate
Silbinin
Recombina
nt LTBP1

CXCL
5
ANG
PTL4
HHIP
C1QT
NF1
UNC5
B
MMP
13
S100
P
EP30
0
FOX
M1
APEX
1
AGPS
TME
M16
7A
LTBP
1

Reported
Concentratio
n
IC50 = 0.6µM

Dose 1

Dose 2

Dose 3

Dose 4

Dose 5

Dose 6

0.6µM

1.2µM

2.4µM

3.6µM

4.2µM

25µM

IC50 =
53.5nM
IC50 = 70nM

53.5n
M
70nM

160.5n
M
210nM

2500n
M
630nM

1
µg/ml
0.625
µg/ml

215n
M
350n
M
4
µg/ml
5
µg/ml

267.5n
M
490nM

1 IU = 1
µg/ml
Reported =
10 µg/ml

107n
M
140n
M
2
µg/ml
1.25
µg/ml

7.5
µg/ml

10
µg/ml

ED50 = 3 –
15ng/ml
IC50 = 0.052µg/ml
ED50 = 0.1 –
0.42 µg/ml
ED50 = 0.63.62 µg/ml
ED50 = 0.5 –
2.0 µg/ml
IC50 = 17nM

3ng/ml

6ng/m
l
0.2
µg/ml
0.2
µg/ml
2.4
µg/ml
1.0
µg/ml
34nM

12ng/ml

24ng/
ml
1
µg/ml
0.4
µg/ml
4.75
µg/ml
4.0
µg/ml
68nM

48ng/ml

144ng/
ml
4 µg/ml

0.5
µg/ml
5.65
µg/ml
5.0
µg/ml
85nM

50
µg/ml
-

IC50 =
100nM
IC50 =
0.05µM
IC50 =
22.5µM
IC50 =
600nM 12µM
IC50 = 2 5µM
IC50 =
30.9µM

100nM

200n
M
0.1µM

1000nM

2000n
M
0.3µM

10µM

20µM

0.4µM

2.6 µM

33.75
µM
600n
M

45uM

56.25
µM
1200n
M

67.5µM

-

2400nM

1.6mM

2µM

4µM

8µM

10µM

12µM

200µM

30.9µ
M

61.8µ
M

123.6µ
M

185.4
µM

247.2µ
M

12mM

IC50 =
2µg/ml

2µg/ml

4µg/m
k

6µg/ml

8µg/m
l

10µ/ml

-

0.1
µg/ml
0.1
µg/ml
1.2
µg/ml
0.5
µg/ml
17nM

0.05µ
M
22.5µ
M
60nM
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3 µg/ml
2.5
µg/ml

0.5
µg/ml
0.3
µg/ml
3.6
µg/ml
2.0
µg/ml
51nM

0.2µM

900nM

5 µg/ml

2 µg/ml

-

500nM

Figure C.1. Cell cycle inhibition by Mitomycin C prevent sphere formation.
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Figure C.2. FOXD1 status effects ability to grow in 3D tumors, requires ECM addition.
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Figure C.3 3D tumor cultures treated with FOXD1 related drugs.
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